US20040053832A1 - Immunological methods of treating cancer - Google Patents
Immunological methods of treating cancer Download PDFInfo
- Publication number
- US20040053832A1 US20040053832A1 US10/406,077 US40607703A US2004053832A1 US 20040053832 A1 US20040053832 A1 US 20040053832A1 US 40607703 A US40607703 A US 40607703A US 2004053832 A1 US2004053832 A1 US 2004053832A1
- Authority
- US
- United States
- Prior art keywords
- cells
- donor
- tumor
- drugs
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001900 immune effect Effects 0.000 title claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 title claims description 110
- 238000000034 method Methods 0.000 title claims description 62
- 201000011510 cancer Diseases 0.000 title claims description 17
- 239000012636 effector Substances 0.000 claims abstract description 81
- 239000005557 antagonist Substances 0.000 claims abstract description 62
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 35
- 230000003834 intracellular effect Effects 0.000 claims abstract description 29
- 230000030833 cell death Effects 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims description 359
- 102000005962 receptors Human genes 0.000 claims description 62
- 108020003175 receptors Proteins 0.000 claims description 62
- 210000002540 macrophage Anatomy 0.000 claims description 59
- 230000000735 allogeneic effect Effects 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 33
- 208000023275 Autoimmune disease Diseases 0.000 claims description 30
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 239000002254 cytotoxic agent Substances 0.000 claims description 16
- 238000003379 elimination reaction Methods 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000036142 Viral infection Diseases 0.000 claims description 13
- 229960000876 cinnarizine Drugs 0.000 claims description 13
- 230000008030 elimination Effects 0.000 claims description 13
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 11
- 230000001575 pathological effect Effects 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 7
- 229960003712 propranolol Drugs 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000003828 downregulation Effects 0.000 claims description 3
- 102000000543 Histamine Receptors Human genes 0.000 claims description 2
- 108010002059 Histamine Receptors Proteins 0.000 claims description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 103
- 238000000338 in vitro Methods 0.000 description 67
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 58
- 238000001727 in vivo Methods 0.000 description 49
- 239000000126 substance Substances 0.000 description 40
- 102000004127 Cytokines Human genes 0.000 description 39
- 108090000695 Cytokines Proteins 0.000 description 39
- 210000004881 tumor cell Anatomy 0.000 description 39
- 239000000427 antigen Substances 0.000 description 37
- 230000001965 increasing effect Effects 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 229960004857 mitomycin Drugs 0.000 description 30
- 239000011575 calcium Substances 0.000 description 26
- 210000004408 hybridoma Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 210000001185 bone marrow Anatomy 0.000 description 24
- 230000002637 immunotoxin Effects 0.000 description 24
- 229940051026 immunotoxin Drugs 0.000 description 24
- 239000002596 immunotoxin Substances 0.000 description 24
- 231100000608 immunotoxin Toxicity 0.000 description 24
- 238000010322 bone marrow transplantation Methods 0.000 description 23
- 210000004698 lymphocyte Anatomy 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000556 agonist Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 20
- 230000001976 improved effect Effects 0.000 description 19
- 230000004913 activation Effects 0.000 description 18
- 210000003719 b-lymphocyte Anatomy 0.000 description 18
- 230000008901 benefit Effects 0.000 description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- -1 oxygen radicals Chemical class 0.000 description 18
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 17
- 230000001506 immunosuppresive effect Effects 0.000 description 17
- 230000001717 pathogenic effect Effects 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 239000002202 Polyethylene glycol Substances 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 15
- 244000052769 pathogen Species 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 208000030507 AIDS Diseases 0.000 description 14
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 14
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 229960001340 histamine Drugs 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 230000002779 inactivation Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 208000002839 megalencephalic leukoencephalopathy with subcortical cysts Diseases 0.000 description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 11
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000004180 plasmocyte Anatomy 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 9
- 229960005305 adenosine Drugs 0.000 description 9
- 108060000200 adenylate cyclase Proteins 0.000 description 9
- 102000030621 adenylate cyclase Human genes 0.000 description 9
- 239000002876 beta blocker Substances 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 229960002986 dinoprostone Drugs 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 9
- 229960004027 molsidomine Drugs 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 150000002828 nitro derivatives Chemical class 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 102100033805 Alpha-protein kinase 1 Human genes 0.000 description 8
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 8
- 229940097320 beta blocking agent Drugs 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 229940044627 gamma-interferon Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 229940028617 conventional vaccine Drugs 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 7
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 6
- 230000000970 DNA cross-linking effect Effects 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000003969 glutathione Nutrition 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000037417 hyperactivation Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229960002508 pindolol Drugs 0.000 description 6
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 6
- 229960001722 verapamil Drugs 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 108010078321 Guanylate Cyclase Proteins 0.000 description 5
- 102000014469 Guanylate cyclase Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 5
- 208000007660 Residual Neoplasm Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940072107 ascorbate Drugs 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 229960000278 theophylline Drugs 0.000 description 5
- 230000002476 tumorcidal effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000051325 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 229950006790 adenosine phosphate Drugs 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 150000001447 alkali salts Chemical class 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000009460 calcium influx Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000002619 cytotoxin Substances 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000016507 interphase Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 229960002460 nitroprusside Drugs 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229960001639 penicillamine Drugs 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 108010066676 Abrin Proteins 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000961 alloantigen Effects 0.000 description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
- 229960002576 amiloride Drugs 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 3
- 229960001330 hydroxycarbamide Drugs 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000002512 suppressor factor Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 229960001130 urapidil Drugs 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- PBOPJYORIDJAFE-UHFFFAOYSA-N 2,4-dinitrobromobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C([N+]([O-])=O)=C1 PBOPJYORIDJAFE-UHFFFAOYSA-N 0.000 description 2
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 2
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- WJUUZHQWGKSLIJ-UHFFFAOYSA-N Bupranolol hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 WJUUZHQWGKSLIJ-UHFFFAOYSA-N 0.000 description 2
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 2
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
- 101000690306 Homo sapiens Aldo-keto reductase family 1 member C3 Proteins 0.000 description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101150056637 Hrh2 gene Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 2
- 108010058907 Tiopronin Proteins 0.000 description 2
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- LHLMOSXCXGLMMN-CLTUNHJMSA-M [(1s,5r)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide Chemical compound [Br-].C([C@H]1CC[C@@H](C2)[N+]1(C)C(C)C)C2OC(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-CLTUNHJMSA-M 0.000 description 2
- KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 229960003116 amyl nitrite Drugs 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940098165 atrovent Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 2
- 229960003665 bepridil Drugs 0.000 description 2
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 230000001275 ca(2+)-mobilization Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- OESHPIGALOBJLM-REOHCLBHSA-N dehydroascorbate Chemical compound OC[C@H](O)[C-]1OC(=O)C(=O)C1=O OESHPIGALOBJLM-REOHCLBHSA-N 0.000 description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 2
- 239000011615 dehydroascorbic acid Substances 0.000 description 2
- 229940099238 diamox Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229960002474 hydralazine Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000002861 immature t-cell Anatomy 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 108010008429 immunoglobulin-binding factors Proteins 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229960002056 indoramin Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 108010032809 mucopolysaccharidase Proteins 0.000 description 2
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 101150012634 panT gene Proteins 0.000 description 2
- 230000001499 parasympathomimetic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- FEDSNBHHWZEYTP-ZFQYHYQMSA-N penbutolol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 FEDSNBHHWZEYTP-ZFQYHYQMSA-N 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229940106721 tagamet Drugs 0.000 description 2
- NZMOFYDMGFQZLS-UHFFFAOYSA-N terazosin hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 NZMOFYDMGFQZLS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OPPDZGGNDGEPAW-DNOVUIPZSA-N (2s)-2,6-diaminohexanoic acid;(2r)-2,5-diamino-5-oxopentanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@H](N)CCC(N)=O OPPDZGGNDGEPAW-DNOVUIPZSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical class C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- SRUQARLMFOLRDN-UHFFFAOYSA-N 1-(2,4,5-Trihydroxyphenyl)-1-butanone Chemical compound CCCC(=O)C1=CC(O)=C(O)C=C1O SRUQARLMFOLRDN-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- DBUJVRULIBQHKT-UHFFFAOYSA-N 1-[5-amino-2-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethanone Chemical compound CC(C)NCC(O)COC1=CC=C(N)C=C1C(C)=O DBUJVRULIBQHKT-UHFFFAOYSA-N 0.000 description 1
- CJAOGUFAAWZWNI-UHFFFAOYSA-N 1-n,1-n,4-n,4-n-tetramethylbenzene-1,4-diamine Chemical compound CN(C)C1=CC=C(N(C)C)C=C1 CJAOGUFAAWZWNI-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 1
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JCBIVZZPXRZKTI-UHFFFAOYSA-N 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;sulfuric acid Chemical group OS(O)(=O)=O.ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 JCBIVZZPXRZKTI-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical compound NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 1
- 238000013030 3-step procedure Methods 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical class C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- CBPBJKQTVKFOOQ-UHFFFAOYSA-N CGP 28-392 Chemical compound CCOC(=O)C1=C(C)NC(COC2=O)=C2C1C1=CC=CC=C1OC(F)F CBPBJKQTVKFOOQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 241000514744 Cyclina Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004131 EU approved raising agent Substances 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 101000757797 Geobacillus stearothermophilus Aminopeptidase 2 Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001190382 Glympis concors Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102100039386 Ketimine reductase mu-crystallin Human genes 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 101000772180 Lithobates catesbeianus Transthyretin Proteins 0.000 description 1
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 1
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-J NADPH(4-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-J 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- BVAYTJBBDODANA-UHFFFAOYSA-N Prednisolon Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 BVAYTJBBDODANA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 101000733766 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Aminopeptidase 2, mitochondrial Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- RRCPAXJDDNWJBI-UHFFFAOYSA-N alprenolol hydrochloride Chemical compound [H+].[Cl-].CC(C)NCC(O)COC1=CC=CC=C1CC=C RRCPAXJDDNWJBI-UHFFFAOYSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 150000007657 benzothiazepines Chemical class 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 102000014992 beta1-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006808 beta1-adrenergic receptor activity proteins Proteins 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 1
- 230000001707 blastogenic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- ZNDJOCJUBZZAMN-USYHLRJESA-N bmy-25067 Chemical compound C([C@@H]1N[C@@H]1[C@@]1([C@@H]2COC(N)=O)OC)N1C(C(C=1C)=O)=C2C(=O)C=1NCCSSC1=CC=C([N+]([O-])=O)C=C1 ZNDJOCJUBZZAMN-USYHLRJESA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010027836 endotoxin receptor Proteins 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000012057 exposure response modelling Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 229940103893 gliotoxin Drugs 0.000 description 1
- 229930190252 gliotoxin Natural products 0.000 description 1
- 229960003236 glisoxepide Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 108010079530 gold keratinate Proteins 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- IRPYFWIZKIOHQN-XTZHGVARSA-N gold;[(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-sulfanyloxan-2-yl]methyl acetate;triethylphosphane Chemical compound [Au].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O IRPYFWIZKIOHQN-XTZHGVARSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- AFJSFHAKSSWOKG-UHFFFAOYSA-N hydron;n-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]benzamide;chloride Chemical compound Cl.C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 AFJSFHAKSSWOKG-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000001689 kallikreinlike Effects 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000013580 kinin cascade Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 108010003265 lipomodulin Proteins 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- IZJGDPULXXNWJP-UHFFFAOYSA-M lithium orotate Chemical compound [Li+].[O-]C(=O)C1=CC(=O)NC(=O)N1 IZJGDPULXXNWJP-UHFFFAOYSA-M 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 229960004493 penbutolol sulfate Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002047 photoemission electron microscopy Methods 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 230000003823 potassium efflux Effects 0.000 description 1
- 230000003805 potassium influx Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108700035380 rat macrocortin Proteins 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940063638 ridaura Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940028870 thiola Drugs 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
Definitions
- the invention deals with an agent, able to affect the hyperactivated immununological effector cells and with its use.
- immunological-effector cells e.g. by cytokines
- cytokines cytokines
- the immune system is impaired or even switched off in such situations. This occurs e.g. following a persistent stimulation during a prolonged infection or in situations of cell hyperactivation due to an excessive release of endogenous cytokines.
- immunological effector cells comprises e.g. T cells, macrophages/monocytes, NK cells and other immunological cells.
- a variety of immunological processes include on the cellular level the cyclic adenosine phosphate (cAMP) which is produced by the enzyme adenylate cyclase (AC) from adenosine triphosphate (ATP).
- cAMP cyclic adenosine phosphate
- AC adenylate cyclase
- ATP adenosine triphosphate
- the cAMP plays as “second messenger” a central role in the hormonal regulation as well as in the metabolism (through activation of protein kineses, e.g. protein kinase A (PKA).
- PKA protein kinase A
- the PKA phosphorylates proteins which in turn depress the immune response. In this way, the hyperactivation of effector cells results in the down regulation of the immune function.
- This reaction cascade is regulated by the production of cyclic guanosine monophosphate (cGMP) which antagonizes the cAMP.
- cGMP cyclic guanosine monophosphate
- This reaction cascade is also influenced by the group of G-protein coupled receptors, comprising receptors such as adrenergic, muscarinic, histamine, serotonin and adenosine receptors.
- the G-proteins (guanine nucleotide-binding proteins) are able to stimulate (Gs) or to inhibit (Gi) the production of second messengers.
- Gs- or the Gi-receptors the stimulation of AC and herewith the cAMP-production can be regulated.
- Situations with a disturbed equilibrium are e.g. cancer, viral diseases and autoimmune disorders, as well as the inducing and disease-maintaining component of the atherosclerosis.
- the objective of the invention was to provide an agent, able to fight with such disorders and to restore the susceptibility of the hyperactivation-depressed immune system for signals and a normal immune response.
- This objective can be achieved by an agent, capable to affect the hyperactivated immunological effector cells which comprises (I) a Ca-antagonist, and (II) an agent, able to decrease the intracellular cAMP/cGMP-ratio.
- an agent capable to affect the hyperactivated immunological effector cells which comprises (I) a Ca-antagonist, and (II) an agent, able to decrease the intracellular cAMP/cGMP-ratio.
- the principle of the agent is the prevention of Ca 2+ -influx and reduction of cAMP/cGMP-ratio in immune effector cells. This can be achieved by the combination of component I and II.
- diseases as different as cancer, autoimmune disorders, arteriosclerosis which seems to need an autoimmune promotor for its provocation, further bacterial, viral, including retro viral infections, as well as some “modern” diseases, based on immunological derailment or deviations, e.g. the CFS (chronic fatigue syndrome) can be treated. All these situations and disorders appear to contain—in the immunological sense—common disregulation elements. These common elements are e.g.
- leukocyte-subpopulations mostly macrophages and helper T cells, as well as suppressor cells.
- macrophages and helper T cells as well as suppressor cells.
- a mutual stimulation of both interdependent leukocyte-subpopulations can occur.
- a further common element is the deblockade of blastogenically pretransformed T4 and plasma (B) cells as consequence of preceding, persistent latent or manifest immunosuppression; it is based on a “critical drop” of autoantigen or pathogen-specific surveyor cells or suppressor T cells.
- B blastogenically pretransformed T4 and plasma
- the combination of components I and II deblocks the misprogrammed immunocytes or effector cells, primarily those in the hyperactivated state, and has therefore impact on the “wound healing” or “tissue repair”—function of misprogrammed macrophages and cytokine-hyper secreting helper T cells.
- This hyperactivated or persistently activated state of effector cells can be prevented through component I by breaking the Ca 2+ -rigidity, i.e. by breaking the Ca i 2+ -overload of effector cells; on the other hand, the Ca i 2+ -level is regulated by the intracellular pHi.
- An additional mechanism is the control of the electrolyte transport through the cell membrane, i.e.
- the combination was able to reduce the primary tumor and metastases in cancer patients by ⁇ fraction (1/3) ⁇ to 2 ⁇ 3 within few weeks, without a simultaneous radio- or chemotherapy.
- the CFS-patients also showed surprising therapeutic results.
- component I and II can be combined as well. Their effect in patients with neoplastic and autoimmune diseases, atherosclerosis, amyloidosis, Alzheimer disease and CFS can further be potentiated by combining them with known immunostimulators and BRMs. In addition, these combinations can be used therapeutically in bacterial and viral infections.
- the initial derailment i.e. the hyperactivation of leukocyte-subpopulations can be reversed.
- the restoration of the original immune state then occurs spontaneously.
- the therapeutic protocol can consist of 2 or 3 steps. So, in the first phase a deblockade of immunocompetent, misprogrammed effector cells, primarily macrophages and T cells, can occur, and in the second phase, a controlled stimulation of immunocytes can follow.
- a “freezing-up” of the controlled stimulated cell state i.e. a prolongation of the second phase (phase 3) is foreseen.
- the drug combination according to the invention, is used in the first phase.
- the second phase well known immunostimulators and in the third phase, the same combination as in the first phase, but at reduced concentration, e.g. 20 to 50% of the concentration, used in the first phase, are foreseen.
- Hyper- or persistently activated macrophages consume up to 10-20 times more oxygen than resting macrophages; in the presence of gamma-interferon, this O 2 -consumption increases additionally.
- the glycolysis leads via the excessive production and secretion of lactic acid to a strong acidification of the macrophage micro milieu.
- the pH-drop results in the suppression of immunocyte function.
- the impaired synthesis of Leukotrien C, D and E, additionally affected by ROI, results in an inhibited glycosylation and secretion of cytokines and immunoglobulins.
- hypoxia inflammation tissue e.g. necrotic tumor tissue
- impaired angiogenesis and hyperactivated macrophages leads to pH-drop which results in cell depression (below pH 6,8) and cell death at a continued pH-drop.
- the cell death is accelerated in the presence of oxygen as terminal electron acceptor if the cell is activated and herewith the intracellular Cai-level is increased. Therefore, under hypoxic or ischemic conditions, the glucose catabolism via the TCC/citrate cycle should be inhibited by special drugs.
- the overproduction of NADH 2 (and NADPH 2 ) which leads to an accelerated glycolytic lactate synthesis and to pH drop, can be prevented.
- BRMs have to be combined with deblocking substances, or the deblocking of immunocompetent cells has to precede other (immuno)therapeutic steps.
- the component II comprises an agent which is able to affect the cAMP/cGMP-ratio.
- One variant proposes the increase of intracellular cGMP-level.
- the increased cAMP-level arises primarily from the activation of adenylate cyclase by hyperproduced prostaglandins (PGE2/El); these prostaglandins are secreted by hyperactivated macrophages, fibroblasts and synovial cells. They activate, together with catecholarnines, the enzyme adenylate cyclase which results in cAMP-increase in cytosol.
- PGE2/El hyperproduced prostaglandins
- these prostaglandins are secreted by hyperactivated macrophages, fibroblasts and synovial cells. They activate, together with catecholarnines, the enzyme adenylate cyclase which results in cAMP-increase in cytosol.
- the intracellular cAMP-rise inhibits different cell functions of various immunocyte subclasses. Therefore the induction of guanylate cyclase and herewith the cGMP-rise in immunocompetent cells is recommended according the invention. In this way, the blocked (preinactivated) effector cells switch their function from the suppressor to the effector.
- the following agents can be used therapeutically (a) as single agents, or (b) combined with each other, or (c) combined as single agents or as mutual combinations (see (b)) with different BRMs:
- alkalizing substances such as alkali-(bi)carbonate and alkali-salts of metabolizable organic acids (e.g. Nalactate, Na-gluconate, Na-, K-citrate)
- reversible competitive inhibitors of citrate oxidation in Krebs/citrate cycle i.e. inhibitors of tricarboxylic acids in citrate cyclus (e.g. tricarballylate, methyl/ethyl-succinate, malonate etc.).
- the working mechanism is the prevention of cell (e.g. macrophage) hyperactivation in situations, associated with O 2 -deficit.
- Substances preventing phi-drop by penetrating into the cell and binding the excessive H + -ions.
- This class of substances comprises all representatives of alkaline compounds, e.g. derivatives of TRIZMA, HEPES, mono-, di- and triethanolamines, as well as chloroquine and other antimalaria drugs, further monensin and compounds which are able to release NH 3 intracellularly, such as glutamine and asparagine.
- Further pH i -increasing substances are LI-, Cs- and Rb-salts of carbonic acid and organic acids.
- the weak bases have to be used as free bases, as (bi)carbonate or as salts of metabolizable organic acids, but not as chloride, sulfate, nitrate etc. These substances can be combined with alkali-salts of metabolizable organic acids (see point (1)) and/or with inhibitors of TCC/citrate cycle.
- Inhibitors of LDH lactate dehydrogenase
- XOD xanthin oxydase
- the working mechanism is the inhibition of lactate production which prevents the excessive acidification of cytosol and extracellular milieu.
- LDH- and XOD-inhibitors can be combined with inhibitors of TCC/Krebs-cycle.
- Substances able to correct the intracellular redox-potential, e.g. fumarate/maleinate, vitamin .C, vitamin A, vitamin E, alkali (K)-ferrocyanide, Se-compounds (e.g. Na-selenite), Na-/K-thiosulfate, alkali-sulfate and compounds carrying reduced forms of mercaptylt/thionyl (-SH)-groups, e.g. glutathione, penicillamine, thiola(thiopronine), cysteine, methionine etc.
- -SH mercaptylt/thionyl
- ROI-scavengers and/or antioxidants e.g. (a) phenols such as tocopherols, flavonoids, phenolic acid plus esters, benzodioxols, lignanes (NDGA), BHT, BHA, THBP (b) amines such as tetramethyl-p-phenylenediamine (c) heterocyclic compounds such as ethoxyquinine, barbiturates, carbazols, phenothiazines, levamisole, nafazatron, naloxone and tinoridine (d) different compounds such as vitamin C, glutathione (GSH), ⁇ -carotine and vitamine A-derivatives.
- phenols such as tocopherols, flavonoids, phenolic acid plus esters, benzodioxols, lignanes (NDGA), BHT, BHA, THBP
- amines such as tetramethyl-p-pheny
- H 2 -specific antihistaminics antagonists of the H 2 -histamine receptor, e.g. cimetidine
- inhibitors of the cAMP- and cGMP-phosphodiesterase methylxanthines; e.g. theophylline or theobromine
- the immune complexes (IC) suppress—via special receptors, such as the Fc(gamma)-R and/or CR1, CR3, CRq and other receptors—both the macrophages/monocytes and NK cells and stimulate suppressor T cells (T G /Ts), the IC interaction with immunocyte receptors has to be blocked, according to the invention, (a) by the Fc(gamma)-subunit of Ig (IgG), (b) by the biotechnologically modified complement subunits (replacement of key amino acids), e.g. c3b, c3bi or clq and/or (c) by an IgG-excess.
- special receptors such as the Fc(gamma)-R and/or CR1, CR3, CRq and other receptors—both the macrophages/monocytes and NK cells and stimulate suppressor T cells (T G /Ts
- the IC interaction with immunocyte receptors has to be blocked
- a Ca-overload blocker especially cinnarizin (component I) should be combined with an antagonist of ⁇ -adrenoceptor, histamine-H 2 -receptor and/or A 2 -purinergic receptor, especially propranolol (component II).
- some selected preparations should be listed which can be used in combination with 1 , 2 or more other substances (A+B, A+C . . . , B+C, B+D . . . , A+B+C, ABD . . . ). They have a special advantage to represent -as single substances- preparations which can be directly used clinically. They can be combined -as single or as complex preparations- with BRMs.
- Ca-antagonists objective: prevention of the intracellular Ca-over-load which results in the deblockade of guanylate cyclase and 5 -lipcxygenase and in the inhibition of CaM (calcium modulin)-mediated activation of Ca-ATPase and adenylate cyclase).
- diclofenac-Wolff-25/50 (05.142) or diclo-OPT 50, 100 retard (05.143) or diclophlogent (05.144)
- indometacin indo Tablinen (05.170) or indomat retard-rqatiopharm 75 (05.167) or amuno/retard (MSD) (05.129)
- ketoprofen alrheumun (05.128)
- 6.1 drugs improving the mercaptyl-/thionyl-, sulflhydryl-/disulfide-ratio (a) acetyl cysteine (23.119) or acetylcystein-ratiopharm 100/200 (23.120) (b) metalcaptase 150/ ⁇ 300 (05.201) or trolovol (05.206)
- 6.2 reducing drugs cebion (83.099) or cedoxon Cassis (83.100) or cetebe (83.102) or resochin (05.203) or quensyl (05.202) or tauredon (10/20/50).
- the first two drugs are recommended ecially for their oral administration.
- methylxanthines e.g. theophylline
- the working mechanism on the cellular level corresponds to that of org. nitrates; In both cases, the activity of guanylate cyclase and herewith the intracellular cGMP-level is increased.
- carboanhydrase-blocker e.g. acetazolamide (due to the impact on the pHi, on the glycolysis, gluconeogenesis and TCC/Krebs (citrate) cycle, as well as due to the depression of the glycolysis inhibiting FPK/fructose phosphate kinase): diamox retard (67.151) or diamox (39.006)
- oxygen carriers objective: an improved O 2 -transport to the hypoxic inflammatory tissue
- oxoferin or TCDO titanium dioxide
- TCDO titanium dioxide
- Oxoferin and TCDO can be combined with ascorbate, succinate and/or fumarate.
- PTH parathormone-antagonizing drugs
- adenylate cyclase and cAMP immunosuppressive like e.g. glucagon, histamine (via H2-receptor), adenosine, PGE2, noradrenaline (via ⁇ 1-adrenoceptor), adrenaline and isoproterenol (via ⁇ 2-adrenoceptor).
- the macrophages express receptors for (a) insulin (b) glucagon (c) histamine (d) serotonine (e) parathormone (f) calcitonine (g) somatotropine (h) somatostatine (i) PGE2 (j) cAMP (k) ⁇ -adrenoceptor (l) neuropeptides (endorphine) (m) arginin-vasopressin, and (n) transferrin.
- Li-aspartate Lithium-aspartat-Dragees 120 (70.235)
- Especially recommendable are: in the group 1 1.3, in the group 5 hanooxygen and in the group 6 6.1a and/or 6.2. These preferred combinations can be further combined with 4, 12, 17 and/or 18, 7, 8, and 10.
- An especially preferred combination comprises cinnarizine as component I and propranol as component II.
- the conventional stimulation e.g. by BRMs can be supported by sub-dosed 11 and/or low-dosed lymphokines (e.g. IL-2, gamma IFN).
- ⁇ -blockers are able to focus the activity of the physiological agonists noradrenaline (norepinephrine) and adrenaline (epinephrine) on the alpha1- and alpha2-adrenoceptor which favours cell activation (cGMP-rise and cAMP-drop).
- a combination of agents with a double impact on Ca i 2+ -level i.e. by increasing Ca 2+ -influx and by maintaining the so elevated Ca i 2+ -level in cytosol through the later blockade of Ca-channels
- Such drug combinations comprise on the one hand alpha-sympathomimetes, Ca-agonists and ⁇ -blockers, and on the other hand Ca-channel blockers (Ca-antagonists, such as nifedipin, verapamil and diltiazem).
- Examples of cGMP-increasing compounds are organic nitrites and nitrates, i.e. esters of the nitrous and nitric acid, such as amylnitrite, nitroglycerol, isosorbitnitrate and 5-isosorbitmononitrate, further Na-nitroprusside and parasympathomimetics; the latter can be subdivided in 3 groups: (a) choline ester (e.g. carbachol, bethanechol, metacholin); (b) alkaloids with parasympathomimetic activity (e.g.
- inhibitors of choline esterase reversible inhibitors: physostigmin, neostigmine and pyridostigmin; irreversible inhibitors: fluostigmin and tetrastigmin.
- a preparation consisting of (I) an agent, eliminating the hyperactivated effector cells, and (II) of alloreactive cells with preprogrammed cell death.
- the working mechanism of this preparation is based on the replacement of “handicapped”, misprogrammed immunocompetent cells of the patient by the corresponding, in vitro pregenerated (specifically tailored) autologous or homologous/allogeneic immunocompetent cells, a procedure called “microimmunosurgery”. This “microimmunosurgery” can be used in patients (a).
- this preparation represents a combination (a) of breaking down (by impairing or eliminating) the resistance of the pathological set of patient's immunocytes, and (b) of reinfusion of the ex vivo pregenerated (specifically tailored) immunocompetent cells.
- An additional effect is the circumvention of the critical labile interphase by allogeneic and/or autologous immunocompetent cells, pretreated in vitro in a novel way.
- graft-versus-leukemia (GvL)-effect of the non-depleted donor T cells helps to increase the resistance against the infection and the tumor; this advantage is, however, associated with the disadvantage of the graft-versus-host (GvH)-reaction which shows similar fatal complications.
- GvH graft-versus-host
- a further advantage is the replacement of the patient-compromising whole-body-irradiation and/or high-dose chemotherapy by a selective depletion of immunocompetent T cells by different Mabs and Mab-based immunoconjugates.
- This improvement opens new ways for BMT, both in patients with solid tumors and in those, suffering from autoimmune disorders.
- the preparation is suitable for a therapeutic procedure, consisting of 3 phases:
- phase II is subject of the patent application PCT/EP89/00403 (author: P. Leskovar), only phase II and III will be described here.
- Allogeneic (i.e. donor-) T cells/lymphocytes are cultured first in an isoleucine- or serum free medium to synchronize their cell cycle. Then, isoleucine or serum, respectively, is added and following progression in cell cycle (G 1 . . . S . . . G 2 -phase), the cells are treated by mitomycin C. The mitomycin-concentration is adjusted in the way to allow a 2-5 cell division before cells die (e.g. 1-5 mg/10 6 cells). Instead of isoleucin or serum, other essential cell substrates can be used for the cell cycle arrest.
- mitomycin C can be replaced by different mitomycinC-homologs, such as BMV 25282 and BMY 25067, as well as by other DNA-damaging, RNA-sparing substances, such as inhibitors of DNA-polymerase, DNA crosslinking cytotoxic agents and irradiation.
- mitomycinC-homologs such as BMV 25282 and BMY 25067
- RNA-sparing substances such as inhibitors of DNA-polymerase, DNA crosslinking cytotoxic agents and irradiation.
- the allogeneic (donor-)T cells are resuspended in a fresh medium.
- donor lymphocytes of the bone marrow and/or peripheral blood can be preincubated in a kind of one-way-MLC/MLR with the recipient lymphocytes (favorably with T-depleted or preselected MHC II-positive B cells and/or adherent cells).
- the so premanipulated donor cells are activated during the contact with patient's MHC II-positive cells (B cells, monocytes/macrophages, activated T cells), following their infusion into the patient; they secrete IL 2 and other cytokines which are reduced or absent in immunoincompetent recipients (due to the lack of mature helper T cells.)
- B cells monocytes/macrophages, activated T cells
- donor's mitomycin C-pretreated PBMs(without bone marrow) are injected in the first phase, and donor's T-depleted bone marrow is post-transfused in the second phase.
- the donor T cells, pretreated in this way, can be replaced or combined with allogeneic (donor-) LAK cells.
- allogeneic (donor-)instead of or in addition to autologous LAK cells should be used therapeutically.
- the GvHD-complication is not a problem, because the LAK cells consist of up to 90% activated NK cells and of up to 10% non-MHC-restricted CD 3 +(T) cells.
- the T subpopulations which are responsible for the alloreaction and GVHD cannot survive during the LAK-generation in vitro, due to the lack of antigen (i.e. alloantigen of recipient MHC II-positive cells).
- T cells can, however, be depleted in vitro by specific Mabs or immunotoxins for reasons of an additional security.
- L AIC cells can be pretreated in vitro by mitomycin C (or other DNA-damaging substances), as described above.
- the donor (first donor) cells have to be pretreated by proliferation-preventing mitomycin C-doses in order to be able to act as stimulator cells in the MLC.
- the responder cells (from recipient or 2 nd donor) are thereafter treated by mitomycin C (or other DNA-damaging substances) in a way, allowing the cells to divide for 2-5 times before they die.
- the autoaggressive subpopulation of patient T cells can be preeliminated by immunotoxins, consisting of cytotoxin (e.g. abrin, ricin, doxorubicin, 131 I-radionuclid) plus IL-2 or anti-Tac/II-2-R-Mab.
- cytotoxin e.g. abrin, ricin, doxorubicin, 131 I-radionuclid
- IL-2 anti-Tac/II-2-R-Mab.
- the so pretreated effector cells can be frozen, similar to the effector cells with restricted lifespan, described under (a),(b) and (c), in a medium, containing 8-15% DMSO and PVP or PEG of different concentration and mol weight (patent application DE 3812605 A1 and PCT/EP89/00403).
- An additional improvement is the separation of donor adherent cells (macrophages/monocytes) before the mitomycin C-treatment, followed by their later readdition to the mitomycin C-pretreated effector cells (T cells, lymphocytes) and infusion into the patient.
- Mitomycin C can be combined with interferon (alpha, beta, gamma), TNFalpha, DMSO, vitamin A and E, as well as the (re)differentiation substances, such as butyrate.
- Patient's lymphocytes can be clonally expanded in vitro into tumoricidal CTLs and plasma cells by mitogenic lectins (PHA,ConA) and mitogenic antibodies (anti-CD3/Ti, anti-CD2/T11).
- PHA,ConA mitogenic lectins
- anti-CD3/Ti, anti-CD2/T11 mitogenic antibodies
- This in vitro postexpansion comprises only the blastogenically pretransformed T and B clones, i.e. memory T and B cells. Since tumor patients have a persistent contact with tumor cells and AIDS/ARC/LAS-patients with HIV and opportunistic infections, respectively, their blood contains corresponding memory cells.
- these memory cells can be directed toward CTLs (CD8 + , and CD4 + ) or Ts cells; this opens new ways for their therapeutic use (a) in tumor- and AIDS-patients, and (b) in patients with autoimmune disorders.
- T cells in vitro clonally postexpanded patient's lymphocytes
- the expansion of CTLs can be achieved e.g., by the PHA-treatment for 3-6 days.
- the autotolerant Ts cells, necessary for the therapy of autoimmune disorders, can be generated e.g. by the treatment with PWM for 7 days or with the PHA for 3-4 weeks.
- the CD 8 +-rise is accompanied by a CD4 + -drop.
- Ts cells can be cultured for more than 6 months under following conditions: 2 times weekly, IL 2 is added to the medium and cells are restimulated by feeder cells and PHA every 2 weeks. These cells suppress the proliferation of autologous and heterologous CD4 + T cells when stimulated by PWM, OKT 3 or tetanus-toxoid.
- Ts cells can be generated in vitro in the presence of PGE2, anti-IL1, anti-IL2, anti-IL4, cyclosporinA, rapamycin and/or FK506.
- the Ts-depleted cytotoxic effector cells needed in the tumor and AIDS/ARC-therapy, can alternatively be enriched by the elimination of CD8 + cells (by means of Mabs or immunotoxins).
- the spared CD4 + T cells are able to induce in vivo new CTLS; this process is accelerated by anti-PGE2, anti-lipocortin/macrocortin and anti-TGF-beta.
- a healthy donor can be preimmunized (a) ,with a viral antigen (8p 120) and (b) with mentioned lysate.
- T and B cells The so generated clonally postexpanded allogeneic memory cells (T and B cells) can be treated by mitomycin C, washed and injected into the AIDS-patient.
- Atherosclerosis and other coronary diseases show an autoimmune genesis (our own experiments, reports of others, e.g. W. Hollander); therefore, the agent(s), based on “microimmunosurgery”, are able to replace or support the “conventional” treatment.
- hyperactivated B or T or both B and T cells of atherosclerotic patients are depleted/inactivated by means of “microimmunosurgery”. It is advantageous to replace them by the in vitro pregenerated Ts fraction.
- These Ts cells can be generated by a simple, 3-5 week incubation of patient's PBMs with ConA or PHA.
- the patient can be treated by special preparations which inactivate the hyperactivated macrophages; they consist of Fab/F(ab′) 2 -subunits (labeling) or immunotoxins (depletion), directed (a) against the (acid-labile and acid-resistant) Fc(gaTnma)-receptor, (b) against the complement receptor (CRT, CR3), (c) against the scavenger/AcLDL-receptor (I and II), (d) against the gamma-interferon-receptor and /or (e) against the LPs/endotoxin-receptor.
- the biotechnologically synthesized receptor per se or its subunits can be used therapeutically.
- denatured e.g. heat-denatured
- complement subunits clq, c3b, c3d etc.
- biotechnologically produced defect C-components can be used; they can be combined with antioxidants (vitamin E,A, probucol).
- antioxidants vitamin E,A, probucol.
- An alternative way comprises a combination (a) with Ca-antagonists/Ca-channel blockers (verapamil, nifedipin, dilthiatem), (b) with cGMP-increasing substances (e.g. Na-nitroprusside, org. nitrates), and (c) with pHi-raising substances.
- Ca-antagonists/Ca-channel blockers verapamil, nifedipin, dilthiatem
- cGMP-increasing substances e.g. Na-nitroprusside, org. nitrates
- pHi-raising substances e.g. Na-nitroprusside, org. nitrates
- the protracted or repeated microimmunosurgery includes the prevention of neutralizing antibodies against xenogeneic (mostly murine) Mabs and Mab-based immunoconjugates by substances, specified in the patent application PCT/EP89/00403, as well as by some procedures, described here:
- hyperactivated, suppressive macrophages can be inactivated as follows:
- Ts -stimulating substances anti-HLA-DR-Mab, anti -LFA- lbeta-Mab, cyclosporinA, corticosteroids, FK 506, rapamycin, ConA
- Tc(CTL)-promoting substances anti-HLA-DQ-Mab, anti-LFA-alpha-Mab, cyclooxygenase-inhibitors such as aspirin, indomethacin, anti-PGE-Mab etc.
- Tc instead of Ts cells can be observed in vitro also when adherent cells are removed.
- This technique is based on the effect of ex vivo specifically tailored effector cells on the disease regression; the patient's immunologic resistance has to be temporarily reduced by anti-CD8-Mab and/or anti-CD3-Mab (in the case of tumor- and AIDS-patients) and by anti-CD3-Mab (in patients with autoimmune disorders):
- the therapeutic efficiency in tumor patients is further increased if patient's tumor cells are incubated in the presence of gamma-interferon, TNFalpha and/or 5-HETE in order to induce MHC I and/or MHC II-postexpression on the cells and are then reinjected along with patient's specifically tailored, in vitro postexpanded memory cells.
- a further increase in efficiency can be achieved by the confusion of patient's glutaraldehyde-pretreated macrophages which have been preincubated with tumor antigen.
- An additional advantage is the confusion of patient's inactivated (preirradiated or glutaraldehyde-pretreated) leukocytes (PBMs) which results in the induction of antiidiotypes, directed against patient's Ts cells.
- PBMs leukocytes
- the infusion of hybridoma cells, based on patient's tumor cells and MHC II-positive autologous and homologous cells is advantageous, as well.
- LAK/TIL-techniques can be further improved by adding mitomycin C-pretreated allogeneic (donor) T cells to LAK or TIL cells. This increases the number of lymphokine-secreting cells which is especially important for the TIL-technique.
- premanipulated allogeneic cells are able to play a similar positive role in bone marrow recipients.
- the preexpanded allogeneic cells can be used also in the treatment of autoimmune disorders and GvHD, if they are pretreated by DNA-damaging agents.
- the RES-elimination (99%) of LAK and TIL cells due to their “xenogenization” during the ex vivo manipulation can be reduced, according to the invention, by addition of alpha2-macroglobulin, antitrypsin and/or cortisone to the medium.
- a variant of the described procedure renders the externally controlled in vivo production (a) of cytokines (e.g. TNFalpha, IL-1, IL-2, IL4, IL-6, IL-3, G-CSF, M-CSF, GM-CSF), (b) of hormones (e.g. insulin, parathormone etc.), and (c) of other physiologically important cell factors possible.
- cytokines e.g. TNFalpha, IL-1, IL-2, IL4, IL-6, IL-3, G-CSF, M-CSF, GM-CSF
- hormones e.g. insulin, parathormone etc.
- the principle is the transfection of donor specific recipient T cells by corresponding, these cytokines or hormones encoding genes; the preselection of alloreactive, donor-specific recipient T cells can be achieved by a (repeated) one-way- MLC (stimulator cells: donor-PBMs; responder cells: recipient-PBMs
- transfected recipient T cells After the reinfusion of the transfected recipient T cells, these can be repeatedly reactivated in vivo to secrete cytokines or hormones by injecting i.v. inactivated (mitomycin C-pretreated or preirradiated) donor-PBMs.
- i.v. inactivated donor-PBMs After the in vitro pregeneration of autologous, alloreactive T memory cells, directed against donor A, donor B, donor C etc., different functions can be transfected donor-dependently into these recipient memory cells and “recalled” in vivo, following the reinjection of these manipulated autologous cells into the recipient. By the intratumoral injection of these cells, the effect can be localized to the tumor tissue.
- a similar in vivo “switching on” of the desired function can be achieved by the following procedure: the recipient T cells are first primed in vivo by a model antigen and then clonally postexpanded in vitro in the presence of the same antigen. In the next step, these cells are transfected by the gene of interest, e.g. cytokine- or hormone encoding gene(s) and reinjected into the recipient, favorably after the temporary depletion of recipient's immunocompetent cells. Later restimulation of the recipient by the same model antigen “turns on” the desired (“transfected”) cell function.
- the gene of interest e.g. cytokine- or hormone encoding gene(s)
- reinjected into the recipient favorably after the temporary depletion of recipient's immunocompetent cells.
- Later restimulation of the recipient by the same model antigen “turns on” the desired (“transfected”) cell function.
- Representatives of such antigens are tuberculin and other antigen
- transplantation (a) of organs (b) of bone marrow and (c) of mitomycin C-pretreated, hormones (e.g. insulin) and cytokines-secreting allogeneic or xenogeneic cells and hybridomas can be essentially improved by the following procedure: First, the immune resistance of the recipient must be temporarily down-regulated (“broken”) by specific antibodies (anti-panT- or anti-CD 8 -Mabs) or Mab-based immunotoxins. Then, the in vitro pregenerated suppressor T cells (Ts)(see above! are reinjected, immediately before the transplantation.
- hormones e.g. insulin
- the main advantage over the “conventional” grafts is that here—in contrast to the “conventional” grafts—the recipient is not confronted “unexperienced” with the MHC II-positive donor cells (bone marrow macrophages and B cells, as well as “passenger lymphocytes” in organ grafts) but preinjected by allotolerant Ts cells; these donor-specific Ts-memory cells direct the CD4/CD8-double positive precursor cells (inducer/transducer suppressor cells) towards the Ts-effector cells before the alloreactive Tc/CTL cells predominate. This seemingly minimal deviation in the procedure can decide about the survival of organ- and bone marrow recipients.
- Alloreactive donor-specific recipient T cells are selected and expanded in vitro by means of MLC (responder cells: recipient PBMs, stimulator cells: donor PBMs). The repeated MLC results in a 95% enrichment of these alloreactive T cells.
- the next step is the inactivation of recipient's donor-specific alloreactive PBMs or T cells by irradiation or mitomycin C: Before they are injected into the recipient, the latter must be temporarily rendered immunoincompetent (by anti-CD3- or anti-CD1- or anti-CD8-Mab).
- the principle here is the induction of anti-idiotypes in the recipient (in vivo), before this encounters MHC II-positive donor cells (bone marrow cells or “passenger lymphocytes”). Therefore, this induction of anti-idiotypes has to be carried out several days before the real transplantation.
- MHC II-positive cells B cells, macrophages
- Ts cells allogeneic cells
- MHC II-positive cells can be pregenerated in vitro by a kind of MLC (responder cells: recipient-PBMs, stimulator cells: donor-PBMs), frozen and during or after the transplantation repeatedly reinjected into the recipient.
- the precursor cells can be directed toward Ts cells by the addition of anti-HLA-DR- and/or anti-LFA-lbeta-Mabs.
- Tc/CTLs can be induced in the presence of anti-HLA-DQ- and/or anti-LFA-lalpha-Mabs.
- MHC II-positive APCs (“passenger lymphocytes”), which is critical for the graft failure, can be prevented by the addition of anti-HLA-DR-Mab or the corresponding Fab/F(ab′) 2 -subunit and/or Ca-channel blocker (verapamil,nifedipin, dilthiazem).
- a further improvement of the above discussed LAK/TIL-technique can be-achieved (a) by co-infusion of mitomycin C- preinactivated allogeneic, MHC II-positive cells (B cells, adherent cells), and (b) by the addition of sub-dosed corticosteroids and/or serum proteinase inhibitors (alpha2-macroglobulin or alphal-antitrypsin) to the medium during LAK or TIL generation.
- the so modified culture medium prevents the in vitro xenogenization of LAK and TIL cells and herewith their early RES-elimination in vivo.
- NK cells tumoricidal/virucidal effector cells
- NK cells tumoricidal/virucidal effector cells
- macrophages a controlled treatment of these effector cells (NK cells, T cells, macrophages) (a) by fusogenic substances in sub-fusogenic concentrations (e.g. PEG, PVP), further (b) by electrofusion under sub-fusogenic conditions (1000-5000 kHz; 10-150 V/cm 2 ) and/or (c) by proteolytic enzymes and lipases.
- hybridomas can be used, according to the invention, also to stabilize and to establish herewith new cell lines which normally wouldn't survive in vitro.
- the “conventional” anti-tumor-Mabs which are normally of the IgG-isotype, can be combined with anti-tumor-Mabs of the IgE-isotype.
- the latter can be produced in vitro by the “isotype switching” of plasma cells from the IgG- to the IgE-production; the process of “isotype switching” can be induced by addition of anti-gamma interferon and anti-IL2-Mab, as well as IL3, IL4 and IL5 to the medium.
- a simultaneous addition of anti-CD8-Mab is advantageous.
- anti-tumor-IgGs the immortalization (hybridoma formation) is carried out before and in the case of anti-tumor-IgEs after the “isotype switching” of plasma cells.
- anti-tumor-Mabs of the IgE-isotype can be constructed by the conjugation of xenogeneic (murine) anti-tumor-Mabs (more precisely: Fab/F(ab′) 2 -subunits) with human Fc-subunits.
- hybridoma cells produced before (IgG) or after (IgE) the “isotype switching” is recommended; these hybridoma cells have to be pretreated by DNA-damaging, RNA-sparing agents (e.g. MMS, mitomycin C etc.)
- anti-gamma-interferon plus IL4 (IL-3, IL-5) are directly injected into the patient; herewith the activity of T H2 cells is increased and that of T H1 cells depressed which leads to an early “isotype-switching”.
- the next strategy is the replacement of the immortalizing (transformed) partner cell (e.g. NS-1) in the hybridoma and quadroma cell by MHC II/HLA-DR-positive (allogeneic) cell.
- the hybridoma and quadroma cells can be externally switched on and off.
- the new procedure is based (a) on the in vitro pregeneration of alloreactive T cells of the recipient, directed against the donor A and further donors (donor B. donor C etc.) by means of the (repeated) MLC, (b) on the fusion of preselected alloreactive memory-T-cells with partner cells which are used for “conventiona” hybridizations (e.g.
- hybridoma cells which are well tolerated, as they are fully (in the case of human autologous plasma cells) or partially autologous (in the case of murine plasma cells), can be later reactivated repeatedly by the injection of donor-lymphocytes.
- a kind of tumor-directed “autoreactivity” can be achieved as follows: tumor cells of the patient are stimulated in vitro by gamma-interferon (TNFalpha, 5 HETE) to post-express MHC II (and MHC I) on the cell surface.
- tumor cells can be fused (a) with autologous or (b) allogeneic, MHC II-positive cells and washed thoroughly.
- a further xenogenization of patient's tumor cells can be achieved by the fusion with LPS-containing gram-negative bacteria and/or yeast cells. After their inactivation, these manipulated tumor cells are injected into the patient who has to be rendered immunoincompetent temporarily (by injection of anti-CD3-, anti-CD1, anti-CD2- or anti-CD8-Mab). In this way, the autoaggression against tumor cells can be induced.
- Hybridoma cells arising from patient's tumor cells and MHC II-positive allogeneic cells (e.g. allogeneic B cells) are able to accelerate the induction of the autoaggressive reaction against tumor cells if they are combined with (repeated) injection of inactivated PBMs from that donor whose MHC II-positive cells were used as partner cells for the hybridization with patient's tumor cells (see above).
- MHC II-positive allogeneic cells e.g. allogeneic B cells
- the same techniques can also be used for the improvement of conventional vaccines (e.g. against bacterial and (retro)viral infections, including HIV). So, the efficiency of conventional vaccines is essentially increased if they are combined with anti-CD8-Mabs (or the corresponding immunotoxins) and/or with complete and incomplete (Freud)-adjuvant. It is also advantageous to combine the 1 st vaccination (“priming”) but not the 2nd vaccination (“boosting”) with anti-B-cell-Mabs (e.g. anti-CD19-, anti-20-, anti-CD21-, anti-CD22-Mab).
- primary but not the 2nd vaccination
- anti-B-cell-Mabs e.g. anti-CD19-, anti-20-, anti-CD21-, anti-CD22-Mab.
- the in vitro preformed immune complexes composed of pathogen and anti-pathogen (IgM-isotype) with or without bound complement or complement-subunits (clq, c3b/c3d etc) can also be promising.
- the efficacy of the vaccine can be improved by IgE-inducing IL3, IL4, IL5 and anti-gamma-interferon.
- the above discussed GvHD can be prevented also by autologous PBMs which have been also preactivated by a repeated MLC.
- the responder cells are autologous (recipient) PBMs and stimulator cells the allogeneic (donor) PBMs; the latter have to be preirradiated or mitomycin C-pretreated.
- the repeated co-incubation of donor- and recipient-PBMs leads to the generation of highly efficient alloreactive memory cells which are able to eliminate the GvHD-causing donor-T-cells.
- the autologous BMT can be improved: (a) by preelimination of suppressor-T-cells in vitro, e.g. by anti-CD 8 -Mabs or corresponding immunotoxins, (b) by in vitro preactivation of effector cells, (c) by addition of autologous and/or allogeneic LAK-cells (the allogeneic LAK-cells can, but need not be predepleted of CD 3 -positive cells), (d) by addition of autologous, CD8 + -depleted PBMs to the autologous bone marrow cells (the PBMs should be preactivated in a tumor-specific way), as well as (e) by the addition of allogeneic, favorably preactivated allogeneic PBMs which have to be pretreated by mitomycin C or other DNA-damaging and RNA-sparing substances in order to confer to the alloreactive subpopulation a restricted lifespan.
- the stepwise addition of increasing doses of anti-CD8- or anti-CD3-Mab plus complement (or of corresponding immunotoxins) to the patient's PBMs allows the determination of the critical T cell number/ml which directs the immune response from suppression to stimulation (deblockade) of T4 and B memory cells.
- the so premanipulated autologous PBMs mimic the favorable clinical situation, when autologous marrow cells are collected during remission (PR or CR) and not during relapse.
- LAK dells show the special advantage that they cannot be contaminated with (tumor-specific) Ts cells; a further advantage is the lymphokine-production by autologous T cells, directed against allogeneic LAK-cells, which is especially important for immunocompromized recipients.
- the LAK-cells of one or more persons could be frozen and used for different patients, especially after an anti-CD3-pretreatment (“standardized LAK-cells”).
- the restricted lifespan of hybridoma cells can be achieved by the change of the ratio of partner cells during hybridization, instead of the treatment of hybridoma cells with DNA-damaging and RNA-sparing agents. it concerns the chemical (PEG) and viral (SV-40) fusion, as well as the electrofusion.
- hybridoma constructs can be achieved, similar to that, achievable by low-dose mitomycin C.
- instable cell lines which don't grow ex vivo, with transformed cells, these cells can be “stabilized” and are able to survive in vitro.
- the fusion of lymphokine and hormone-producing cells with transformed cells, followed by the mitomycin C-treatment opens for the first time the possibility of a direct in vivo implantation of cytokine and hormone-producing cells (e.g. insulin production).
- cytokine and hormone-producing cells e.g. insulin production.
- the so pretreated secretory cells die after a limited number of cell divisions and can be substituted by a new set of premanipulated cells; this allows an efficient control of the cytokine and hormone level.
- the tolerance against such secretory cells can be achieved (a) by the simultaneous treatment with immunosuppressive substances (cytotoxic agents, sub-dosed anti-CD4- or anti-MHC II-Mab), (b) by cell implantation in thymus and/or (c) by “autologization”, i.e. by use of autologous partner cells for hybridization.
- immunosuppressive substances cytotoxic agents, sub-dosed anti-CD4- or anti-MHC II-Mab
- autologization i.e. by use of autologous partner cells for hybridization.
- T cells patient's lymphocytes
- T cells mitomycin C-pretreated donor-lymphocytes
- T cells mitomycin C-pretreated donor-lymphocytes
- a part of transfected cells can carry the gene for the IgG-isotype and the other part that for the IgE-isotype.
- the later “switching on” of the cytokine and antibody-production occurs by the injection of inactivated donor lymphocytes.
- the patient's T cells in general, not only his donor-specific alloreactive T-subclones can be transfected in vitro with cytokine and/or anti-HIV-antibodies-encoding genes, and reinjected into-the patient. Again, the later “switching on” of the in vivo cytokine and antibody production occurs by the injection of donor-lymphocytes; the system works because patient's lymphocytes always contain T cells which are alloreactive against the donor.
- the ratio between “positive” (Th andTc/CTL) and “negative” (Ts) memory cells can be increased as follows: (a) In the 2 nd phase, i.e. 4-6 days after the vaccination, the couterregulation of persistently activated macrophages can be delayed by Ca-channel blockers and macrophages-inactivating measures (ROI-inactivating agents, such as retinol, tocopherol or carotinoids, glutathione, ascorbate, radical-scavengers). (b) With anti-HLA-DQ (not DR) and anti-LFA-lalpha (not beta), the (Th+Tc)/Ts-ratio can be positively influenced.
- ROI-inactivating agents such as retinol, tocopherol or carotinoids, glutathione, ascorbate, radical-scavengers.
- ROI-inactivating agents such as retinol, tocopherol or carotinoids, glutathione
- the efficiency of vaccines can be also increased by anti-PGE 2 (El) and by PGF 2 alpha.
- the resistance against pathogenic microbes can be increased as well, if first contact with antigen structures of the pathogen (e.g. gp 120/160 or gp 41 of HIV) occurs via alveolar macrophages which prevents its early contact with Ts cells (as in the case of the i.v. administration). Therefore, the sensibilization by aerosol-spray as the only or at least first step (“priming”) is recommended.
- the Ts generation should be prevented by anti-PGE2- and anti-interferon-Mabs.
- IgE.antigen:IgE-complexes are able to activate the IgE-R-expressing cells (macrophages, NCF-A-, ECF-A- and kininprotease-secreting mast cells) in the critical early phase.
- Tumor patients can be treated by inactivated hybridoma cells, arising from patient's tumor cells and allogeneic (donor) cells of the same origin, i.e. the same organ like tumor.
- An example are leukemia cells, fusioned by the same lymphocyte-subclass of the healthy donor.
- the TS(T G ) cells can be stimulated in vivo by the successive infusion of IgG and the corresponding antigen.
- autologous lymphocytes can be primed in vitro by a model antigen and the resulting memory cells transfected by cytokine and Mab-encoding genes. After the reinfusion they respond to the resensibilization by the same model antigen. The strongest response show the cutaneous antigens. It is advantageous to use the preexistent memory cells which stem e.g. from previous vaccinations (e.g. tuberculin) or sensibilization (DNCB, DNBB, TNBS) .
- previous vaccinations e.g. tuberculin
- naive Th-cells an APC-independent activation of naive Th-cells is possible which can be of relevance in immunosuppressed AIDS and tumor patients.
- the tumoricidal and/or virucidal effector cells can be activated in a novel way by conjugating Mabs or their Fab/F(ab′) 2 -subunits, recognizing (a) cytokine receptors or (b) growth factors (EGF, IGF, PDGF etc.) with spacer molecules, e.g. the CH 2 )n-chain or D-GL.
- spacer molecules e.g. the CH 2 )n-chain or D-GL.
- D-polylysine as spacer molecule is of special interest, as it is a tolerogen and as it facilitates—through the positive charge—the approach of the Mab-construct to the target cell.
- spacer molecules e.g. the CH 2 )n-chain or D-GL.
- spacer molecules e.g. the CH 2 )n-chain or D-GL.
- D-polylysine as spacer molecule is of special interest, as it is a tolerogen and as it facilitates
- LAK cells consist to 90% of NK cells and to 10% of non-MHC-restricted CD3 + -cells and are free of alloreactive, GvH-inducing T cells
- the allogeneic LAK cells can be used to circumvent the immunoincompetent phase which is critical for later relapses (a) in bone marrow recipients and (b) in patients, immediately following tumor surgery.
- LAK cells can be depleted of T cells before their infusion into the patient.
- LAK cells can be frozen by a special procedure (with PEG/PVP-addition to DMSO), preserving their preactivated state.
- Atherosclerosis seems to be induced by an autoimmune primer, including hyperactivated macrophages.
- the latter can be depressed (a) by corticosteroids (b) by Ca-antagonists (c) by masking the Fc and CR1/CR3-receptors with Fab/F(ab′) 2 -subunits of the anti-receptor-Mabs (d) by ROI-reducing agents and radical-scavengers, and (e) by anti-CD19(CD20, CD21, CS22)-Mabs (temporary depletion of CIS-producing B-cells).
- the immunocytes are exposed (a) to hypoxic/anoxic and/or (b) acidic micromilieu.
- other electrone acceptors e.g. ascorbate, dehydro-ascorbate, (poly)unsaturated fatty acids.
- the low pH in the inflammation tissue inhibits immunocompetent cells. By the pH-rise, the H + /Na + -pump of immunocytes must be relieved.
- pH i ,-raising agents examples include quaternary bases and their salts (carbonate, citrate, maleate), further TRIZMA (as base or as salt), THAM/tromethamine/trometanol, mono-, di- and triethanolamine, etc.
- An intracellular pH-rise to 7.3-7.6 is the prerequisite for cell proliferation.
- the O 2 -deficit is associated also with prostaglandin instead of leukotrien-synthesis.
- the proteases are able to switch the cell from the suppressor- to the effector function.
- the GEF glycoslation enhancing factor
- a kallikreinlike kinin-protease prevents the GIF (glycosylation inhibition factor)-induced immune suppression; a membrane-associated serine-protease is directly involved in the process of cell activation.
- the lipases are able to activate -via lysophosphatideimmunocytes (macrophages, NK-, K-, T-cells). This activation results partly from the mimicking of membrane-associated phospholipases (PLC, PLA2).
- PLC membrane-associated phospholipases
- mucopolysaccharidase is similar to that of proteases. Therefore, the deblockade of immunocytes by proteases, lipases and mucopolysaccharidases is recommended, both per se or in combination with the above described cell activators.
- Interferons TNFalpha and TGFB switch the cell from proliferation to dedifferentiation. Their pathologically increased levels exert an antiproliferative effect on precursor cells, depressing in this way the recruitment of immunocompetent cells.
- Such pathologically raised levels of cytokines can be measured in AIDS- and tumor-patients, but also in autoimmune disorders and persistent infections. Therefore, these antiproliferative cytokines should be neutralized by specific Mabs.
- the immune response can be improved by special conjugates, consisting of the Fab/F(ab′) 2 -subunit of tumor- or HIV-specific Mabs of murine origin plus the Fc epsilon-subunit of human origin.
- membrane-associated immunorelevant structures e.g. MHC II, MHC I, CD 4 , CD 8 , B 2 m
- MHC II, MHC I, CD 4 , CD 8 , B 2 m become immunosuppressive if they are shedded into the plasma.
- the neutralization of such solubilized membrane structures by specific Mabs helps to prevent their immunosuppressive effect.
- a further advantage is the use of anti-HLA-DQ- and anti-LFA-lalpha Mabs.
- tumor cells are treated in vitro by IFN gamma and/or TNF allpha (postexpression of MHC II and MHC I), inactivated by anti-HLA-DQ- and/or anti -LFA-lalpha or their Fab/F(ab′)-subunit and reinjected into the patient.
- the tumor cells can be fusioned (in the presence of PEG) with autologous and/or allogeneic MHC II-positive cells (B cells or macrophages)., treated by anti-HLA-DQ- and/or anti-LFA-lalpha-Mab and reinjected into the patient. Both alternative procedures include the immune reactivation of the patient as an important step.
- the principle of the here discussed novel tumor therapy is to combine (a) the temporary breaking of resistance of immunocompetent cells with (b) the reinfusion of in vitro pregenerated tumor-specific T cells. It is essential that these cells are memory cells; according to laws of the so-called “restricted” CML (CML to non-MHC-molecules), only the blastogenically pretransformed T cells are able to induce in vitro the response to the (soluble) antigen in question.
- CML restrictive CML
- the tumor-specific T cells are capable to induce in vivo a kind of autoimmune reaction against the tumor antigen if they are generated as follows:
- T cells Patient's lymphocytes (T cells) are postexpanded in vitro polyclonally, e.g. by PHA, then the CD 8 -positive Ts cells are eliminated e.g. by specific Mabs or immunotoxins, and the residual CD4-positive T cells are reinjected into the patient, along with the memory cells. In vivo, these T4 cells are able to induce the CTLs with specificity for tumor cells. Instead of the CD8 + -postdepletion, the inducer-suppressor subpopulation can be inactivated in advance by a 500 Rad-preirradiation.
- T cells patient's lymphocytes
- his malignant cells after these have been induced to post-express the MHC II-antigen.
- organ- and bone marrow transplantation can be essentially improved if the donor organ, more precisely its “passenger lymphocytes”. or donor bone marrow cells, respectively, are pretreated in vitro by anti-HLA-DR- and/or anti-LFA-lalpha-Mabs (or their Fab/F(ab′) 2 -subunit)
- the MHC-postexpression on “passenger lymphocytes” can be depressed by Ca-antagonists (e.g. verapamil, nifedipin, diltiazem) or by anti-mitogenic substances (colchicin, domecolcin, gliotoxin).
- Ca-antagonists e.g. verapamil, nifedipin, diltiazem
- anti-mitogenic substances colchicin, domecolcin, gliotoxin.
- This MHC II- postexpression, following the organ surgery seems to be critical for the later organ rejection.
- the bone marrow cryopreservation can be essentially improved by the addition of PEG and/or PVP of dofferent mol weight to DMSO.
- An interesting novel approach in tumor therapy is the use of hybridoma cells with restricted lifespan, constructed of tumor-specific immunocytes and mitomycinC-pretreated immortalized partner cells.
- One variant proposes (a) to fuse the pregenerated immunocytes with myeloma cells which are routinely used for hybridization purpose, and to treat the resulting hybridoma cells with mitomycin C.
- (b) The other possibility is to fuse the pregenerated immunocytes with mitomycinc-pretreated myeloma partner cells, or(c) to use the commercially available non-transformed fibro-blasts or embryonal cells instead of myeloma cells as partner cells.
- mitomycin C other cell proliferation-limiting agents or a controlled cell irradiation can be foreseen.
- a typical mitomycin-concentration is 10 ug/ml, a typical incubation time 18 hours (for 5 ug/106 cells).
- hybridoma cells based on tumor-specific plasma cells, CTLs, NK-, K/ADCC-cells and preactivated macrophages can be constructed. They can be kept in culture or frozen (PEG and/or PVP addition to DMSO); the preservation of the preactivated state by this improved cryoprotective mixture is of special relevance for repeated infusion.
- the use of the HAT- or HAs-medium guarantees a sufficient selection of the hybridoma cells; a time-consuming cloning is not necessary.
- anti-CD 15-, anti-CD 14-, anti-CD11c- and anti CD 11b-Mates examples: anti-CD 15-, anti-CD 14-, anti-CD11c- and anti CD 11b-Mates.
- the Mabs can be replaced by their conjugates with cytokines, radionuclids and/or cytotoxic agents to increase their efficacy.
- the Mabs can be also replaced by Fab/Fab′) 2 -subunits, masking—not eliminating—B cells and macrophages.
- An essential progress in tumor therapy is the introduction of tumor cells with post-expressed MHC II, induced by interferons and/or TNFaipha. Before the reinjection, tumor cells are inactivated by mitomycin C, by heat or formaldebyde and/or glutaraldehyde.
- hybridoma cells arising from the fusion (in 20-40% PEG) of tumor cells with patient's MHC II-positive cells (macrophages, B cells), can be used. This cell fusion can be carried out with non-viable cells and doesn't include cell cloning.
- a new principle in tumor therapy is the mimicking of the strong immune reaction, observed (a) during graft rejection and (b) during the autoimmune reaction.
- the immune system encounters the antigen (the allogen in organ grafts and the autoantigen in autoimmune reaction), first in its “processed” form, i.e. in context with the MHC II-complex. This favours the generation of Th and Tc cells and depresses the Ts cells being able to interact with soluble antigens directly, i.e. without antigen processing.
- the in vivo situation in graft recipients and patients with autoimmune disorders should be mimicked in tumor-excised cancer patients by the injection of patient's tumor cells with the post-expressed MHC II-antigen.
- An additional improvement of the therapy is the use of the above-mentioned constructs, consisting of the Fab/F(ab′) 2 -subunit of tumor-specific IgG or IgM, plus Fc-subunit of IgE, alone or combined with IL4.
- IL2/Tac/CD25- and T11/CD2/Leu5a/IL4-receptor further various receptor: ligand-systems of cooperating immunocytes (integrins such as CD2: LFA3, ICAM-1: LFA1), or immunorelevant structures in general, such as CD4, CD8 and MHC II.
- immunocytes such as CD2: LFA3, ICAM-1: LFA1
- immunorelevant structures such as CD4, CD8 and MHC II.
- One procedure comprises the admixing of donor lymphocytes, whose lifespan has been predetermined (preprogrammed) by a special 3-step-procedure, to the donor bone marrow cells.
- the patient gets immunocompetence, until he restores his own immune response; he is continuously able to combat infections and to prevent the reinduction of tolerance against residual tumor cells and herewith the later relapses.
- the donor T cells can provoke the GvH-disease, they die due to the preprogrammed cell death.
- the cell death can be predetermined by a controlled in vitro pretreatment of donor T cells with DNA-crosslinking agents.
- the preprogrammed cell death of immunocompetent donor T cells can be achieved also—via the intracellular irradiation—by the in vitro incorporation of radiolabeled, i.e. radionuclid/radioisotope-containing nucleosides, nucleotides, free bases and their derivatives into the DNA.
- radiolabeled nucleosides are: 2′-deoxyuridine-2-′ 14 C, further 2′-deoxyuridine-5- 3 , 2′-deoxycytidine-S- 3 H and 5-bromo-2′-deoxyuridine-2-′ 14 C. All nucleosides and nucleotides, labeled by various redionuclides (e.g. from H, P, S and other) and added to the culture medium, are subject of this patent application.
- the prelabeled immunocompetent donor's T cells added to the T-depleted donor-bone marrow, can be treated after the restoration of patient's own immune system ex vivo by UV-irradiation to support additionally the self-destruction of these cells by radio labeling.
- a similar technique of radionuclide-incorporation into the cell nucleus can be used, according to the invention, for killing of tumor cells in situ.
- the carriers of the radioactive, tumor-destroying radiation are not tumor-specific Mabs but (a) the tumor-recognizing TIL (tumor infiltrating lymphocytes), and (b) the tumor-specific Tc/CTL(cytotoxic T cells).
- a special advantage of the cellular over the molecular, i.e. Mab-mediated transport of the tumor-destroying radionuclides into the immediate neighborhood of tumor cells is the essentially intensity (density) of the cellular irradiation source.
- the selectivity (a) of TIL cells as carriers of radioactivity is guaranteed by the tumor-specificity of TIL-cells (Rosenberg, Anderson, Blaese), and (b)) that of tumor-specific Tc/CTL by their selective recognition of tumor antigens (TATA, TSTA, TSA).
- TIL cells belong both to the CD4-and to the CD8-positive T cells, a clear cut-off between TIL- and Tc/CTL-cells is not possible.
- TIL- and Tc/CTL-cells as carriers of tumoricidal irradiation includes radiolabeled amino acids and other radiolabeled cellular components (precursors), in addition to the radiolabeled nucleosides; they must be added to the culture medium and are incorporated into TIL- and/or Tc/CTL-cells.
- a further possibility of bridging the fatal immunosuppressive phase after the removal of primary tumor or after following the BMT is the in vitro pretreatment of donor's immunocompetent cells by photosensitive dye-stuffs (e.g. psoralen), followed by their addition to the donor's T-depleted bone marrow, and their transfusion into the recipient. Later, after having protected the patient (recipient) from infections and from the clonal expansion of residual tumor cells, these photolabeled cells are selectively eliminated ex vivo by UV-irradiation. The used technique (photopheresis/PUVA) profits of predeveloped devices. For efficiency reasons, the combination of this technique with other here described techniques is recommended.
- photosensitive dye-stuffs e.g. psoralen
- a further way is the in vitro transfection of donor's immunocompetent T cells with strongly immunogenic surface antigens, followed by their addition to the T cell-depleted donor bone marrow and by later transfusion into the recipient (e.g. tumor patient).
- the later in vivo elimination of the mature donor T cells which helps to bridge the immunoincompetent phase is carried out by antibodies, directed against the transfected membrane antigen. These antibodies can be conjugated with cytotoxins in order to increase their efficacy.
- a further modification of this technique is based on the addition of T cells of a second MHC-incompatible donor to the T depleted bone marrow of the first donor.
- the immunocompetent cells of the donor are treated first in vitro by the sub-lethal dose of the DNA damaging cytotoxic agent and/or irradiation and later in vivo after the finished mission (bridging of the fatal immunosuppressive interphase, before the restoration of patient's immune competence) by a second (lethal) dose of cytotoxic agent(s) or irradiation.
- the strong GvL-effect of the so pretreated donor bone marrow can be further intensified if the donor's immunocompetent T cells to be admixed to the donor bone marrow are predepleted of alloreactive subclones and activated in a tumor-specific or non-specific way, before they have been injected into the patient.
- the technique based on a novel type of immunocompetent T cells which is characterized by a “frozen” activated functional state, should be described briefly. Details about this novel cell type, implicating a constitutively activated state without cell proliferation, follow below.
- Cells of this novel type can be added to T-depleted donor bone marrow and must not be later on eliminated in vivo, because their ability to proliferate is genetically switched off. Characteristically for all these techniques is (a) a strongly increased GvL-effect, without a simultaneous GvH-reaction, (b) opening of new ways for histoincompatible BMT, (c) the option of an additional tumor-specific and/or non-specific preactivation of immunocompetent T cells, admixed to the T-depleted donor bone marrow, and (d) the impact on both the GvH- and HvG-reaction which minimizes the BMT-associated complications.
- the classical BMT could be replaced by the simple exchange of patient's (recipient's) T cells by T lymphocytes of the donor in patients with solid tumors. This can be carried out by an in vivo depletion of patient's T cells by specific Mabs or immunotoxins and transfusion of healthy donor T cells; the histoincompatibility problems can be overcome by the above described special pretreatment of immunocompetent T cells.
- the bridging of the fatal immunosuppressive phase, following the tumor excision or BMT can be achieved by autologous or allogeneic LAK-cells plus rIL-2. Since LAK-cells consist of ca. 90% NK-cells and of ca. 10% non-MHC-restricted CD3 + -T cells, the in vitro predepletion of CD3 + , cells is recommended in the case of allogeneic LAK-cells. Alternatively, the complete LAK-population can be treated by one of the above described cell death-preprogramming procedures. The so pretreated allogeneic LAK cells are added to the donor bone marrow before their injection into the recipient.
- a further improvement is the addition of fibroblast to the donor BM.
- the situation following BMT shows a common element with the situation of immunocytes in the limiting dilution-test, in which the added fibroblasts, by secretion of growth factors, make the growth and the survival of immunocompetent cells possible.
- This in vivo inactivation of LAK- and TlL-cells stems from the induction of lipocortin/lipomodulin by plasma corticosteriods (cortisol) and can be prevented in two ways: (1) by the constitutive, proliferation-free activation of LAK- and TlL-cells, and (2) by the transfection of LAK- and TIL-cells with the CDNA, encoding the cortisol-cleaving enzymes, such as 20alpha-hydroxysteroid-dehydrogenase and B-glucuronidase.
- T cell-activation (a) by different cytokines, such as IL-2, IL-3 and CSF-1/M-CSF, and (b) by (processed) antigen occurs in the same way, i.e. via the activation of the PI (phosphoinositol)-dependent PLC (phospholipasec) and results in the increase of the intracellular Ca, 2+ -level.
- cytokines such as IL-2, IL-3 and CSF-1/M-CSF
- antigen occurs in the same way, i.e. via the activation of the PI (phosphoinositol)-dependent PLC (phospholipasec) and results in the increase of the intracellular Ca, 2+ -level.
- the constitutively increased Ca, 2+ -level in the cell cycle-arrested cells opens a novel way of cell activation.
- a special advantage is the cell activation and the maintaining of this activated state even in the absence of the specific signal, e.g. the processed antigen in the case of helper T cells.
- the constitutively increased cai2+ -level in the cell cycle-arrested cells confers to these cells the genetically predetermined (highly specialized) function, e.g. the production of specific antibodies or the CTL- or ADCC-activity.
- a further advantage is the inner stability, i.e. the resistance against the specific or non-specific suppression by suppressor factors, such as prostaglandins (e.g. PGE1/E2) or corticosteroids, without the danger of an uncontrolled cell proliferation (because of the cell cycle-arrest).
- This goal can be reached in two ways: (a) by hybridization of cells with the desired function, e.g. plasma cells, CTL/Tc, T4/Th etc. with immortalized cells (autologous tumor cells of the patient or transformed cells of other origin), followed by the treatment of formed hybridoma cells by cell death-preprogramming techniques, as described above, and (b) by a double transfection of the cells, showing the desired function (B, T4, T8), with the sense-cDNA, encoding the constitutive cell activation plus antisense-cDNA, encoding the switching off of cell proliferation.
- the desired function e.g. plasma cells, CTL/Tc, T4/Th etc.
- immortalized cells autologous tumor cells of the patient or transformed cells of other origin
- Ad (a) The cell death-preprogramming treatment can occur either in hybridoma cells or in immortalized partner cells, before these have fused to give hybridoma cells.
- Candidates for the immortalized partner cells are those transformed cells which maintain an increased intracellular Ca i 2+ -level by autocrine or paracrine mechanisms or such transformed cells which are able to maintain—independently of external signals—the activated state either by the constitutive, ligand-dependent activity of tyrosine- or serine/threonine-kinases or by the continuing PI-conversion to PIP2.
- B,T4,T8 . . . The double transfection of the target cells, showing the desired function (B,T4,T8 . . . ) (b1) with sense-cDNA, encoding the constitutive expression of cell-activating signals, plus (b2) with antisense-cDNA, encoding the turning off of cell proliferation, creates a permanently “turned on”, non-proliferating cell which doesn't need any specific signals (e.g. processed antigen) for its activation.
- NGF nerve growth-factor
- DOPA DOPA-secreting, long-lasting, fibroblast-based cells constructs which cannot be down-regulated by plasma suppressor factors and are of special interest in the treatment of M. Alzheimer and M. Parkinson
- cytokines and growth factors-producing cell constructs which support patient's immune system, following high-dose (radio)chemotherapy and BMT, as well as (3) cell constructs, based on tumor-specific plasma cells which are able to produce anti-tumor-Mabs in situ, preventing in this way the induction of neutralizing immunoglobulins.
- the sense-cDNA encoding cell activating signals (1) the cDNA, encoding various cytokines or (hematologic) growth factors and/or their receptors, further (2) the PLC- and PLA2-encoding cDNA, (3) the cDNA, encoding different cytoplasmic serine/threonine-kinases, and (4) the cDNA, encoding various protein-kinases, such as C-kinase, Ca/calmodulin-kinase, casein-kinase II and G-kinase, are recommended.
- the prevention of cell proliferation can be achieved by the antisense-cDNA of all cell division-inducing factors.
- examples are (a) cyclinA, cyclinB 1, c-ras, c-raf, PSTAIRE, MPF, p34 cdc2 , pl3, further (b) the DNA-transcription factors like AP-1 (AP-I) and AP-2(AP-II), and (c) DNA-polymerase-alpha, PCNA and (protein)elongation factor (elF-2/elF-2p).
- PSTAIRE is a cdc2-subregion (aminoacids 42-56) and belongs, like p34 cdc2 , to the family of cell cycle-specific protein-kineses.
- the PCNA proliferating cell nuclear antigen
- the MPF stands for mitose- or M-phase-promoting-factor.
- various sense-cDNAs, encoding suppressor-oncogenes, such as plO5RB and p53 can be transfected to prevent uncontrolled cell proliferation.
- suppressor-oncogenes such as plO5RB and p53
- the uncontrolled proliferation can be switched off also by cell fusion with normal cells, expressing the wild type or the wild-type p53.
- One of the points, according to the invention, is the prevented expression of the MHC II or MHC I complex on the cell construct, achieved by the transfection of the MHC II or MHC I-encoding antisense-cDNA.
- the antisense-cDNA can be replaced (a) by ribozymes, (b) by psoralent derivatives of the antisense-oligonucleosides or—oligonucleosidemethylphosphonates, and (c) by antigen—and antisense-oligonucleotid-intercalator-conjugates.
- ribozymes called also “catalytic RNA”, over the corresponding antisense-cDNA is their irreversibility as they cleave the sense-DNA.
- the smallest and simplest self-cleaving domain of ribosome is the “hammerhead”-structure, e.g. the “structure I”, described by Uhlenbeck or the “form IV”, reported by Haselhoff and Gerlach.
- the immunotherapy of malignancies and autoimmune disorders, as well as of bacterial and (retro)viral infections is based on the same principles as the improvement of conventional vaccines and prevention of graft rejection, namely (a) on the deblockade of the hyperactivated state of immunocompetent cells and/or (b) on the elimination or inactivation of hyperactivated effector cells (“microimmunosurgery”).
- This deblockade of the hyperactivated state of immunocytes can be achieved, according to the invention, by combining agents which block the “voltage-operated” and/or “receptor-operated” Ca 2+ -channels (“component I”), with agents which reduce the intracellular cAMP or the cAMP/cGMP-ratio, respectively (“component II”).
- the “component I” comprises “classical” Ca-antagonists (Ca-channel-blockers) of all subtypes, e.g. phenylalkylamines, dihydropyridines, benzothiazepines, piperazines, quinoxalines, quinazolines (e.g. bepridil and perhexilin).
- a parallel inhibition (blockade) of alpha-plus B adrenoceptors, of H2-plus H1-histamine receptors, of A2-plus Al-adenosine receptors, of 5-HT/serotonine) receptors and/or receptors of various inflammation mediators e.g.
- bradykinin, kinin-cascade, complement-cascade, especially c5a, c4a, c3a, PAF etc. is recommended.
- Examples of preferred combinations are listed below; they can be combined with sub-dosed nitro-compounds, including molsidomine, Ca-overload.blockers, e.g. cinnarizine, Ca-antagonists, BRM and/or cytokines.
- the combination of molsidomine and nicerogoline (an alpha-blocker), with or without Ca-overload-blocker(s) (e.g.cinnarizine) is of a special interest.
- the “component II” comprises cAMP/cGMP- or cAMP-reducing agents.
- Examples are antagonists of all cell receptors which are coupled via the Gs-protein to the membrane-associat,ed adenylate cyclase (AC). This effect is increased if agonists of G p -, G i - or G o -protein-coupled receptors and/or of cGMP-increasing, Ca i , reducing nitro-compounds (e.g.
- Gs-coupled receptors whose normal, physiological agonists bind at the same time P p -,G i - or G o - coupled receptors are of a special interest. After having blocked the. Gs-coupled receptors, the Gs-coupled receptors, the endogenous ligand bind the G p -, G i - or G o -coupled receptors to a higher degree.
- B-blocker achieve 2 effects, the cAMP-drop and the cGMP-rise in cytosol of immunocompetent target cells.
- endogenous agonists are catecholamines (adrenaline and nonadrenaline), histamine and adenosine.
- the antagonists of B-adrenoceptor on immunocytes, e.g. T cells and monocytes/macrophages) cause catecholamines, primarily adrenaline, to interact with the alpha- instead of B-adrenoceptor.
- the antagonists of H2-histamine receptor make the histamine ligate the cAMP-lowering H1- instead of the cAMP-increasing H 2 -receptor.
- the endogenous agonist adenosine binds to the cAMP-depressing A1- instead of to the cAMP-raising A2-subtype P1-adenosine receptor.
- This class of substances comprises (a) some Ca-antagonists like cinnarizine, flunarizine, fendiline, bepridil, tiapamil and partly verapamil and gallopamil, further (b)sub-dosed antiarrhytmics (class I to IV), especially the combination of class IB with class III, due to the equilibrated K-efflux (class IB) and K-influx (class III) and synergism in the inhibition of Na-channel (among these agents are adrenoceptor-blockers sotalol and propranolol).
- the combination of cinnarizine and propranolol is of a special interest.
- the central point of this invention is the combination of agents which decrease the cAMP-level or the cAMP/cGMP-ratio with those which block the “voltage-operated” and/or “receptor-operated” Ca-channels.
- the “component I” and “component II” are identic. So, some special nitro-compounds, such as syndnonimine derivatives (e.g. mosidomine), show both effects (cGMP-rise, Ca i -decrease); they are also subject of this invention.
- the principle of this in vivo inactivation or depletion of hyperactivated effector cells is the “microimmunosurgery”, a new technique which would compete with or complement the gene-therapy in future.
- the principle is the selective inactivation of disease-inducing and disease-maintaining lymphocyte-subclones by the combination of (b1) panT- or T subclass-specific Mabs or Mab-derived immunotoxins, plus (b2) alloreactive-T cells of a healthy donor.
- This combination of humoral (Mab) and cellular (allogeneic T cells) technique is able to increase essentially the efficiency of the Mab-mediated depletion of pathogenic immunocyte-subclones, as shown in animal model.
- Ts CD 8 -positive
- HLA-DR(MHC II)-positive T cells By the combination of anti-CD3- or anti-CD8-Mabs plus allogeneic donor-PBM/PBL or donor T cells whose cell death is “preprogrammed”/“predetermined” by a special in vitro-treatment, the meotioned pathologic (hyperactivated) CD8:HLA-DR-positive effector cells can be selectively eliminated in vivo. In this way, a 94-100%-survival rate in tumor-bearing mice could be achieved.
- the “preprogramming” of cell death in allogeneic donor PBM/PBL or T cells is a multistep in vitro procedure, comprising the following steps:
- [0257] (1) Synchronization of “donor effector cells” (a) by their incubation in serum-free medium, followed by the incubation in serum-containing medium, or (b) by cell incubation first in the absence and later in the presence of essential aminoacids (e.g. isoleucin), or (c) by cell incubation in the presence of synchronizing cytotoxic agents, such as vinchristine, hydroxyurea or bleomycin.
- donor effector cells (a) by their incubation in serum-free medium, followed by the incubation in serum-containing medium, or (b) by cell incubation first in the absence and later in the presence of essential aminoacids (e.g. isoleucin), or (c) by cell incubation in the presence of synchronizing cytotoxic agents, such as vinchristine, hydroxyurea or bleomycin.
- Donor-effector cells Treatment of “donor-effector cells” by (a) bifunctional alkylating agents, i.e. DNA-cross-linking agents (e.g. mitomycin C) and/or (b) by inhibitors of the enzyme ribonucletoid-reductase (e.g. hydroxyurera) which block the DNA- but not the RNA- or protein-synthesis.
- bifunctional alkylating agents i.e. DNA-cross-linking agents (e.g. mitomycin C) and/or
- ribonucletoid-reductase e.g. hydroxyurera
- An alternative procedure consists of the incubation of “donor effector cells” (a) with radiolabeled DNA-constituents (purine- and pyrimidine bases) and/or (b) with radiolabeled aminoacids.
- a further alternative is the irradiation of “donor effector cells”, followed by their incubation in the presence of inhibitors of DNA-reparases (e.g.hydroxyurea).
- the target cells of “preprogrammed” alloreactive donor T cells are also the HLA-DR(MHC II)-positive autoaggressive T cells (mostly T4, partly T8 cells).
- the procedure consists of the in vivo depletion of T cells (by anti-panT/CD3-Mabs) or their T8 and/or T4 subclass. Because of the high costs for the “pure” Mabs and Mab-derived immunotoxins, their combination with cytotoxic agents, especially cyclophosphamide is recommended.
- a further improvement of the technique is the reinfusion of patient's peripheral blood cells which have been preactivated ex vivo against the donor PBMs/PBLs, into the patient, after the premanipulated donor effector cells have eliminated the pathologically activated recipient lymphocytes.
- a further possibility (a) to bridge the critical immunoincompetent phase, e.g. after the excision of primary tumor or following the BMT, and (b) to prevent GvHR (but not GVLR), is as follows:
- the next step is the in vivo depletion of donor effector cells by patient's (i.e. autologous) T cells or PBMs/PBLs.
- the ratio between the autologous T cells or PEMs/PBLs (point (c)) on the one hand and the corresponding leukocyte-subpopulations of the healthy donor (point (b)) on the other hand should be 3:1 to 10:1; in this case, the cell death-programming can be omitted.
- the donor effector cells (point(b)) and the autologous effector cells (point (c)) can, but must not be prealloactivated. It is advantageous if parental PBMs/PBLs are used as donor effector cells.
- the presensibilization of donor alloreactive effector cells against the recipient lymphocytes brings an additional advantage:
- the so presensibilized (primed) donor effector cells are blastogenically pretransformed and can be activated in vivo, in some analogy to the effector cells of the secondary MLC and those of the PLT 1-2 days earlier as the non-primed clones.
- This fact confers to the presensibilized (primed) donor cells the crucial advantage, that they are able to eliminate—following their infusion into the patient—his pathologically (hyper)activated, MHC II-positive subpopulations before the patient's defense against these therapeutically utilized donor-effectors can be organized. For this reason, the number of donor effectors to be transfused can be reduced and the cell death-preprogramming possibly omitted.
- (d) Improvement of conventional vaccines The same principle (deblockade and/or inactivation /elimination of hyperactivated effector cells) can be used to improve the conventional antibacterial and anti(retro)viral vaccines, including the anti-HIV-vaccines; the target cells are here the CD8: MHC II-double positive suppressor effector cells.
- the principle is the increase of the absolute number of blastogenically pretransformed, pathogen-specific Th-, Tc/CTL- and/or B(plasma) cells by (a) deblockade and/or (b) inactivation /elimination of pathogen-specific Ts cells.
- these Ts inhibit the generation of pathogen-specific Th-, Tc/CTL- and B-memory cells.
- the clonal expansion of “positive” memory cells is strongly increased and the protection of infection significantly improved.
- the “immunologic memory”, induced in a pathogen-specific way by vaccination, can be further improved by eliminating in vivo the pathogen-specific Ts-cells of the vaccinated person with subset (CD8/Ts)- and/or panT(CD3)-specific Mabs or corresponding immunotoxins
- the number of pathogen-specific Th-, Tc- and B-cells can be increased also by delaying the antibody-production through Mabs (and immunotoxins), directed against (d1) B-cells, (d2) Th(T4)-cells, (d3) B-plus Th(T4)-cells, (d4) monocytes/macrophages (“suppressor monocytes”), and/or (d5) B-cells plus suppressor-monocytes.
- Mabs-saving mixture of cytotoxic agents e.g. cyclophosphamide
- Mab Mab
- Glucocortocoids characterized by strong side-effects, can be supported or partly replaced by sub-dosed blockers of Gi-, Gpor Go-coupled receptors and/or by low-dosed ligands of Gs-coupled receptors. These agents can be combined with sub-dosed Ca-antagonists.
- T cells, macrophages etc. Since the hyperactivated state of effector cells (T cells, macrophages etc.) is an important element in the pathogenesis (a) of cancer (b) of autoimmune disorders (c) atherosclerosis (d) infectious diseases (including HIV), the procedures, described under the point (a) (“Deblocking of hyper- or persistently activated immunocompetent cells”) and under the point (b) (“Inactivation/elimination of hyper- or persistently activated immunocompetent cells”) are valid for all these diseases.
- Pindolol-basis e.g. durapindol/ ⁇ 15/-retard (26.039) or pinbetol/forte (26.067) plus preparations on phenoxybenzamine-basis (e.g. dibenzyran 1/5/10(81.091)).
- Pindolol is a B1- plus B2-sympatholytic, phenoxybenzamin an alphal- plus alpha 2 -blocker. Recommended dose: 1 ⁇ 15 mg/d or 3 ⁇ 5 mg/d or 2-3 ⁇ 1 mg/d dibenzyran.
- Sub-dosed antagonists under the points (1) (2) (3) and (4) can be combined. In this case, the dose has to be reduced to 5-50% of the dose, quoted under the points (1)(2)(3) and (4).
- the strongly sub-dosed antagonist under the points (1)(2)(3) and (4) can be combined with conventional Ca-antagonists and/or with sub-dosed agonists of Gp- and Gi-coupled receptors.
- cytokines such as M-CSF or GM-CSF are combined with (a) antagonists of Gs-coupled receptors, (b) agonists of Gi(Gp/Go)-coupled receptors, and/or (c) Ca-antagonists.
- tumor patients are (a) first treated by the combination of Mab-saving cyclophosphamide plus anti-CD 3 - or anti-CD 8 -Mab, then (b) injected by alloreactive donor effector cells (PBM/PBL or T cells) which can be primed against the recipient and (c) treated again by cyclophosphamide plus anti-CD 3 - or anti-CDB-Mabs in order to eliminate the alloreactive donor cells, and (d) finally reinjected with the autologous PBM or T cells, collected before the start of therapy, to restore the recipient's immunocompetence.
- the step (c) can be omitted.
- the reinduction of tumor-specific Ts cells can be prevented (a) by Mabs, directed against immature T cells (e.g. anti-T6-, antiT9-, anti-T10-Mabs), (b) by antagonists of Gs-coupled receptors, and/or (c) by agonists of Gi-coupled receptors.
- Mabs directed against immature T cells
- immature T cells e.g. anti-T6-, antiT9-, anti-T10-Mabs
- antagonists of Gs-coupled receptors e.g. anti-T6-, antiT9-, anti-T10-Mabs
- Gi-coupled receptors e.g., Gi-coupled receptors
- hyper- or persistently activated effector cells represent a common element (a) in neiplastic, (b) in autoimmune diseases (c) in atherosclerosis, (d) in bacterial and (retro)viral infections, including HIV, and (e) in vaccines, the use of antagonists of Gs-coupled receptors and of agonists of Gi(Gp)-coupled receptors, as well as of Ca-antagonists/Ca-overload-blockers is recommended in all these situations.
- Agents, increasing the intracellular cGMP such as (a) nitrocompounds (e.g. glycerolnitrates, isosorbit-mono- and dinitrates), vasodilators (e.g. minoxidil, (di)hydralazine, Na-nitroprusside) and (c) molsidomine can be used alone or in combination with BRMs, lymphokines, growth factors, methylxanthines (e.g.
- Ca-antagonists or Ca-overload-blockers agonists of Gi(Gp)-coupled receptors, antagonists of Gs-coupled receptors and/or pHi-increasing or redox potential-correcting substances.
- vasodilators e.g. nitrocompounds
- molsidomine inhibit the IP3-mediated Ca 2+ -mobilization
- they can be used, alone or combined with Ca-antagonists, for a rapid deblockade of those hyperactivated effector cells which show a strongly increased Ca 2+ -level due to an excess of signals, as observed e.g. in chronic inflammation and autoimmune disorders.
- a rapid deblockade of those hyperactivated effector cells which show a strongly increased Ca 2+ -level due to an excess of signals, as observed e.g. in chronic inflammation and autoimmune disorders.
- pHi-increasing and/or redox potential correcting agents are examples of pHi-increasing and/or redox potential correcting agents.
- Infection and inflammations can be treated by combining NSAID with sub-dosed (a) antagonists of Gs-coupled receptors (b) agonists of Gi(Gp)-coupled receptors and/or (c) sub-dosed Ca-antagonists (optimally: Ca- and Na-channels-inhibiting Ca-overload-blockers, such as cinnarizine).
- the suppressor-monocytes seem to play a crucial negative role in the process of immunosuppression. Therefore, they have to be depleted in vivo by anti-Macrophage-Mabs (or immunotoxins), along with the neutralization of their secretory products (monokins) by Mabs, directed against TNFalpha and IL-1.
- the macrophage-stimulating gamma-IFN must be neutralized by the specific Mab.
- the cGMP-synthesizing guanylate cyclase can be stimulated, according to the invention, (a) by nitro compounds (“organic nitrates”), such as glycerol-, erythrite- and isosorbite-nitrate, (b) by further vasodilators, such as minoxidil, (di)hydralazine, Na-nitroprusside, (c) by compounds such as arginine, N-methyl-D-aspartate(NMDA), L-glutamate, S-acetylthiocholin-iodide, paraquate, D- and L-ornithine, further extreme low concentrations of NO and cb.
- organic nitrates such as glycerol-, erythrite- and isosorbite-nitrate
- vasodilators such as minoxidil
- NMDA N-methyl-D-aspartate
- L-glutamate such as arg
- NOS NO-synthetase
- the monokines such as TNFalpha and L-1 and lymphokines, such as IFN-gamma
- a) switch the cell function from the cell proliferation to the cell differentiation, and (b) induce the secretion of numerous cytokines via the H 2 O 2 -intermediate.
- the H 2 O 2 per se is able to induce, at very low concentrations, the TNF-production.
- the NO-synthesis goes parallel with the ROI (H 2 O 2 ) -formation and is dependent in its last step (oxydation of the hydroxylamine-intermediate) on the cooperation with the compound I (catalase: H 2 O 2 -complex).
- the NO is oxydized to N 0 2 and N 0 3 .
- cGMP-synthesis and mediately the secretion of cytokines can be achieved also by extremely low concentrations of ROI (e.g. H 2 O 2 or Mg-peroxide or (NH 4 ) 2 S 2 O 4 ).
- ROI e.g. H 2 O 2 or Mg-peroxide or (NH 4 ) 2 S 2 O 4 ).
- the efficacy of the treatment can be increased by the intratumoral/intralesional application (a) of NOS-activators (b) of agonists of Gi(Gp)-coupled receptors and/or (c) of antagonists of Gs-coupled receptors.
- Ca-overload-blockers e.g. piperazines (cinnarizine, lidoflazine, flunarizine) with Ca-antagonists (controlled Ca i - and cGMP-rise)
- the pretreatment (“conditioning”) of recipient i.e. tumor patient with the cyclophospharnide plus anti-CD3- or anti-CD8-Mab as part of the “microimmunosurgery” can be replaced by the treatment with the cyclophosphamide plus anti-T6 (anti-T9; anti-T10; anti-TdT)Mab.
- a combination (a) of antagonists of Gi(Gp)-coupled receptors, (b) of Ca 2 +-influx inhibiting Ca-antagonists, (c) of Ca 2+ -mobilization-inhibiting nitrocompounds, (d) of agonists of Gs-coupled receptors (B-sympathomimetics) and/or (e) of alkalizing agents could be lifesaving even during a fatal immune over-reaction (septic or anaphylactic shock).
- the K-preparations, O 2 -scavengers and tolbutarnide or biguanine plus glucose can support this treatment.
- the Ts-cells can be converted to the CTL/Tc-cells (and vice versa).
- the intracellular ADP/ATP-ratio seems to be critical: a n ATP-drop or an ADP-rise seems to signalize the Tc:Ts-interconversion.
- the ADP/ATP-decrease (in different stress situations, such as O 2 -deficit, physical work, cold, heat) is associated by catecholamine (adrenaline)-rise.
- catecholamine adrenaline
- the adrenaline causes also the rise of intracellular cAMP-level.
- the following agents are recommended:
- (a) O 2 or O 2 -carriers (b) glucose, di- and tricarbonic acids (as alkali-salts), along with antidiabetics (tolbutamide, biguanine etc.), (c) ribose and/or (d) glutamine, glycine and other ATP-precursors.
- the adenosine or adrenaline-induced cAMP-rise can be inhibited by the corresponding receptor blockers.
- the therapy of (a) lymphomas and (b)leukemias of the T-type can be performed by the “microimmunosurgery” like in solid tumors; again, the sublethal whole body irradiation or high-dose chemotherapy is replaced by the T cell depletion (by Mab-saving cyclophosphamide plus anti-CD 3 -Mabs).
- the transformed T cells are eliminated by allogeneic donor effector cells.
- the mature (post-thymus) malignant,cells are MHC II-positive.
- the immature (pre-thymus) cells are recognized and depleted via blast-specific structures.
- the HF-currents must be significantly lower than those, used in the electroporation or electrofusion (Zimmermann).
- the deblocked or reactivated state can be “frozen” by Ca-antagonists.
- the efficacy of “microimmunosurgery” can be increased also by the pretreatment of the recipient (a) with the ERMs or (b) with the lymphokines (e.g. IFNgamma or IL-4), to render target cells, i.e. pathological subclones more vulnerable.
- lymphokines e.g. IFNgamma or IL-4
- the standardized “microimmunosurgery” comprises the following steps: (a) Pooled PBs/PBLs or T cells (from donor A, B, C) whose pathogen-specific subclones can be clonally postexpanded in vitro, e.g. by lectins, are (b) “cell death-preprogrammed” and (c) frozen in a medium (e.g. RPMI1640), containing special cryoprotectants (based on PEG and/or PVP) which warrant the preservation of the preactivated cell state, in addition to an improved cell viability. (d) Treatment of patients, suffering e.g. of cancer or autoimmune disorders is restricted to the T cell depletion because the “microimmunosurgery” is based on the simple replacement of the pathologic patient's T set by the healthy donor's T set.
- a medium e.g. RPMI1640
- special cryoprotectants based on PEG and/or PVP
- the effector cells can be supported by allogeneic LAK-cells; these can be either premanipulated to express a preprogrammed cell death or depleted of their T cells (10% of cells). In certain situations, the so pretreated allogeneic LAK-cells can be used alone to eliminate the pathologic subclones.
- Immunocompetent cells e.g. macrophages express a variety of additional, not typically “immunologic” receptors (e.g. for the insuline, the glucagon, the parathormone etc.) which have been neglected up to date though they contribute essentially to the activity of immunocompetent cells.
- immunocompetent cells e.g. macrophages express a variety of additional, not typically “immunologic” receptors (e.g. for the insuline, the glucagon, the parathormone etc.) which have been neglected up to date though they contribute essentially to the activity of immunocompetent cells.
- the therapeutic manipulation of all these receptors by agonists and antagonists is subject of this invention.
- Fibroblasts support the immunosuppressive “tissue repair”/“wound healing”-function of macrophages and increase e.g. their PGE2 secretion. Therefore, the neutralization of specific fibroblast growth factors, e.g. PDGF, bFGF, FAF, FGTB, PF4 and LTBS is recommended.
- specific fibroblast growth factors e.g. PDGF, bFGF, FAF, FGTB, PF4 and LTBS is recommended.
- the combination of antibodies of the IgG- or IgM-isotype with those of the IgE-isotype is recommended.
- the latter can be constructed by the replacement of the Fc gamma or Fcu-subunit by the Fc epsilon-subunit.
- the IgE-percentage in vivo can be increased by the simultaneous injection of anti-IFNgamma and IL-4(IL-5).
- the patient's PBMs are first incubated in vitro with lectins (e.g.PHA) and thereafter treated by increasing concentrations of anti-CD 8 -Mab (+complement), until the onset of the Tc- and Th-deblockade.
- lectins e.g.PHA
- anti-CD 8 -Mab (+complement)
- tumor-specific clones can be expected; after a further clonal expansion, these tumoricidal subclones can be reinjected into the patient.
- the erythrocytes lose the nuclea. Therefore, the ennucleated precursors (reticulocytes) are of a special interest as carriers of temporarily limited functions (e.g. in vivo production of cytokines, Mabs and suppressor factors or local source of irradiation). In these cells, the cell death need not be preprogrammed.
- the controlled DNA-damaging described above (“cell death preprogramming”) can be carried out by DNA-selective cytotoxic agents, primarily vinca alkaloids, bleomycin, ICRF-159, busulfan, DDP, VP16231 (EPE) and EPT, in addition to the above mentioned mitomycinc.
- the controlled DNA-cross-linking can be achieved by so called “bifunctional alkylating agents”.
- the use of the combination of a Ca-antagonist plus an agent, decreasing the cAMP/cGMP-ratio is recommended as the drug for the treatment of cancer, viral and bacterial infections, as well as autoimmune disorders.
- an additional approach in the treatment of cancer, viral infections and autoimmune disorders based on the elimination or down-regulation of immunological effector cells, enables the patient's own immune system to restore the pre-disease state.
- a drug, affecting the hyperactivated.immunologic effector cells comprising (I) a Ca-antagonist and (II) an agent, reducing the intracellular cAMP/cGMP-ratio, is being described.
- a drug, affecting the hyperactivated immunologic effector cells consisting (I) of an agent, eliminating the hyperactivated effector cells and (II) of alloreactive cells with predetermined cell death, is being described as well.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A drug, affecting the hyperactivated immunologic effector cells, comprising (I) a Ca-antagonist and (II) an agent, reducing the intracellular cAMP/cGMP-ratio, is being described. In addition, a drug, affecting the hyperactivated immunologic effector cells, consisting of (I) an agent, eliminating the hyperactivated effector cells and (II) alloreactive cells with predetermined cell death, is being described.
Description
- The invention deals with an agent, able to affect the hyperactivated immununological effector cells and with its use.
- Different situations and disorders of humans are associated with a hyperactivated state of the immunological-effector cells, caused e.g. by cytokines; such effector cells lose their ability to respond to new specific signals. The immune system is impaired or even switched off in such situations. This occurs e.g. following a persistent stimulation during a prolonged infection or in situations of cell hyperactivation due to an excessive release of endogenous cytokines. The term “immunological effector cells” comprises e.g. T cells, macrophages/monocytes, NK cells and other immunological cells.
- A variety of immunological processes include on the cellular level the cyclic adenosine phosphate (cAMP) which is produced by the enzyme adenylate cyclase (AC) from adenosine triphosphate (ATP). The cAMP plays as “second messenger” a central role in the hormonal regulation as well as in the metabolism (through activation of protein kineses, e.g. protein kinase A (PKA). The PKA phosphorylates proteins which in turn depress the immune response. In this way, the hyperactivation of effector cells results in the down regulation of the immune function.
- This reaction cascade is regulated by the production of cyclic guanosine monophosphate (cGMP) which antagonizes the cAMP. This reaction cascade is also influenced by the group of G-protein coupled receptors, comprising receptors such as adrenergic, muscarinic, histamine, serotonin and adenosine receptors. The G-proteins (guanine nucleotide-binding proteins) are able to stimulate (Gs) or to inhibit (Gi) the production of second messengers. By affecting either the Gs- or the Gi-receptors, the stimulation of AC and herewith the cAMP-production can be regulated. Situations with a disturbed equilibrium are e.g. cancer, viral diseases and autoimmune disorders, as well as the inducing and disease-maintaining component of the atherosclerosis.
- The objective of the invention was to provide an agent, able to fight with such disorders and to restore the susceptibility of the hyperactivation-depressed immune system for signals and a normal immune response. This objective can be achieved by an agent, capable to affect the hyperactivated immunological effector cells which comprises (I) a Ca-antagonist, and (II) an agent, able to decrease the intracellular cAMP/cGMP-ratio. Surprisingly, it could be found out that such a combination reduced or prevented the hyperactivation of effector cells. In this way, these cells re-acquire their susceptibility for specific signals and show a normal immune reaction. It could be shown that hyperactivated cells contain an excess of calcium ions and are characterized by an increased cAMP/cGMP-ratio.
- According to the invention, the principle of the agent is the prevention of Ca2+-influx and reduction of cAMP/cGMP-ratio in immune effector cells. This can be achieved by the combination of component I and II. Surprisingly, in this way, diseases as different as cancer, autoimmune disorders, arteriosclerosis which seems to need an autoimmune promotor for its provocation, further bacterial, viral, including retro viral infections, as well as some “modern” diseases, based on immunological derailment or deviations, e.g. the CFS (chronic fatigue syndrome) can be treated. All these situations and disorders appear to contain—in the immunological sense—common disregulation elements. These common elements are e.g. a persistent or excessive activation of certain leukocyte-subpopulations, mostly macrophages and helper T cells, as well as suppressor cells. During a simultaneous hyperactivation of macrophages and helper T cells, as observed in HIV-patients, a mutual stimulation of both interdependent leukocyte-subpopulations can occur.
- A further common element is the deblockade of blastogenically pretransformed T4 and plasma (B) cells as consequence of preceding, persistent latent or manifest immunosuppression; it is based on a “critical drop” of autoantigen or pathogen-specific surveyor cells or suppressor T cells. From the molecular-biologic point of view, the persistence of an increased intracellular Cai 2+-level, leading to an immunosuppressive counter regulation and to an impaired sensitivity to new antigenic signals, is a common element of a variety of disorders mentioned above. This results not only in the impairment of the existent set of immunocompetent cells but, in addition, in a disturbed recruitment of new, intact immunocytes.
- The combination of components I and II, according to the invention, deblocks the misprogrammed immunocytes or effector cells, primarily those in the hyperactivated state, and has therefore impact on the “wound healing” or “tissue repair”—function of misprogrammed macrophages and cytokine-hyper secreting helper T cells. This hyperactivated or persistently activated state of effector cells can be prevented through component I by breaking the Ca2+-rigidity, i.e. by breaking the Cai 2+-overload of effector cells; on the other hand, the Cai 2+-level is regulated by the intracellular pHi. An additional mechanism is the control of the electrolyte transport through the cell membrane, i.e. the regulation of the Ca2+-, Na+- and K+-channels and of the Na+/K+-, Na+/H+-, K+/H+-, HCO3-/CI- and Ca2+/Na+-antiport, symport and different ATPases, respectively. According to the invention, the combination was able to reduce the primary tumor and metastases in cancer patients by {fraction (1/3)} to ⅔ within few weeks, without a simultaneous radio- or chemotherapy.
- The CFS-patients also showed surprising therapeutic results. Here presented examples of component I and II can be combined as well. Their effect in patients with neoplastic and autoimmune diseases, atherosclerosis, amyloidosis, Alzheimer disease and CFS can further be potentiated by combining them with known immunostimulators and BRMs. In addition, these combinations can be used therapeutically in bacterial and viral infections. Herewith, the initial derailment, i.e. the hyperactivation of leukocyte-subpopulations can be reversed. The restoration of the original immune state then occurs spontaneously. The therapeutic protocol can consist of 2 or 3 steps. So, in the first phase a deblockade of immunocompetent, misprogrammed effector cells, primarily macrophages and T cells, can occur, and in the second phase, a controlled stimulation of immunocytes can follow.
- In a further modification, a “freezing-up” of the controlled stimulated cell state, i.e. a prolongation of the second phase (phase 3) is foreseen. In the first phase, the drug combination, according to the invention, is used. In the second phase, well known immunostimulators and in the third phase, the same combination as in the first phase, but at reduced concentration, e.g. 20 to 50% of the concentration, used in the first phase, are foreseen.
- Details about the deblocking of immunocompetent cells in hypoxic and/or acidified milieu-of chronically inflammated tissues, including necrotic tumor tissue are described.
- Hyper- or persistently activated macrophages consume up to 10-20 times more oxygen than resting macrophages; in the presence of gamma-interferon, this O2-consumption increases additionally.
- The phagocytosis of opsonized particles (bacteria, latex etc.) as well as of immune complexes via the Fc-gamma-receptor switches on the Embden-Mayerhof-glycolysis pathway. Herewith, the generation of the microbicidal oxygen radicals (ROI) from molecular oxygen is stimulated. In addition, the synthesis of leukotriens C, D and E (via reduced glutathione) is impaired due to a direct electron and proton transfer on O2-radicals (mediated by cytochrome P450). Leukotrien B which is synthesized instead of the leukotriens C, D and E stimulates directly the cytochrome P450-mediated ROI-generation.
- The glycolysis leads via the excessive production and secretion of lactic acid to a strong acidification of the macrophage micro milieu. The pH-drop results in the suppression of immunocyte function. The impaired synthesis of Leukotrien C, D and E, additionally affected by ROI, results in an inhibited glycosylation and secretion of cytokines and immunoglobulins.
- The hypoxia inflammation tissue, e.g. necrotic tumor tissue, caused by the impaired angiogenesis and hyperactivated macrophages leads to pH-drop which results in cell depression (below pH 6,8) and cell death at a continued pH-drop.
- Both, the apoptotic and the autolytic cell death appear to arise from the drop of intracellular pH which is associated with the activation of lysosomal enzymes. A defect in the H+-pump which maintains a lysosomal pH of 4.5-5.0 precedes the cell death.
- As known from the myocard cells, the cell death is accelerated in the presence of oxygen as terminal electron acceptor if the cell is activated and herewith the intracellular Cai-level is increased. Therefore, under hypoxic or ischemic conditions, the glucose catabolism via the TCC/citrate cycle should be inhibited by special drugs. Herewith, the overproduction of NADH2 (and NADPH2) which leads to an accelerated glycolytic lactate synthesis and to pH drop, can be prevented. For this reason, BRMs have to be combined with deblocking substances, or the deblocking of immunocompetent cells has to precede other (immuno)therapeutic steps. The component II comprises an agent which is able to affect the cAMP/cGMP-ratio. One variant proposes the increase of intracellular cGMP-level.
- One of the main reasons for the blocked function of immunocompetent cells (mononuclear and polymorphonuclear phagocytes, NK cells, K cells, T cells) in situ/in vitro e.g. in tumor lesions or in chronic inflammation tissues is the low cGMP-level or the increased cAMP-level in the cytosol of immunocompetent cells.
- The increased cAMP-level arises primarily from the activation of adenylate cyclase by hyperproduced prostaglandins (PGE2/El); these prostaglandins are secreted by hyperactivated macrophages, fibroblasts and synovial cells. They activate, together with catecholarnines, the enzyme adenylate cyclase which results in cAMP-increase in cytosol.
- The intracellular cAMP-rise inhibits different cell functions of various immunocyte subclasses. Therefore the induction of guanylate cyclase and herewith the cGMP-rise in immunocompetent cells is recommended according the invention. In this way, the blocked (preinactivated) effector cells switch their function from the suppressor to the effector.
- According to the invention, the following agents can be used therapeutically (a) as single agents, or (b) combined with each other, or (c) combined as single agents or as mutual combinations (see (b)) with different BRMs:
- (1) alkalizing substances, such as alkali-(bi)carbonate and alkali-salts of metabolizable organic acids (e.g. Nalactate, Na-gluconate, Na-, K-citrate)
- (2) reversible competitive inhibitors of citrate oxidation in Krebs/citrate cycle, i.e. inhibitors of tricarboxylic acids in citrate cyclus (e.g. tricarballylate, methyl/ethyl-succinate, malonate etc.). The working mechanism is the prevention of cell (e.g. macrophage) hyperactivation in situations, associated with O2-deficit.
- (3) β-blockers in general. The working mechanism is the inhibition of intracellular cAMP-rise and of A-kinase (PKA) -activity.
- (4) Ca-antagonists in general. The working mechanism is the inhibition of Ca2+-influx into the hyperactivated (hypoxic) cell which prevents the Cai-stimulated oxidation in Krebs cycle during O2-deficit and herewith the cell death. In the case of hyperactivated macrophages, the ROI generation can be inhibited in this way. These ROIs block in turn the glycosylation and secretion of cytokines.
- (5) Ca-agonists in general. The working mechanism is like in the case of β-blocker (point (3)), the Cai-increase. The following 2-step-protocol is recommended: first, the activity of the “misprogrammed”, i.e. hyperactivated macrophages has to be blocked by Ca-antagonists (point (4)); the 2nd step is the activation of immunocompetent cells by Ca-agonists and/or β-blockers.
- (6) Substances, preventing phi-drop by penetrating into the cell and binding the excessive H+-ions. This class of substances comprises all representatives of alkaline compounds, e.g. derivatives of TRIZMA, HEPES, mono-, di- and triethanolamines, as well as chloroquine and other antimalaria drugs, further monensin and compounds which are able to release NH3 intracellularly, such as glutamine and asparagine. Further pHi-increasing substances are LI-, Cs- and Rb-salts of carbonic acid and organic acids. The weak bases have to be used as free bases, as (bi)carbonate or as salts of metabolizable organic acids, but not as chloride, sulfate, nitrate etc. These substances can be combined with alkali-salts of metabolizable organic acids (see point (1)) and/or with inhibitors of TCC/citrate cycle.
- (7) Inhibitors of LDH (lactate dehydrogenase) and XOD (xanthin oxydase). The working mechanism is the inhibition of lactate production which prevents the excessive acidification of cytosol and extracellular milieu. These LDH- and XOD-inhibitors can be combined with inhibitors of TCC/Krebs-cycle.
- (8) Substances, able to correct the intracellular redox-potential, e.g. fumarate/maleinate, vitamin .C, vitamin A, vitamin E, alkali (K)-ferrocyanide, Se-compounds (e.g. Na-selenite), Na-/K-thiosulfate, alkali-sulfate and compounds carrying reduced forms of mercaptylt/thionyl (-SH)-groups, e.g. glutathione, penicillamine, thiola(thiopronine), cysteine, methionine etc.
- (9) Substances, correcting the intracellular NAD(P)+/NAD(P)H2- or the GSSG/2GSH-ratio, e.g. N-acetyl cysteine.
- (10) Substances, replacing the terminal electron-acceptor (molecular O2) of the oxidative phosphorylation, e.g. ascorbate, dehydroascorbate, insaturated fatty acids.
- (11) ROI-scavengers and/or antioxidants, e.g. (a) phenols such as tocopherols, flavonoids, phenolic acid plus esters, benzodioxols, lignanes (NDGA), BHT, BHA, THBP (b) amines such as tetramethyl-p-phenylenediamine (c) heterocyclic compounds such as ethoxyquinine, barbiturates, carbazols, phenothiazines, levamisole, nafazatron, naloxone and tinoridine (d) different compounds such as vitamin C, glutathione (GSH), β-carotine and vitamine A-derivatives.
- (12) Cl−-channel blockers
- (13) Cyclooxygenase inhibitors/NSAIDs
- (14) H2-specific antihistaminics (antagonists of the H2-histamine receptor), e.g. cimetidine
- (15) inhibitors of the cAMP- and cGMP-phosphodiesterase (methylxanthines; e.g. theophylline or theobromine
- (16) Since the immune complexes (IC) suppress—via special receptors, such as the Fc(gamma)-R and/or CR1, CR3, CRq and other receptors—both the macrophages/monocytes and NK cells and stimulate suppressor T cells (TG/Ts), the IC interaction with immunocyte receptors has to be blocked, according to the invention, (a) by the Fc(gamma)-subunit of Ig (IgG), (b) by the biotechnologically modified complement subunits (replacement of key amino acids), e.g. c3b, c3bi or clq and/or (c) by an IgG-excess.
- (17) Substances, acting anti-denaturing and partially re-naturing on biorelevant proteins, e.g. formamide, acetamide, anilide (fomlanilide, acetanilide), and their alkyl- and dialkyl derivatives, especially the non-toxic mono methyl-derivatives and other water-miscible compounds. They act by weakening the hydration and the dielectric constant (DK) of the medium. These substances can be combined with PEG, PVP and/or DMSO. The same substances and their combinations with PEG, PVP, glycerol and/or DMSO are at the same time, according to the invention, highly efficient cryoprotectants for cells and proteins. The PVP seems to be non-toxic, as it has been clinically used for years as plasma expander. Each class of the above described deblocking substances can also be used as additive to conventional vaccines.
- (18) Anti-gamma-interferon, anti-M-CSF, anti-GM-CSF and anti-TNFalpha
- (19) Liposomes, containing (a) cytotoxic agents (b) other cytotoxins, e.g. ricin, abrin
- (20) Substances, preventing histamine release from mast cells, e.g. cromoglycin and intal
- (21) Substances, reducing the Cl-concentration of the extracellular fluid (ECP)
- (22) Substances, increasing-the ECF-concentration of HCO3-ions.
- According to the invention, a Ca-overload blocker, especially cinnarizin (component I) should be combined with an antagonist of β-adrenoceptor, histamine-H2-receptor and/or A2-purinergic receptor, especially propranolol (component II). In addition, some selected preparations should be listed which can be used in combination with 1,2 or more other substances (A+B, A+C . . . , B+C, B+D . . . , A+B+C, ABD . . . ). They have a special advantage to represent -as single substances- preparations which can be directly used clinically. They can be combined -as single or as complex preparations- with BRMs.
- 1 Ca-antagonists (objective: prevention of the intracellular Ca-over-load which results in the deblockade of guanylate cyclase and5-lipcxygenase and in the inhibition of CaM (calcium modulin)-mediated activation of Ca-ATPase and adenylate cyclase).
- 1.1 based on nifedipin: adalate (26.071) or aprical 5/−10/-retard (26.072), or bayotensin/-mite (26.075)
- 1.2 based on verapamil: azuparnil 40/−80/−120 (26.073) or dignover 40/−80 (2.081) or drostreakard 40/−80/−120 (26.083) or verapamil-ratiopharm (26.108)
- 1.3 based on cinnarizin: cinnarizin-ratiopharm (36.035) or cinnarizin Siegfried (36.036) or cinnarizin R.A.N. 36.034) or cinnacet (36.633) or cerepae (36.032).
- 2 β-blockers (Objective: inhibition of the cAMP-increasing sub-receptors for catecholamin, PGE1/PGE2 and histamine (H2-R)
- 2.1 based on acetolol: neptal 400 (26.036) or prent 400 (26.040)
- 2.2 based on metoprolol: lopresor/-mite (26.035)
- 2.3 based on propranolol: indobloc 10/40/80 (26.032) or efectolol 10/40/80 (26.024) or elbrol 40 (elbrol 80) 26.027)
- 3 combination drugs: Ca-antagonists plus β-blockers: beloif (26.070) or tredalat (16.132) or nif-ten 50 (16.131)
- 4 non-steroidal antiflogistics/antirhumatics (inhibitors of cyclooxygenase/prostaglandin-synthetase)
- 4.1 based on diclofenac: diclofenac-Wolff-25/50 (05.142) or diclo-OPT 50, 100 retard (05.143) or diclophlogent (05.144)
- 4.2 based on ibuprofen: dolgit 200/400/SL (05.149) or ibuphlogent 200/−400 (05.161)
- 4.3 based on indometacin: indo Tablinen (05.170) or indomat retard-rqatiopharm 75 (05.167) or amuno/retard (MSD) (05.129)
- 4.4 based on ketoprofen: alrheumun (05.128)
- 4.5 based on acetylsalicylic acid: spelt (05.122) or solpyron (05.121) or gepan/mite (05.117)
- 5 drugs, affecting the intracellular pHi (objective: impact on intracellular pH, K- and Na-ion, as well as on the HCO3/CI−-ratio and herewith on the deblockade of hyper- or persistently activated immunocompetent cells, primarily macrophages) (a) hanooxygen (03.007) or gelum oral -rd (03.006(b)) acidovert (03.005) or acetolyt (03.001) or nephrotrans (03.004) or NaHCO3 lg (03.003) (c) histinorm (05.210)
- 6 drugs, correcting the redox-potential (NAD(P)H2/NAD(P) and GSH/GSSG)
- 6.1 drugs, improving the mercaptyl-/thionyl-, sulflhydryl-/disulfide-ratio (a) acetyl cysteine (23.119) or acetylcystein-ratiopharm 100/200 (23.120) (b) metalcaptase 150/−300 (05.201) or trolovol (05.206)
- 6.2 reducing drugs: cebion (83.099) or cedoxon Cassis (83.100) or cetebe (83.102) or resochin (05.203) or quensyl (05.202) or tauredon (10/20/50). The first two drugs are recommended ecially for their oral administration.
- 7 gold-based drugs (contribute -like chloroquine- to the stabilization of hyperactivated macrophages): ridaura (05.204) (oral) or aureostan 10/25/50/100 (05.199)
- 9 methylxanthines (e.g. theophylline) (objective: stabilization of the increased cGMP-level following the corrector of the cAMP/cGMP-ratio; methyl-xanthines inhibit not only the cAMP-phosphodiesterase but also the cGMP-PDE): theophyllin retard-ratiopharm 125/250/350/500 (27.082) or theospirex (27.084)
- 10 antidiabetics (objective: mimicking of the insulin activity or antagonization of the glycolysis- and TCC-inhibiting and gluconeogenase-stimulating activity of glucagon)
- 10.1 based on biguanidine (metformine): glucophage retard/-mite (11.070)
- 10.2 based on tolbutamide: artosin 1.0 (11.037) or rastin-Hoechst (11.065) or tolbutamide 0,5 g/1 g (11.067)
- 10.3 based on glibenclamide: azuglucon −3,5/−1,75 (11.038) or diamicron (11.041) or glucononn 1,75/3,5 (11.051)
- 10.4 based on glisoxepid: pro-diaban (11.064)
- 11 guanylate cyclase (cGMP)-stimulating drugs
- 11.1 based on isosorbid-dinitrate: coleb 20/−40 (54.044) or dignonitrat 40/−60/−100 (54.049)
- 11.2 based on isosorbid-mononitrate: conpin 20/−40 (54.054) or coragin 20/60 (54.046)
- 11.3 based on glycerol-trinitrate: nitroglycerin retard-ratiopharm (54.023) . An alternative is the sydnonimin-derivative molsidomine (e.g. molsidomine 1/2/4 from ct/Berlin). The working mechanism on the cellular level corresponds to that of org. nitrates; In both cases, the activity of guanylate cyclase and herewith the intracellular cGMP-level is increased.
- 12 inhibitors of xanthin-oxidase (XOD), with the aim to depress the generation of oxygen radicals (see point (5)): allopurinol 300 Stada (43.007) or allopurinol Dorsch (43.008) or allopurinol-retard Woelm (43.011)
- 13 some K-saving diuretics (due to K-retard-effect or indirectly due to the stimulation of the H+/K+-antiport and herewith the pHi-rise).
- 13.1 based on aldosteron-antagonist spironolacton: spironolacton-ratiopharm 50/−100 (02.016)
- 13.2 based on triemteren: jatropur (35.060)
- 13.3 based on amiloride: amiloride per se or in combination with hydrochlorothiazide as amilorid comp.-ratiopharm (35.063)
- 14 carboanhydrase-blocker, e.g. acetazolamide (due to the impact on the pHi, on the glycolysis, gluconeogenesis and TCC/Krebs (citrate) cycle, as well as due to the depression of the glycolysis inhibiting FPK/fructose phosphate kinase): diamox retard (67.151) or diamox (39.006)
- 15 oxygen carriers (objective: an improved O2-transport to the hypoxic inflammatory tissue): oxoferin or TCDO (tetrachlorodekaoxid). The same or a better effect can be achieved with an oxygen therapy. Oxoferin and TCDO can be combined with ascorbate, succinate and/or fumarate.
- 16 parathormone-antagonizing drugs (PTH acts via adenylate cyclase and cAMP immunosuppressive, like e.g. glucagon, histamine (via H2-receptor), adenosine, PGE2, noradrenaline (via β1-adrenoceptor), adrenaline and isoproterenol (via β2-adrenoceptor). The macrophages express receptors for (a) insulin (b) glucagon (c) histamine (d) serotonine (e) parathormone (f) calcitonine (g) somatotropine (h) somatostatine (i) PGE2 (j) cAMP (k) β-adrenoceptor (l) neuropeptides (endorphine) (m) arginin-vasopressin, and (n) transferrin.
- 16.1 based on etidronacid :diphos (65.005)
- 16.2 based on clodronacid: ostac (65.007)
- 17 serene-compounds (objective: ROI-neutralization, stimulation of glutathione-peroxidase)
- 17.1 based on Na-selenite-pentabydrat: selenase (GN-Pharm)
- 17.2 based on ebselen
- 18 Li-compounds (objective: increase of cytoplasmic pHi)
- 18.1 based on Li-aspartate: Lithium-aspartat-Dragees 120 (70.235)
- 18.2 based on Li-orotate: Lithium-orotat Tabl. (70.237)
- 18.3 based on Li-carbonate: hypnorex retard (70.234)
- 18.4 based on Li-sulfate: Lithium-duriles (70.236)
- 19 some essential precursors, needed during switching from catabolic to anabolic function: 19.1. L-glutarnine 19.2. ribose 19.3. creatin(in) 19.4. ATP(ADP,AMP) and/or GTP (GDP, GMP, guanin) 19.5. unsaturated fatty acids+ascorbic acid 19.6. EPL 19.7. vanadin-compounds 19.8. glutathion 19.9. folic acid
- The best combinations are 1+2; 1 or 3+5; 1 or 3+6; 1 or 3+5+6 and 5+6.
- Especially recommendable are: in the group 1 1.3, in the group 5 hanooxygen and in the group 6 6.1a and/or 6.2. These preferred combinations can be further combined with 4, 12, 17 and/or 18, 7, 8, and 10. An especially preferred combination comprises cinnarizine as component I and propranol as component II. The conventional stimulation e.g. by BRMs can be supported by sub-dosed11 and/or low-dosed lymphokines (e.g. IL-2, gamma IFN).
- The fact that immunocytes react—like other somatic cells—on different, Cai 2+-increasing signals has not been considered up to now.
- Therefore, the activation of immunocytes, as well as the in situ/in vivo deblockade of inactivated effector cells (monocytes/macrophages, Ts, NK-cells, K-cells) by alpha-sympathomimetics (e.g. phenylephrine), by Ca-agonists (e.g. Bay K 8644 or CGP 28392) and by β-receptor blockers (beta-blockers, β-sympatholytics) is recommended according the invention. These, Cai 2+-increasing compounds can be used alone or combined with each other and/or with immunostimulators and BRMs. They are suitable for the in vitro and in vivo activation and reactivation/ deblockade of immunocompetent cells. β-blockers are able to focus the activity of the physiological agonists noradrenaline (norepinephrine) and adrenaline (epinephrine) on the alpha1- and alpha2-adrenoceptor which favours cell activation (cGMP-rise and cAMP-drop).
- According to the invention, a combination of agents with a double impact on Cai 2+-level, i.e. by increasing Ca2+-influx and by maintaining the so elevated Cai 2+-level in cytosol through the later blockade of Ca-channels, is of a special interest. Such drug combinations comprise on the one hand alpha-sympathomimetes, Ca-agonists and β-blockers, and on the other hand Ca-channel blockers (Ca-antagonists, such as nifedipin, verapamil and diltiazem).
- Examples of cGMP-increasing compounds are organic nitrites and nitrates, i.e. esters of the nitrous and nitric acid, such as amylnitrite, nitroglycerol, isosorbitnitrate and 5-isosorbitmononitrate, further Na-nitroprusside and parasympathomimetics; the latter can be subdivided in 3 groups: (a) choline ester (e.g. carbachol, bethanechol, metacholin); (b) alkaloids with parasympathomimetic activity (e.g. pilocarpin); (c) inhibitors of choline esterase (reversible inhibitors: physostigmin, neostigmine and pyridostigmin; irreversible inhibitors: fluostigmin and tetrastigmin).
- In accordance with the further aspect of the invention, a preparation, consisting of (I) an agent, eliminating the hyperactivated effector cells, and (II) of alloreactive cells with preprogrammed cell death, is recommended. The working mechanism of this preparation is based on the replacement of “handicapped”, misprogrammed immunocompetent cells of the patient by the corresponding, in vitro pregenerated (specifically tailored) autologous or homologous/allogeneic immunocompetent cells, a procedure called “microimmunosurgery”. This “microimmunosurgery” can be used in patients (a). with cancer (especially solid tumors) (b) with (retro)viral infections, including AIDS, (c) with autoimmune disorders, and (d) with atherosclerosis-based disorders. In other terms, according to the invention, this preparation represents a combination (a) of breaking down (by impairing or eliminating) the resistance of the pathological set of patient's immunocytes, and (b) of reinfusion of the ex vivo pregenerated (specifically tailored) immunocompetent cells. An additional effect is the circumvention of the critical labile interphase by allogeneic and/or autologous immunocompetent cells, pretreated in vitro in a novel way.
- The impairment or elimination of the “misprogrammed” (pathologic) immunocompetent cells of the recipient (patient) has been described in all details in the patent applications DE 3812605A1 and PCT/EP89/00403. Here, the novel in visor preparation of immunocompetent cells (a) for the critical labile interphase, and (b) for the reinfusion of a new (healthy) set of specifically tailored immunocompetent cells, is dealt with in detail. The problems, associated with bone marrow transplantations (BMT) are an extreme susceptibility of patients for infections and the unevitable “explosion” of residual tumor cells due to the immunocompromized state of the patients. If the donor-bone marrow cells are not completely depleted of immunocompetent T cells, so called graft-versus-leukemia (GvL)-effect of the non-depleted donor T cells helps to increase the resistance against the infection and the tumor; this advantage is, however, associated with the disadvantage of the graft-versus-host (GvH)-reaction which shows similar fatal complications. With autologous BMT, this GvHR can be prevented. A broader clinical use, e.g. in patients with solid tumors, is however dampened by the extreme immunologic lability of the BMT-conditioned patients and the herewith associated enormous costs (ca. 160.000 dollars/patient).
- Both problems, the GvHR in allogeneic system and the extreme immunological instability, associated with extreme costs, both in autologous and allogeneic BMT, can be solved by the 2nd variant of the preparation according to the invention, implicating a novel in vitro premanipulation of allogeneic immunocompetent cells. In this way, both the infection and the tolerancereinduction against the inevitable residual tumor cells in the critical phase, following the removal of primary tumor can be prevented. In autologous BMT, the patient benefits from the “inner immunological stability”, which minimizes the outer, extremely expensive sterility measures. This opens the ways to the introduction of BMT in patients with solid tumors. A further advantage is the replacement of the patient-compromising whole-body-irradiation and/or high-dose chemotherapy by a selective depletion of immunocompetent T cells by different Mabs and Mab-based immunoconjugates. This improvement opens new ways for BMT, both in patients with solid tumors and in those, suffering from autoimmune disorders.
- According to the invention, the preparation is suitable for a therapeutic procedure, consisting of 3 phases:
- (a) In the phase I, the “misprogrammed” immunocompetent cells are eliminated by whole-body-irradiation, by high-dose chemotherapy, by specific Mabs (or corresponding immunotoxins), directed against T cells or their subpopulations (Ts in tumor patients, Tac-R+-cells in autoimmune disorders)
- (b) In the phase II, the in vitro premanipulated, specifically tailored immunocompetent cells are injected into the patient, to confer on the patient immunocompetence in the critical, labile interphase.
- (c) In the phase III, the patient is injected by ex vivo pregenerated effector cells (CTLs, TILs, LAKs in the case of tumor patients and autoantigen-specific Ts in patients with autoimmune disorders).
- Since the phase I is subject of the patent application PCT/EP89/00403 (author: P. Leskovar), only phase II and III will be described here.
- The effector cells, needed for the phase II are generated in vitro as follows:
- (a) Allogeneic (i.e. donor-) T cells/lymphocytes are cultured first in an isoleucine- or serum free medium to synchronize their cell cycle. Then, isoleucine or serum, respectively, is added and following progression in cell cycle (G1. . . S . . . G2-phase), the cells are treated by mitomycin C. The mitomycin-concentration is adjusted in the way to allow a 2-5 cell division before cells die (e.g. 1-5 mg/106 cells). Instead of isoleucin or serum, other essential cell substrates can be used for the cell cycle arrest. Similarly, mitomycin C can be replaced by different mitomycinC-homologs, such as BMV 25282 and BMY 25067, as well as by other DNA-damaging, RNA-sparing substances, such as inhibitors of DNA-polymerase, DNA crosslinking cytotoxic agents and irradiation.
- After 12-24 hrs, ideally 18 hrs of incubation with mitomycin C (or other compounds, damaging DNA in a reversible or irreversible way), the allogeneic (donor-)T cells are resuspended in a fresh medium.
- To improve the in vitro activation, donor lymphocytes of the bone marrow and/or peripheral blood can be preincubated in a kind of one-way-MLC/MLR with the recipient lymphocytes (favorably with T-depleted or preselected MHC II-positive B cells and/or adherent cells).
- This preincubation occurs in isoleucin- or serum free medium; the recipient MHC II-positive cells (B cells) have to be, however, pretreated by mitomycin C or irradiation so that they stay metabolically active but unable to proliferate. During the later mitomycin C-treatment of allogeneic (donor-)lymphocytes (T cells), they get an additional dose of cytotoxic agent, leading to their selective death. The so premanipulated donor cells are activated during the contact with patient's MHC II-positive cells (B cells, monocytes/macrophages, activated T cells), following their infusion into the patient; they secrete IL2 and other cytokines which are reduced or absent in immunoincompetent recipients (due to the lack of mature helper T cells.)
- These donor cells can, however, not induce the fatal GvHR or GvHD, as they are “preprogrammed” and die after few cell divisions.
- (b) By an alternative procedure donor's mitomycin C-pretreated PBMs(without bone marrow) are injected in the first phase, and donor's T-depleted bone marrow is post-transfused in the second phase. The donor T cells, pretreated in this way, can be replaced or combined with allogeneic (donor-) LAK cells.
- Normally, only autologous LAK cells are used therapeutically.
- According to the invention, allogeneic (donor-)instead of or in addition to autologous LAK cells should be used therapeutically. The GvHD-complication is not a problem, because the LAK cells consist of up to 90% activated NK cells and of up to 10% non-MHC-restricted CD3+(T) cells. The T subpopulations which are responsible for the alloreaction and GVHD, cannot survive during the LAK-generation in vitro, due to the lack of antigen (i.e. alloantigen of recipient MHC II-positive cells). T cells can, however, be depleted in vitro by specific Mabs or immunotoxins for reasons of an additional security. Alternatively, L AIC cells can be pretreated in vitro by mitomycin C (or other DNA-damaging substances), as described above.
- (c) If for unknown reasons GvHR or GvHD are observed, so a novel strategy can prevent these complications and the GvHD-establishment in general, according to the invention. The principle is the in vitro generation of alloreactive T cells (a) from recipient or (b) from a third person (second donor), directed against donor cells by means of the MLC/MLR-technique.
- The donor (first donor) cells have to be pretreated by proliferation-preventing mitomycin C-doses in order to be able to act as stimulator cells in the MLC.
- The responder cells (from recipient or 2nd donor) are thereafter treated by mitomycin C (or other DNA-damaging substances) in a way, allowing the cells to divide for 2-5 times before they die.
- To increase further the efficiency, the autoaggressive subpopulation of patient T cells can be preeliminated by immunotoxins, consisting of cytotoxin (e.g. abrin, ricin, doxorubicin,131I-radionuclid) plus IL-2 or anti-Tac/II-2-R-Mab.
- According to the invention, the so pretreated effector cells can be frozen, similar to the effector cells with restricted lifespan, described under (a),(b) and (c), in a medium, containing 8-15% DMSO and PVP or PEG of different concentration and mol weight (patent application DE 3812605 A1 and PCT/EP89/00403).
- The addition of PVP and/or PEG improves the viability and preserves-in contrast to the sole DMSO-addition-the preactivated state of cryopreserved effector cells. In this way, a repeated infusion of effector cells into the recipient became possible.
- An additional improvement is the separation of donor adherent cells (macrophages/monocytes) before the mitomycin C-treatment, followed by their later readdition to the mitomycin C-pretreated effector cells (T cells, lymphocytes) and infusion into the patient.
- Mitomycin C can be combined with interferon (alpha, beta, gamma), TNFalpha, DMSO, vitamin A and E, as well as the (re)differentiation substances, such as butyrate.
- The following procedure is also especially preferred: Patient's lymphocytes can be clonally expanded in vitro into tumoricidal CTLs and plasma cells by mitogenic lectins (PHA,ConA) and mitogenic antibodies (anti-CD3/Ti, anti-CD2/T11). This in vitro postexpansion comprises only the blastogenically pretransformed T and B clones, i.e. memory T and B cells. Since tumor patients have a persistent contact with tumor cells and AIDS/ARC/LAS-patients with HIV and opportunistic infections, respectively, their blood contains corresponding memory cells. Depending on the cell structure conditions, these memory cells can be directed toward CTLs (CD8+, and CD4+) or Ts cells; this opens new ways for their therapeutic use (a) in tumor- and AIDS-patients, and (b) in patients with autoimmune disorders.
- If the resistance (immunocompetence) of the patient is temporarily down-regulated, the infusion of in vitro clonally postexpanded patient's lymphocytes (T cells) can have an essential impact on the disease development. The expansion of CTLs can be achieved e.g., by the PHA-treatment for 3-6 days. The autotolerant Ts cells, necessary for the therapy of autoimmune disorders, can be generated e.g. by the treatment with PWM for 7 days or with the PHA for 3-4 weeks. The CD8+-rise is accompanied by a CD4+-drop. These Ts cells can be cultured for more than 6 months under following conditions: 2 times weekly, IL2 is added to the medium and cells are restimulated by feeder cells and PHA every 2 weeks. These cells suppress the proliferation of autologous and heterologous CD4+T cells when stimulated by PWM, OKT3 or tetanus-toxoid.
- Alternatively, Ts cells can be generated in vitro in the presence of PGE2, anti-IL1, anti-IL2, anti-IL4, cyclosporinA, rapamycin and/or FK506.
- The Ts-depleted cytotoxic effector cells, needed in the tumor and AIDS/ARC-therapy, can alternatively be enriched by the elimination of CD8+cells (by means of Mabs or immunotoxins). The spared CD4+T cells are able to induce in vivo new CTLS; this process is accelerated by anti-PGE2, anti-lipocortin/macrocortin and anti-TGF-beta. In AIDS/ARC/LAS-patients, it is advantageous to preimmunize the patient with the lysate of opportunistic infections, before the in vitro expansion of memory cells; alternatively, a healthy donor can be preimmunized (a) ,with a viral antigen (8p 120) and (b) with mentioned lysate.
- The so generated clonally postexpanded allogeneic memory cells (T and B cells) can be treated by mitomycin C, washed and injected into the AIDS-patient.
- Atherosclerosis and other coronary diseases show an autoimmune genesis (our own experiments, reports of others, e.g. W. Hollander); therefore, the agent(s), based on “microimmunosurgery”, are able to replace or support the “conventional” treatment.
- According to the invention, hyperactivated B or T or both B and T cells of atherosclerotic patients are depleted/inactivated by means of “microimmunosurgery”. It is advantageous to replace them by the in vitro pregenerated Ts fraction. These Ts cells can be generated by a simple, 3-5 week incubation of patient's PBMs with ConA or PHA. Alternatively or supportingly, the patient can be treated by special preparations which inactivate the hyperactivated macrophages; they consist of Fab/F(ab′)2-subunits (labeling) or immunotoxins (depletion), directed (a) against the (acid-labile and acid-resistant) Fc(gaTnma)-receptor, (b) against the complement receptor (CRT, CR3), (c) against the scavenger/AcLDL-receptor (I and II), (d) against the gamma-interferon-receptor and /or (e) against the LPs/endotoxin-receptor. Alternatively, the biotechnologically synthesized receptor per se or its subunits can be used therapeutically.
- In addition, denatured (e.g. heat-denatured) complement subunits (clq, c3b, c3d etc.) or biotechnologically produced defect C-components can be used; they can be combined with antioxidants (vitamin E,A, probucol). The in vivo neutralization of the solubilized ApoB,E- and ApoE-receptor in the patient's plasma, following their quantitative determination in vitro, is also advantageous.
- An alternative way comprises a combination (a) with Ca-antagonists/Ca-channel blockers (verapamil, nifedipin, dilthiatem), (b) with cGMP-increasing substances (e.g. Na-nitroprusside, org. nitrates), and (c) with pHi-raising substances. In this way, the replacement of “wrongly programmed” (hyperactivated) macrophages by “fresh” monocytes should take place.
- The protracted or repeated microimmunosurgery includes the prevention of neutralizing antibodies against xenogeneic (mostly murine) Mabs and Mab-based immunoconjugates by substances, specified in the patent application PCT/EP89/00403, as well as by some procedures, described here:
- (1) Prevention of neutralizing antibodies by the pretreatment of recipient with Mabs which are coupled as a kind of hapten to a tolerogen as carrier. Examples of such tolerogenic carriers are polyethyleneglycol (PEG), polyvinylpyrrolidone (PVP) and different copolymers of D-amino acids (e.g. D-glutamine-lysine, shortly D-GL).
- (2) The same principle (like under (1)) can be applied to different immunoconjugates, e.g. conjugates of Mabs (directed against tumor cells, viral/bacterial infections, leukocytesubpopulations) with (a) cytotoxins, such as ricin or abrin, (b) with cytotoxic agents, such as doxorubicin, (c) with radionuclids, such as131I, and (d) with target cells-starving enzymes, such as arginase, asparaginase etc. A two-step-administration (first sub-immunogenic, then immunogenic dose), can additionally potentiate the effect.
- (3) Neutralizing antibodies against xenogeneic (murine) proteins (e.g.Mabs) can be prevented also by strictly monomeric, molecular-dispersed structure of these xenogeneic proteins, which can be achieved by their pretreatment (a) by mercaptoethanol (b) by glutathione (c) by N-acetyl-cysteine (d) by penicillamine D (e) by other substances which support the disulfide-to-thioVsulfhydril-interconversion, as well as by 6M-urea and guanidine-hydrochloride.
- (4) Prevention of neutralizing antibodies by a direct in vivo use of Mab-producing plasma cells, which induce a low-zone tolerance against xenogeneic proteins by secreting strictly monomeric Mabs; these are not xenogenized by in vitro manipulation.
- (5) Prevention of neutralizing antibodies by the direct in vivo use of Mab-secreting hybridoma cells, which were pretreated in vitro by mitomycin C and/or other DNA-crosslinking cytotoxic agents (restricted lifespan, 2-5 cell divisions only).
- (6) Prevention of neutralizing antibodies by aggregate-preventing substances, e.g. protein-solubilizing tensids (e.g. salts of higher fatty acids, Iysolecithin) at extremely low concentrations).
- As next, some further details to this invention will be dealt with:
- The hyperactivated, suppressive macrophages can be inactivated as follows:
- (a) by antioxydants (b) by inhibitors of enzymes, involved in ROI-synthesis (c) by PAF-blockers (d) by PLAZ/PLC-inhibitors and/or (e) by Ca-channel blockers/ Ca-antagonists. In the 2nd phase, the recruitment of new macrophages from monocytes is foreseen.
- The in vitro generation of blastogenically pretransformed (memory) cells can be accelerated if patient's PBMs are first treated by anti-CD8- and/or anti-CD3-Mabs plus complement or by corresponding immunotoxins. This leads to a partial Ts-depletion and should be followed by the treatment with mitogens (lectins or mitogenic Mabs).
- In patients with autoimmune disorders, the addition of Ts -stimulating substances (anti-HLA-DR-Mab, anti -LFA- lbeta-Mab, cyclosporinA, corticosteroids, FK 506, rapamycin, ConA) and in patients, suffering of cancer or AIDS (and other viral diseases), the addition of Tc(CTL)-promoting substances (anti-HLA-DQ-Mab, anti-LFA-alpha-Mab, cyclooxygenase-inhibitors such as aspirin, indomethacin, anti-PGE-Mab etc.) is recommended. The preferred generation of Tc instead of Ts cells can be observed in vitro also when adherent cells are removed. This technique is based on the effect of ex vivo specifically tailored effector cells on the disease regression; the patient's immunologic resistance has to be temporarily reduced by anti-CD8-Mab and/or anti-CD3-Mab (in the case of tumor- and AIDS-patients) and by anti-CD3-Mab (in patients with autoimmune disorders): The therapeutic efficiency in tumor patients is further increased if patient's tumor cells are incubated in the presence of gamma-interferon, TNFalpha and/or 5-HETE in order to induce MHC I and/or MHC II-postexpression on the cells and are then reinjected along with patient's specifically tailored, in vitro postexpanded memory cells.
- A further increase in efficiency can be achieved by the confusion of patient's glutaraldehyde-pretreated macrophages which have been preincubated with tumor antigen. An additional advantage is the confusion of patient's inactivated (preirradiated or glutaraldehyde-pretreated) leukocytes (PBMs) which results in the induction of antiidiotypes, directed against patient's Ts cells. The infusion of hybridoma cells, based on patient's tumor cells and MHC II-positive autologous and homologous cells is advantageous, as well.
- The above discussed LAK/TIL-techniques can be further improved by adding mitomycin C-pretreated allogeneic (donor) T cells to LAK or TIL cells. This increases the number of lymphokine-secreting cells which is especially important for the TIL-technique.
- These premanipulated allogeneic cells are able to play a similar positive role in bone marrow recipients. The preexpanded allogeneic cells can be used also in the treatment of autoimmune disorders and GvHD, if they are pretreated by DNA-damaging agents. The RES-elimination (99%) of LAK and TIL cells due to their “xenogenization” during the ex vivo manipulation can be reduced, according to the invention, by addition of alpha2-macroglobulin, antitrypsin and/or cortisone to the medium.
- A variant of the described procedure renders the externally controlled in vivo production (a) of cytokines (e.g. TNFalpha, IL-1, IL-2, IL4, IL-6, IL-3, G-CSF, M-CSF, GM-CSF), (b) of hormones (e.g. insulin, parathormone etc.), and (c) of other physiologically important cell factors possible. The principle is the transfection of donor specific recipient T cells by corresponding, these cytokines or hormones encoding genes; the preselection of alloreactive, donor-specific recipient T cells can be achieved by a (repeated) one-way- MLC (stimulator cells: donor-PBMs; responder cells: recipient-PBMs).
- After the reinfusion of the transfected recipient T cells, these can be repeatedly reactivated in vivo to secrete cytokines or hormones by injecting i.v. inactivated (mitomycin C-pretreated or preirradiated) donor-PBMs. After the in vitro pregeneration of autologous, alloreactive T memory cells, directed against donor A, donor B, donor C etc., different functions can be transfected donor-dependently into these recipient memory cells and “recalled” in vivo, following the reinjection of these manipulated autologous cells into the recipient. By the intratumoral injection of these cells, the effect can be localized to the tumor tissue. A similar in vivo “switching on” of the desired function can be achieved by the following procedure: the recipient T cells are first primed in vivo by a model antigen and then clonally postexpanded in vitro in the presence of the same antigen. In the next step, these cells are transfected by the gene of interest, e.g. cytokine- or hormone encoding gene(s) and reinjected into the recipient, favorably after the temporary depletion of recipient's immunocompetent cells. Later restimulation of the recipient by the same model antigen “turns on” the desired (“transfected”) cell function. Representatives of such antigens are tuberculin and other antigens, used in cutaneous tests, as well as haptens (DNCB, DNBB, DNBS, TNBS etc.).
- Instead of the above described alloantigens and model antigens, low-dose allergens can be used.
- This externally controlled in vivo secretion of cytokines is of special interest in the therapy of strongly immunocompromised patients (AIDS/ARC/LAS-patients, patients with advanced cancer, recipients of bone marrow grafts).
- The above discussed transplantation (a) of organs (b) of bone marrow and (c) of mitomycin C-pretreated, hormones (e.g. insulin) and cytokines-secreting allogeneic or xenogeneic cells and hybridomas can be essentially improved by the following procedure: First, the immune resistance of the recipient must be temporarily down-regulated (“broken”) by specific antibodies (anti-panT- or anti-CD8-Mabs) or Mab-based immunotoxins. Then, the in vitro pregenerated suppressor T cells (Ts)(see above!) are reinjected, immediately before the transplantation. The main advantage over the “conventional” grafts is that here—in contrast to the “conventional” grafts—the recipient is not confronted “unexperienced” with the MHC II-positive donor cells (bone marrow macrophages and B cells, as well as “passenger lymphocytes” in organ grafts) but preinjected by allotolerant Ts cells; these donor-specific Ts-memory cells direct the CD4/CD8-double positive precursor cells (inducer/transducer suppressor cells) towards the Ts-effector cells before the alloreactive Tc/CTL cells predominate. This seemingly minimal deviation in the procedure can decide about the survival of organ- and bone marrow recipients.
- The tolerance against the organ or bone marrow graft, as well as against the hormone (e.g. insulin) or cytokine-producing allogeneic cells can be induced also in the following way: Alloreactive donor-specific recipient T cells are selected and expanded in vitro by means of MLC (responder cells: recipient PBMs, stimulator cells: donor PBMs). The repeated MLC results in a 95% enrichment of these alloreactive T cells. The next step is the inactivation of recipient's donor-specific alloreactive PBMs or T cells by irradiation or mitomycin C: Before they are injected into the recipient, the latter must be temporarily rendered immunoincompetent (by anti-CD3- or anti-CD1- or anti-CD8-Mab). The principle here is the induction of anti-idiotypes in the recipient (in vivo), before this encounters MHC II-positive donor cells (bone marrow cells or “passenger lymphocytes”). Therefore, this induction of anti-idiotypes has to be carried out several days before the real transplantation.
- Problems, associated with the transplantation, such as immune suppression or susceptibility for infection can be reduced by the co-infusion of in vitro inactivated allogeneic (donor) MHC II-positive cells (B cells, macrophages), along with the allotolerant Ts cells. These MHC II-positive cells can be pregenerated in vitro by a kind of MLC (responder cells: recipient-PBMs, stimulator cells: donor-PBMs), frozen and during or after the transplantation repeatedly reinjected into the recipient.
- The precursor cells can be directed toward Ts cells by the addition of anti-HLA-DR- and/or anti-LFA-lbeta-Mabs. In contrast, the generation of Tc/CTLs can be induced in the presence of anti-HLA-DQ- and/or anti-LFA-lalpha-Mabs. The rise of MHC II-positive APCs (“passenger lymphocytes”), which is critical for the graft failure, can be prevented by the addition of anti-HLA-DR-Mab or the corresponding Fab/F(ab′)2-subunit and/or Ca-channel blocker (verapamil,nifedipin, dilthiazem).
- A further improvement of the above discussed LAK/TIL-technique can be-achieved (a) by co-infusion of mitomycin C- preinactivated allogeneic, MHC II-positive cells (B cells, adherent cells), and (b) by the addition of sub-dosed corticosteroids and/or serum proteinase inhibitors (alpha2-macroglobulin or alphal-antitrypsin) to the medium during LAK or TIL generation. The so modified culture medium prevents the in vitro xenogenization of LAK and TIL cells and herewith their early RES-elimination in vivo.
- The activation of tumoricidal/virucidal effector cells can be achieved also through a controlled treatment of these effector cells (NK cells, T cells, macrophages) (a) by fusogenic substances in sub-fusogenic concentrations (e.g. PEG, PVP), further (b) by electrofusion under sub-fusogenic conditions (1000-5000 kHz; 10-150 V/cm2) and/or (c) by proteolytic enzymes and lipases.
- The above described hybridomas can be used, according to the invention, also to stabilize and to establish herewith new cell lines which normally wouldn't survive in vitro.
- An improved localization of the above described, transfected, cytokines or hormones secreting T cells can be achieved by “arming” of these transfected cells with bifunctional Mabs which recognize these both transfected cells and the tumor cells.
- In order to induce a kind of allergic reaction against tumor cells, the “conventional” anti-tumor-Mabs which are normally of the IgG-isotype, can be combined with anti-tumor-Mabs of the IgE-isotype. The latter can be produced in vitro by the “isotype switching” of plasma cells from the IgG- to the IgE-production; the process of “isotype switching” can be induced by addition of anti-gamma interferon and anti-IL2-Mab, as well as IL3, IL4 and IL5 to the medium. A simultaneous addition of anti-CD8-Mab is advantageous. In the case of anti-tumor-IgGs the immortalization (hybridoma formation) is carried out before and in the case of anti-tumor-IgEs after the “isotype switching” of plasma cells. Alternatively, anti-tumor-Mabs of the IgE-isotype can be constructed by the conjugation of xenogeneic (murine) anti-tumor-Mabs (more precisely: Fab/F(ab′)2-subunits) with human Fc-subunits.
- According to a further variant, a direct in vivo use of hybridoma cells, produced before (IgG) or after (IgE) the “isotype switching” is recommended; these hybridoma cells have to be pretreated by DNA-damaging, RNA-sparing agents (e.g. MMS, mitomycin C etc.)
- In a further variant, anti-gamma-interferon plus IL4 (IL-3, IL-5) are directly injected into the patient; herewith the activity of TH2 cells is increased and that of TH1 cells depressed which leads to an early “isotype-switching”.
- The next strategy is the replacement of the immortalizing (transformed) partner cell (e.g. NS-1) in the hybridoma and quadroma cell by MHC II/HLA-DR-positive (allogeneic) cell. In this way, the hybridoma and quadroma cells can be externally switched on and off. The new procedure is based (a) on the in vitro pregeneration of alloreactive T cells of the recipient, directed against the donor A and further donors (donor B. donor C etc.) by means of the (repeated) MLC, (b) on the fusion of preselected alloreactive memory-T-cells with partner cells which are used for “conventiona” hybridizations (e.g. anti-tumor-Mab producing plasma cells), as well as (c) on the reinfusion of the so generated hybridoma cells into the temporarily immunocompetent recipient. These hybridoma cells which are well tolerated, as they are fully (in the case of human autologous plasma cells) or partially autologous (in the case of murine plasma cells), can be later reactivated repeatedly by the injection of donor-lymphocytes.
- A kind of tumor-directed “autoreactivity” can be achieved as follows: tumor cells of the patient are stimulated in vitro by gamma-interferon (TNFalpha,5HETE) to post-express MHC II (and MHC I) on the cell surface. Alternatively, tumor cells can be fused (a) with autologous or (b) allogeneic, MHC II-positive cells and washed thoroughly.
- A further xenogenization of patient's tumor cells can be achieved by the fusion with LPS-containing gram-negative bacteria and/or yeast cells. After their inactivation, these manipulated tumor cells are injected into the patient who has to be rendered immunoincompetent temporarily (by injection of anti-CD3-, anti-CD1, anti-CD2- or anti-CD8-Mab). In this way, the autoaggression against tumor cells can be induced.
- Hybridoma cells, arising from patient's tumor cells and MHC II-positive allogeneic cells (e.g. allogeneic B cells) are able to accelerate the induction of the autoaggressive reaction against tumor cells if they are combined with (repeated) injection of inactivated PBMs from that donor whose MHC II-positive cells were used as partner cells for the hybridization with patient's tumor cells (see above).
- The same techniques can also be used for the improvement of conventional vaccines (e.g. against bacterial and (retro)viral infections, including HIV). So, the efficiency of conventional vaccines is essentially increased if they are combined with anti-CD8-Mabs (or the corresponding immunotoxins) and/or with complete and incomplete (Freud)-adjuvant. It is also advantageous to combine the 1st vaccination (“priming”) but not the 2nd vaccination (“boosting”) with anti-B-cell-Mabs (e.g. anti-CD19-, anti-20-, anti-CD21-, anti-CD22-Mab). The in vitro preformed immune complexes, composed of pathogen and anti-pathogen (IgM-isotype) with or without bound complement or complement-subunits (clq, c3b/c3d etc) can also be promising. Alternatively, the efficacy of the vaccine can be improved by IgE-inducing IL3, IL4, IL5 and anti-gamma-interferon.
- The above discussed GvHD can be prevented also by autologous PBMs which have been also preactivated by a repeated MLC. In this MLC, the responder cells are autologous (recipient) PBMs and stimulator cells the allogeneic (donor) PBMs; the latter have to be preirradiated or mitomycin C-pretreated. The repeated co-incubation of donor- and recipient-PBMs leads to the generation of highly efficient alloreactive memory cells which are able to eliminate the GvHD-causing donor-T-cells.
- The autologous BMT can be improved: (a) by preelimination of suppressor-T-cells in vitro, e.g. by anti-CD8-Mabs or corresponding immunotoxins, (b) by in vitro preactivation of effector cells, (c) by addition of autologous and/or allogeneic LAK-cells (the allogeneic LAK-cells can, but need not be predepleted of CD3-positive cells), (d) by addition of autologous, CD8+-depleted PBMs to the autologous bone marrow cells (the PBMs should be preactivated in a tumor-specific way), as well as (e) by the addition of allogeneic, favorably preactivated allogeneic PBMs which have to be pretreated by mitomycin C or other DNA-damaging and RNA-sparing substances in order to confer to the alloreactive subpopulation a restricted lifespan.
- According to the invention, the stepwise addition of increasing doses of anti-CD8- or anti-CD3-Mab plus complement (or of corresponding immunotoxins) to the patient's PBMs allows the determination of the critical T cell number/ml which directs the immune response from suppression to stimulation (deblockade) of T4 and B memory cells. The so premanipulated autologous PBMs mimic the favorable clinical situation, when autologous marrow cells are collected during remission (PR or CR) and not during relapse.
- This technique is recommended especially for patients with solid tumors, as well as for AIDS/ARC/LAS-patients.
- The above mentioned LAK dells show the special advantage that they cannot be contaminated with (tumor-specific) Ts cells; a further advantage is the lymphokine-production by autologous T cells, directed against allogeneic LAK-cells, which is especially important for immunocompromized recipients. The LAK-cells of one or more persons could be frozen and used for different patients, especially after an anti-CD3-pretreatment (“standardized LAK-cells”).
- As next, some additional improvements of the techniques described above should be quoted: So, the restricted lifespan of hybridoma cells can be achieved by the change of the ratio of partner cells during hybridization, instead of the treatment of hybridoma cells with DNA-damaging and RNA-sparing agents. it concerns the chemical (PEG) and viral (SV-40) fusion, as well as the electrofusion.
- If the ratio of partner cells which contribute to the immortalization of hybridoma cells in comparison to those which contribute the desired function is reduced from “classical” 1:1 to 1:2; 1:3; 1:4; 1:51: . . . 1:10, a controlled longevity of hybridoma constructs can be achieved, similar to that, achievable by low-dose mitomycin C. By an early fusion of instable cell lines, which don't grow ex vivo, with transformed cells, these cells can be “stabilized” and are able to survive in vitro.
- According to the invention, the fusion of lymphokine and hormone-producing cells with transformed cells, followed by the mitomycin C-treatment, opens for the first time the possibility of a direct in vivo implantation of cytokine and hormone-producing cells (e.g. insulin production). The so pretreated secretory cells die after a limited number of cell divisions and can be substituted by a new set of premanipulated cells; this allows an efficient control of the cytokine and hormone level.
- The tolerance against such secretory cells can be achieved (a) by the simultaneous treatment with immunosuppressive substances (cytotoxic agents, sub-dosed anti-CD4- or anti-MHC II-Mab), (b) by cell implantation in thymus and/or (c) by “autologization”, i.e. by use of autologous partner cells for hybridization. Further comments: In AIDS-patients, the in vitro presensibilization of patient's lymphocytes (T cells) by preirradiated of mitomycin C-pretreated donor-lymphocytes (T cells), followed by the transfection of alloactivated patient's T cells with cytokine or anti-HIV-Ab-producing genes, and reinfusion of the so transfected autologous T cells into the patient is recommended. A part of transfected cells can carry the gene for the IgG-isotype and the other part that for the IgE-isotype. The later “switching on” of the cytokine and antibody-production occurs by the injection of inactivated donor lymphocytes.
- According to a simplified version, the patient's T cells in general, not only his donor-specific alloreactive T-subclones can be transfected in vitro with cytokine and/or anti-HIV-antibodies-encoding genes, and reinjected into-the patient. Again, the later “switching on” of the in vivo cytokine and antibody production occurs by the injection of donor-lymphocytes; the system works because patient's lymphocytes always contain T cells which are alloreactive against the donor.
- In conventional vaccines, the ratio between “positive” (Th andTc/CTL) and “negative” (Ts) memory cells can be increased as follows: (a) In the 2nd phase, i.e. 4-6 days after the vaccination, the couterregulation of persistently activated macrophages can be delayed by Ca-channel blockers and macrophages-inactivating measures (ROI-inactivating agents, such as retinol, tocopherol or carotinoids, glutathione, ascorbate, radical-scavengers). (b) With anti-HLA-DQ (not DR) and anti-LFA-lalpha (not beta), the (Th+Tc)/Ts-ratio can be positively influenced. (c) A similar effect (increase of the (Th+Tc)/Ts-ratio) can be achieved by antilipomodulin/anti-lipocortin/anti-macrocortin-Mabs and/or mellitin. (d) Ba the conjugation of pathogen antigens (viral or bacterial structures) to carriers which are used as components of common vaccines, such as tetanus and diphterytoxoids, tuberculin, inactivated M. tuberculosis and BCG; the efficiency of conventional vaccines can be further increased. (e) an additional improvement is the use of anti-thymosine-alpha7 (not alphal). (f) The efficiency of vaccines can be also increased by anti-PGE2(El) and by PGF2alpha. (g) The resistance against pathogenic microbes can be increased as well, if first contact with antigen structures of the pathogen (e.g. gp 120/160 or gp 41 of HIV) occurs via alveolar macrophages which prevents its early contact with Ts cells (as in the case of the i.v. administration). Therefore, the sensibilization by aerosol-spray as the only or at least first step (“priming”) is recommended. (h) In the 2nd phase of vaccination, i.e. 4-7 days after vaccination, the Ts generation should be prevented by anti-PGE2- and anti-interferon-Mabs. (i) The in vitro preformed IgE.antigen:IgE-complexes are able to activate the IgE-R-expressing cells (macrophages, NCF-A-, ECF-A- and kininprotease-secreting mast cells) in the critical early phase.
- Some additional techniques: (a) Tumor patients can be treated by inactivated hybridoma cells, arising from patient's tumor cells and allogeneic (donor) cells of the same origin, i.e. the same organ like tumor. An example are leukemia cells, fusioned by the same lymphocyte-subclass of the healthy donor. (b) The Th(=TM) cells can be stimulated in vivo if the injection of antibodies of the IgM-isotype is followed by the injection of the corresponding antigen. Analogously, the TS(TG) cells can be stimulated in vivo by the successive infusion of IgG and the corresponding antigen. (c) Similarly to the above described “allogeneic switching”, autologous lymphocytes can be primed in vitro by a model antigen and the resulting memory cells transfected by cytokine and Mab-encoding genes. After the reinfusion they respond to the resensibilization by the same model antigen. The strongest response show the cutaneous antigens. It is advantageous to use the preexistent memory cells which stem e.g. from previous vaccinations (e.g. tuberculin) or sensibilization (DNCB, DNBB, TNBS) . (d) By anti-CD3-, anti-TCR/Ti-, anti-CD2/T11- and other mitogenic Mabs, the memory but not naive T cells can be stimulated to proliferate; in naive/non-primed T cells, the mean distance between membrane antigens of the same structure, e.g. CD3 or Ti is too long to be “bridged” by both Fab-subunits. Therefore, novel antibodies are recommended according to the invention, containing two or more anti-CD3(Ti, CS2. . . )-Mabs or their Fab/F(ab′)2-subunits, conjugated to different spacer-molecules; this renders a direct crosslinking of CD3-, Ti-, CD2- and other membrane structures possible even on naive Th- cells. In this way, an APC-independent activation of naive Th-cells is possible which can be of relevance in immunosuppressed AIDS and tumor patients.
- In order to prevent at the same time the neutralizing antibodies against xenogeneic (murine) Mabs, the use of strong tolerogens, especially polymers/copolymers of D-amino acids, e.g. D-GL, or PEG or heparin or sialic acid-based polymers, is recommended.
- The efficacy of the novel type of antibodies can be further increased by their combination with interferon which increases the surface density of structures to be crosslinked.
- The tumoricidal and/or virucidal effector cells can be activated in a novel way by conjugating Mabs or their Fab/F(ab′)2-subunits, recognizing (a) cytokine receptors or (b) growth factors (EGF, IGF, PDGF etc.) with spacer molecules, e.g. the CH2)n-chain or D-GL. D-polylysine as spacer molecule is of special interest, as it is a tolerogen and as it facilitates—through the positive charge—the approach of the Mab-construct to the target cell. The same is true with the polymers or copolymers of other basic, D-aminoacids. The here described new principle of introducing spacer molecules as carriers of Mabs with the same or different specifity, is also applicable for all simple or combined Mabs, specified in the patent applications PCT/EP ()/00403 and DE 3812605A1. (e) Since LAK cells consist to 90% of NK cells and to 10% of non-MHC-restricted CD3+-cells and are free of alloreactive, GvH-inducing T cells, the allogeneic LAK cells can be used to circumvent the immunoincompetent phase which is critical for later relapses (a) in bone marrow recipients and (b) in patients, immediately following tumor surgery. LAK cells can be depleted of T cells before their infusion into the patient. LAK cells can be frozen by a special procedure (with PEG/PVP-addition to DMSO), preserving their preactivated state.
- *(f) Atherosclerosis seems to be induced by an autoimmune primer, including hyperactivated macrophages. The latter can be depressed (a) by corticosteroids (b) by Ca-antagonists (c) by masking the Fc and CR1/CR3-receptors with Fab/F(ab′)2-subunits of the anti-receptor-Mabs (d) by ROI-reducing agents and radical-scavengers, and (e) by anti-CD19(CD20, CD21, CS22)-Mabs (temporary depletion of CIS-producing B-cells). Within the inflammatory tissue, the immunocytes are exposed (a) to hypoxic/anoxic and/or (b) acidic micromilieu. (a) The unfavorable redox-potential in this tissue has to be normalized by O2-carriers (e.g. oxoferin, TCDO=tetrachlorodekaoxid) and/or by other electrone acceptors (e.g. ascorbate, dehydro-ascorbate, (poly)unsaturated fatty acids). (b) The low pH in the inflammation tissue inhibits immunocompetent cells. By the pH-rise, the H+/Na+-pump of immunocytes must be relieved. Examples of pHi,-raising agents are quaternary bases and their salts (carbonate, citrate, maleate), further TRIZMA (as base or as salt), THAM/tromethamine/trometanol, mono-, di- and triethanolamine, etc. An intracellular pH-rise to 7.3-7.6 is the prerequisite for cell proliferation. The O2-deficit is associated also with prostaglandin instead of leukotrien-synthesis. In order to down-regulate the immunosuppressive effect of hyperactivated macrophages on immunocompetent cells in inflammatory tissue (tumor, persistent infection etc.), the following steps are recommended: (a) treatment by Mabs and immunotoxins, directed against the surface antigens on end differentiated macrophages (x−4, x−11, x−12, x−14, x−15) and against the differentiation antigens on hyperactivated macrophages (b) treatment by cytotoxic substances, encapsulated in liposomes (c) treatment by agents which stabilize the lysosome-membrane in macrophages (e.g. gold preparations such as aurothioglucose, aurothiopolypeptide or Na-aurothiomalate, further antimalaria-agents such as chloroquine and D-penicillamine).
- The proteases are able to switch the cell from the suppressor- to the effector function. The GEF (glycosylation enhancing factor), a kallikreinlike kinin-protease prevents the GIF (glycosylation inhibition factor)-induced immune suppression; a membrane-associated serine-protease is directly involved in the process of cell activation.
- The lipases are able to activate -via lysophosphatideimmunocytes (macrophages, NK-, K-, T-cells). This activation results partly from the mimicking of membrane-associated phospholipases (PLC, PLA2). The effect of mucopolysaccharidase is similar to that of proteases. Therefore, the deblockade of immunocytes by proteases, lipases and mucopolysaccharidases is recommended, both per se or in combination with the above described cell activators.
- Interferons, TNFalpha and TGFB switch the cell from proliferation to dedifferentiation. Their pathologically increased levels exert an antiproliferative effect on precursor cells, depressing in this way the recruitment of immunocompetent cells. Such pathologically raised levels of cytokines can be measured in AIDS- and tumor-patients, but also in autoimmune disorders and persistent infections. Therefore, these antiproliferative cytokines should be neutralized by specific Mabs. In tumor- and AIDS-patients, the immune response can be improved by special conjugates, consisting of the Fab/F(ab′)2-subunit of tumor- or HIV-specific Mabs of murine origin plus the Fc epsilon-subunit of human origin.
- Some membrane-associated immunorelevant structures (e.g. MHC II, MHC I, CD4, CD8, B2m) become immunosuppressive if they are shedded into the plasma. The neutralization of such solubilized membrane structures by specific Mabs helps to prevent their immunosuppressive effect.
- A further advantage is the use of anti-HLA-DQ- and anti-LFA-lalpha Mabs.
- The following procedure is of special interest:
- (a) Tumor patients are first in vivo depleted of the tumor-protecting suppressor T cells (see patent applications DE3812605A1 and PCT 94/EP89/00403.
- (b) Patient's tumor cells are treated in vitro by IFN gamma and/or TNF allpha (postexpression of MHC II and MHC I), inactivated by anti-HLA-DQ- and/or anti -LFA-lalpha or their Fab/F(ab′)-subunit and reinjected into the patient. Alternatively, the tumor cells can be fusioned (in the presence of PEG) with autologous and/or allogeneic MHC II-positive cells (B cells or macrophages)., treated by anti-HLA-DQ- and/or anti-LFA-lalpha-Mab and reinjected into the patient. Both alternative procedures include the immune reactivation of the patient as an important step.
- The principle of the here discussed novel tumor therapy is to combine (a) the temporary breaking of resistance of immunocompetent cells with (b) the reinfusion of in vitro pregenerated tumor-specific T cells. It is essential that these cells are memory cells; according to laws of the so-called “restricted” CML (CML to non-MHC-molecules), only the blastogenically pretransformed T cells are able to induce in vitro the response to the (soluble) antigen in question.
- The tumor-specific T cells are capable to induce in vivo a kind of autoimmune reaction against the tumor antigen if they are generated as follows:
- (a) Patient's lymphocytes (T cells) are postexpanded in vitro polyclonally, e.g. by PHA, then the CD8-positive Ts cells are eliminated e.g. by specific Mabs or immunotoxins, and the residual CD4-positive T cells are reinjected into the patient, along with the memory cells. In vivo, these T4 cells are able to induce the CTLs with specificity for tumor cells. Instead of the CD8+-postdepletion, the inducer-suppressor subpopulation can be inactivated in advance by a 500 Rad-preirradiation.
- (b) Alternatively, patient's lymphocytes (T cells) can be co-incubated in vitro with his malignant cells, after these have been induced to post-express the MHC II-antigen.
- (c) An interesting further way comprises the reinfusion of patient's lymphocytes (T cells), along with mitomycin C-pretreated patient's macrophages.
- The success of organ- and bone marrow transplantation can be essentially improved if the donor organ, more precisely its “passenger lymphocytes”. or donor bone marrow cells, respectively, are pretreated in vitro by anti-HLA-DR- and/or anti-LFA-lalpha-Mabs (or their Fab/F(ab′)2-subunit)
- Alternatively or additionally, the MHC-postexpression on “passenger lymphocytes” can be depressed by Ca-antagonists (e.g. verapamil, nifedipin, diltiazem) or by anti-mitogenic substances (colchicin, domecolcin, gliotoxin). This MHC II- postexpression, following the organ surgery seems to be critical for the later organ rejection. As mentioned above, the bone marrow cryopreservation can be essentially improved by the addition of PEG and/or PVP of dofferent mol weight to DMSO.
- An interesting novel approach in tumor therapy is the use of hybridoma cells with restricted lifespan, constructed of tumor-specific immunocytes and mitomycinC-pretreated immortalized partner cells. One variant proposes (a) to fuse the pregenerated immunocytes with myeloma cells which are routinely used for hybridization purpose, and to treat the resulting hybridoma cells with mitomycin C. (b) The other possibility is to fuse the pregenerated immunocytes with mitomycinc-pretreated myeloma partner cells, or(c) to use the commercially available non-transformed fibro-blasts or embryonal cells instead of myeloma cells as partner cells. Instead of mitomycin C, other cell proliferation-limiting agents or a controlled cell irradiation can be foreseen.
- A typical mitomycin-concentration is 10 ug/ml, a typical incubation time 18 hours (for 5 ug/106 cells). In this way, hybridoma cells, based on tumor-specific plasma cells, CTLs, NK-, K/ADCC-cells and preactivated macrophages can be constructed. They can be kept in culture or frozen (PEG and/or PVP addition to DMSO); the preservation of the preactivated state by this improved cryoprotective mixture is of special relevance for repeated infusion. The use of the HAT- or HAs-medium guarantees a sufficient selection of the hybridoma cells; a time-consuming cloning is not necessary.
- As next, some novel approaches in the treatment of cancer, chronic infections and autoimmune disorders, respectively, should be discussed briefly.
- (1) In tumor patients and patients with(chronic) infections, especially those with (retro)viral infections, the treatment with anti-B-cell-Mabs is recommended, since the level of immunosuppressive ICs is reduced and CTL-hindering, antigen-masking specific antibodies are prevented to be synthesized. Examples of such Mabs are anti-CD19-, anti-CD20-, anti-CD21- and anti-CD22-Mab, as well as polyclonal anti-B-cell antibodies.
- (2) Due to the negative impact of persistently activated macrophages on the progress of the disease, their elimination by monoclonal and polyclonal antibodies, both in tumor patients and in patients.. with chronic infections, including (retro)viral (HIV)ones, -is recommended.
- Examples: anti-CD 15-, anti-CD 14-, anti-CD11c- and anti CD 11b-Mates.
- (3) The Mabs, described under points (1) and (2) can be injected as coctail too.
- (4) The points (1), (2) and (3) are valid also for the patients with autoimmune disorders.
- (5) The Mabs can be replaced by their conjugates with cytokines, radionuclids and/or cytotoxic agents to increase their efficacy.
- (6) The Mabs can be also replaced by Fab/Fab′)2-subunits, masking—not eliminating—B cells and macrophages.
- (7) An essential progress in tumor therapy, according to the invention, is the introduction of tumor cells with post-expressed MHC II, induced by interferons and/or TNFaipha. Before the reinjection, tumor cells are inactivated by mitomycin C, by heat or formaldebyde and/or glutaraldehyde.
- (8) Alternatively, to point (7), hybridoma cells, arising from the fusion (in 20-40% PEG) of tumor cells with patient's MHC II-positive cells (macrophages, B cells), can be used. This cell fusion can be carried out with non-viable cells and doesn't include cell cloning.
- (9) A further possibility is the presentation of tumor antigen plus autologous MHC II-antigen on the surface of liposomes.
- (10) A new principle in tumor therapy is the mimicking of the strong immune reaction, observed (a) during graft rejection and (b) during the autoimmune reaction. In both cases, the immune system encounters the antigen (the allogen in organ grafts and the autoantigen in autoimmune reaction), first in its “processed” form, i.e. in context with the MHC II-complex. This favours the generation of Th and Tc cells and depresses the Ts cells being able to interact with soluble antigens directly, i.e. without antigen processing. Therefore, the in vivo situation in graft recipients and patients with autoimmune disorders should be mimicked in tumor-excised cancer patients by the injection of patient's tumor cells with the post-expressed MHC II-antigen. An additional improvement of the therapy is the use of the above-mentioned constructs, consisting of the Fab/F(ab′)2-subunit of tumor-specific IgG or IgM, plus Fc-subunit of IgE, alone or combined with IL4.
- (11) As next, the in vitro preprocessing of patient's tumor-antigen is recommended; this occurs by the phagocytosis of the soluble (e.g. 3M-KCI-extract) of tumor antigen or inactivated tumor cells, followed by the reinfusion of the involved macrophages into the patient.
- (12) The procedure, based on the generation of Th-memory cells by the in vitro incubation of patient's T cells with his inactivated tumor cells, followed by the elimination of Ts cells through anti-CD8-Mabs plus complement, is of special interest. Both, the so pretreated macrophages and Th-cells mimic the situation during organ transplantation and autoimmune disorders which are characterized by a strong in vivo immune response. In this case, the in vivo immune reaction is directed against tumor cells.
- (13) By the titration, i.e. “neutralization” of the soluble fraction of immunorelevant membrane structures in plasma by specific Mabs, the immunosuppressive effect of these humoral factors can be prevented. By the quantitative analysis, the patient-dependent amount of the neutralizing Mabs has to be determined in advance. Both the specific diagnostic tests and the in vivo use of the neutralizing Mab are subjects of this patent application. Examples of such molecules are the immune-response-mediating or potentiating membrane receptors in general, e.g. IL2/Tac/CD25- and T11/CD2/Leu5a/IL4-receptor, further various receptor: ligand-systems of cooperating immunocytes (integrins such as CD2: LFA3, ICAM-1: LFA1), or immunorelevant structures in general, such as CD4, CD8 and MHC II.
- (14) The procedures, described under points (11) and (12) are also valid for HIV-infected persons. Classical vaccines can be essentially improved as follows: (1) by the preformation of antigen(pathogen): IgM-immunocomplexes which activates the macrophages before Ts cells are stimulated (2) by the use of preformed complexes, consisting of pathogen: IgM/IgG: complement (or C-subunit) (3) by the use of pathogen-specific IgE and/or conjugates of pathogen-specific Fab/F(ab′)2 subunit of IgG/IgM plus Fc-fragment of IgE (of any specificity) (4) by combining the priming with anti-CD8-Mab plus anti-B-cell-Mab and the boosting with anti-CD8-Mab alone (without anti-B-cell-Mab) (5) by masking the macrophages/monocytes with the Fab/F(ab′)2-subunit of the specific Mabs, after the first or during the second vaccination (6) by injecting Mabs, neutralizing gamma-interferon, TNFalpha, PGE2 and/or TGFbeta (−+IL4) 4-6-days after the first or during the second vaccination.
- The next point is the prevention of tumor relapses after BMT by the potentiation of the GvL-effect, without the danger of the parallelly increased GvH-reaction. After years of research, several procedures, based on the circumvention of the critical, often fatal immunosuppressive. phase immediately after the tumor removal, have been worked out. These procedures can be used per se or in combination with other techniques, described in this patent application.
- One procedure comprises the admixing of donor lymphocytes, whose lifespan has been predetermined (preprogrammed) by a special 3-step-procedure, to the donor bone marrow cells. In this way, the patient gets immunocompetence, until he restores his own immune response; he is continuously able to combat infections and to prevent the reinduction of tolerance against residual tumor cells and herewith the later relapses. Before the donor T cells can provoke the GvH-disease, they die due to the preprogrammed cell death. The cell death can be predetermined by a controlled in vitro pretreatment of donor T cells with DNA-crosslinking agents. The preprogrammed cell death of immunocompetent donor T cells can be achieved also—via the intracellular irradiation—by the in vitro incorporation of radiolabeled, i.e. radionuclid/radioisotope-containing nucleosides, nucleotides, free bases and their derivatives into the DNA. Examples of such radiolabeled nucleosides are: 2′-deoxyuridine-2-′14C, further 2′-deoxyuridine-5-3, 2′-deoxycytidine-S-3H and 5-bromo-2′-deoxyuridine-2-′14C. All nucleosides and nucleotides, labeled by various redionuclides (e.g. from H, P, S and other) and added to the culture medium, are subject of this patent application.
- If donoe's immunocompetent T cells are coincubated with the recipient's mitimycinc- or irradiation-inactivated MHC II (and/or MHC 1)-positive cells, the cell death-preprogramming radiolabeled nucleosides are incorporated nearly selectively into the alloreactive, recipient-recognizing donor T cells.
- In the special case of the radiolabeled bromo-deoxyuridine, the prelabeled immunocompetent donor's T cells, added to the T-depleted donor-bone marrow, can be treated after the restoration of patient's own immune system ex vivo by UV-irradiation to support additionally the self-destruction of these cells by radio labeling. A similar technique of radionuclide-incorporation into the cell nucleus can be used, according to the invention, for killing of tumor cells in situ. Here, the carriers of the radioactive, tumor-destroying radiation are not tumor-specific Mabs but (a) the tumor-recognizing TIL (tumor infiltrating lymphocytes), and (b) the tumor-specific Tc/CTL(cytotoxic T cells).
- A special advantage of the cellular over the molecular, i.e. Mab-mediated transport of the tumor-destroying radionuclides into the immediate neighborhood of tumor cells is the essentially intensity (density) of the cellular irradiation source. The selectivity (a) of TIL cells as carriers of radioactivity is guaranteed by the tumor-specificity of TIL-cells (Rosenberg, Anderson, Blaese), and (b)) that of tumor-specific Tc/CTL by their selective recognition of tumor antigens (TATA, TSTA, TSA). Though TIL cells belong both to the CD4-and to the CD8-positive T cells, a clear cut-off between TIL- and Tc/CTL-cells is not possible.
- The preparation of TIL- and Tc/CTL-cells as carriers of tumoricidal irradiation includes radiolabeled amino acids and other radiolabeled cellular components (precursors), in addition to the radiolabeled nucleosides; they must be added to the culture medium and are incorporated into TIL- and/or Tc/CTL-cells.
- A further possibility of bridging the fatal immunosuppressive phase after the removal of primary tumor or after following the BMT is the in vitro pretreatment of donor's immunocompetent cells by photosensitive dye-stuffs (e.g. psoralen), followed by their addition to the donor's T-depleted bone marrow, and their transfusion into the recipient. Later, after having protected the patient (recipient) from infections and from the clonal expansion of residual tumor cells, these photolabeled cells are selectively eliminated ex vivo by UV-irradiation. The used technique (photopheresis/PUVA) profits of predeveloped devices. For efficiency reasons, the combination of this technique with other here described techniques is recommended.
- In analogous technique, photosensitive dye-stuffs are combined with or replaced by the radiolabeled or non-labeled bromo-deoxyuridine; again, the labeled cells are selectively killed ex vivo by the UV-irradiation. The use of radioactive instead of the cold isotope in BrdUr increases the efficacy of the technique. It should be combined with a preincubation of donor immunocompetent cells with inactivated MHC II (and MHC-1)-positive recipient cells which allows a selective preprogramming of cell death in the recipient-specific alloreactive subpopulation of the donor.
- A further way is the in vitro transfection of donor's immunocompetent T cells with strongly immunogenic surface antigens, followed by their addition to the T cell-depleted donor bone marrow and by later transfusion into the recipient (e.g. tumor patient). The later in vivo elimination of the mature donor T cells which helps to bridge the immunoincompetent phase is carried out by antibodies, directed against the transfected membrane antigen. These antibodies can be conjugated with cytotoxins in order to increase their efficacy. A further modification of this technique is based on the addition of T cells of a second MHC-incompatible donor to the T depleted bone marrow of the first donor. After the restoration of patient's own immunocompetence, mature histoincompatible donor T cells are eliminated in vivo by allotypic antibodies or corresponding immunotoxins. All these techniques can be used alone or in different combinations. The next procedure is based on the cumulative (additive) effect of DNA-damaging by cytotoxic agents and/or irradiation. The immunocompetent cells of the donor are treated first in vitro by the sub-lethal dose of the DNA damaging cytotoxic agent and/or irradiation and later in vivo after the finished mission (bridging of the fatal immunosuppressive interphase, before the restoration of patient's immune competence) by a second (lethal) dose of cytotoxic agent(s) or irradiation. The strong GvL-effect of the so pretreated donor bone marrow can be further intensified if the donor's immunocompetent T cells to be admixed to the donor bone marrow are predepleted of alloreactive subclones and activated in a tumor-specific or non-specific way, before they have been injected into the patient. In addition, the technique, based on a novel type of immunocompetent T cells which is characterized by a “frozen” activated functional state, should be described briefly. Details about this novel cell type, implicating a constitutively activated state without cell proliferation, follow below. Cells of this novel type can be added to T-depleted donor bone marrow and must not be later on eliminated in vivo, because their ability to proliferate is genetically switched off. Characteristically for all these techniques is (a) a strongly increased GvL-effect, without a simultaneous GvH-reaction, (b) opening of new ways for histoincompatible BMT, (c) the option of an additional tumor-specific and/or non-specific preactivation of immunocompetent T cells, admixed to the T-depleted donor bone marrow, and (d) the impact on both the GvH- and HvG-reaction which minimizes the BMT-associated complications.
- These facts support the inventor's idea to introduce BMT obligately in the patients with solid tumors. According to the invention, the classical BMT could be replaced by the simple exchange of patient's (recipient's) T cells by T lymphocytes of the donor in patients with solid tumors. This can be carried out by an in vivo depletion of patient's T cells by specific Mabs or immunotoxins and transfusion of healthy donor T cells; the histoincompatibility problems can be overcome by the above described special pretreatment of immunocompetent T cells.
- According to a further therapeutic model, the bridging of the fatal immunosuppressive phase, following the tumor excision or BMT can be achieved by autologous or allogeneic LAK-cells plus rIL-2. Since LAK-cells consist of ca. 90% NK-cells and of ca. 10% non-MHC-restricted CD3+-T cells, the in vitro predepletion of CD3+, cells is recommended in the case of allogeneic LAK-cells. Alternatively, the complete LAK-population can be treated by one of the above described cell death-preprogramming procedures. The so pretreated allogeneic LAK cells are added to the donor bone marrow before their injection into the recipient. An important positive “side effect” is the in vivo killing of recipient's HvG-inducing residual T cells. In this way, the complications of a radical recipient conditioning could be prevented. This HvGR-inhibiting effect is based on the property of NK- and LAK-cells to recognize and to inactivate—via the 4F2/TNKTar-antigen—fastly proliferating cells. The plasmapheresis brings some additional advantages in the autologous or allogeneic BMT. The removal of immunosuppressive factors, belonging primarily to the immune complexes, to the solubilized cytokine- and growth factor-receptors, as well as to the prostaglandins, has been neglected in conventional BMT. A further improvement is the addition of fibroblast to the donor BM. The situation following BMT shows a common element with the situation of immunocytes in the limiting dilution-test, in which the added fibroblasts, by secretion of growth factors, make the growth and the survival of immunocompetent cells possible.
- Though there are trends to shorten the phase of immunoincompetence in tumor patients and BM-recipients by cytokines (G-CSF, GM-CSF), fibroblasts, admixed to the donor bone marrow are expected to secrete a much broader spectrum of cytokines.
- As next, the addition of donor-macrophages to donor-BM is recommended; in this way, the cooperation of accessory cells (APC) with T cells in the critical post-transplantation phase is guaranteed. The temporary masking of recipient-macrophages (to inhibit the preexistent suppressor monocytes) is also of interest.
- The next point is the selective in vivo depletion of the recipient macrophages/monocytes (e.g. by specific Mabs or immunotoxins) and/or the addition of donor-macrophages to donor bone marrow. Finally, the use of neutralizing Mabs, directed against all those cytokines which allow the mutual activation of macrophages, T4 cells and NK cells in the critical phase of the GvH- and HvG-reaction, is recommended. So, the clonal expansion of alloreactive subpopulations, following allogeneic bone marrow and organ transplantation, can be prevented by neutralization of TNF alpha, IL-1, IL-6 and/or gamma IFN. As next, a novel cell type should be described which is characterized by the “frozen”, i.e. constitutively activated functional state and by a parallel switching off of the cell proliferation. This state is associated with the cell arrest in the G1- or G2-phase and with a permanently increased level of the intracellular Ca2+(Ca1). In the case of ex vivo generated LAK- and TlL-cells, the problem of a rapid activity drop of these cells in vivo could be solved by the corresponding cell modification. This in vivo inactivation of LAK- and TlL-cells stems from the induction of lipocortin/lipomodulin by plasma corticosteriods (cortisol) and can be prevented in two ways: (1) by the constitutive, proliferation-free activation of LAK- and TlL-cells, and (2) by the transfection of LAK- and TIL-cells with the CDNA, encoding the cortisol-cleaving enzymes, such as 20alpha-hydroxysteroid-dehydrogenase and B-glucuronidase.
- The T cell-activation (a) by different cytokines, such as IL-2, IL-3 and CSF-1/M-CSF, and (b) by (processed) antigen occurs in the same way, i.e. via the activation of the PI (phosphoinositol)-dependent PLC (phospholipasec) and results in the increase of the intracellular Ca,2+-level.
- The constitutively increased Ca,2+-level in the cell cycle-arrested cells (subject of this patent application) opens a novel way of cell activation. A special advantage is the cell activation and the maintaining of this activated state even in the absence of the specific signal, e.g. the processed antigen in the case of helper T cells. In other terms, the constitutively increased cai2+-level in the cell cycle-arrested cells confers to these cells the genetically predetermined (highly specialized) function, e.g. the production of specific antibodies or the CTL- or ADCC-activity. A further advantage is the inner stability, i.e. the resistance against the specific or non-specific suppression by suppressor factors, such as prostaglandins (e.g. PGE1/E2) or corticosteroids, without the danger of an uncontrolled cell proliferation (because of the cell cycle-arrest).
- This goal can be reached in two ways: (a) by hybridization of cells with the desired function, e.g. plasma cells, CTL/Tc, T4/Th etc. with immortalized cells (autologous tumor cells of the patient or transformed cells of other origin), followed by the treatment of formed hybridoma cells by cell death-preprogramming techniques, as described above, and (b) by a double transfection of the cells, showing the desired function (B, T4, T8), with the sense-cDNA, encoding the constitutive cell activation plus antisense-cDNA, encoding the switching off of cell proliferation.
- Ad (a): The cell death-preprogramming treatment can occur either in hybridoma cells or in immortalized partner cells, before these have fused to give hybridoma cells.
- The rejection of hybridoma cells, based on non-allogeneic immortalized cells, must be prevented (a) by their repeated incubation in the presence of the alloantigen-specific antibody, or (b) by transfection of the cells with the histospecific antisense-cDNA.
- Candidates for the immortalized partner cells are those transformed cells which maintain an increased intracellular Cai 2+-level by autocrine or paracrine mechanisms or such transformed cells which are able to maintain—independently of external signals—the activated state either by the constitutive, ligand-dependent activity of tyrosine- or serine/threonine-kinases or by the continuing PI-conversion to PIP2.
- Ad (b): The double transfection of the target cells, showing the desired function (B,T4,T8 . . . ) (b1) with sense-cDNA, encoding the constitutive expression of cell-activating signals, plus (b2) with antisense-cDNA, encoding the turning off of cell proliferation, creates a permanently “turned on”, non-proliferating cell which doesn't need any specific signals (e.g. processed antigen) for its activation.
- These novel cell constructs have an enormous practical relevance. Examples are (1) the intracranial injection of NGF (nerve-growth-factor)- and/or DOPA-secreting, long-lasting, fibroblast-based cells constructs which cannot be down-regulated by plasma suppressor factors and are of special interest in the treatment of M. Alzheimer and M. Parkinson, further (2) the cytokines and growth factors-producing cell constructs which support patient's immune system, following high-dose (radio)chemotherapy and BMT, as well as (3) cell constructs, based on tumor-specific plasma cells which are able to produce anti-tumor-Mabs in situ, preventing in this way the induction of neutralizing immunoglobulins.
- As the sense-cDNA, encoding cell activating signals (1) the cDNA, encoding various cytokines or (hematologic) growth factors and/or their receptors, further (2) the PLC- and PLA2-encoding cDNA, (3) the cDNA, encoding different cytoplasmic serine/threonine-kinases, and (4) the cDNA, encoding various protein-kinases, such as C-kinase, Ca/calmodulin-kinase, casein-kinase II and G-kinase, are recommended.
- The prevention of cell proliferation can be achieved by the antisense-cDNA of all cell division-inducing factors. Examples are (a) cyclinA, cyclinB 1, c-ras, c-raf, PSTAIRE, MPF, p34cdc2, pl3, further (b) the DNA-transcription factors like AP-1 (AP-I) and AP-2(AP-II), and (c) DNA-polymerase-alpha, PCNA and (protein)elongation factor (elF-2/elF-2p). PSTAIRE is a cdc2-subregion (aminoacids 42-56) and belongs, like p34cdc2, to the family of cell cycle-specific protein-kineses. The PCNA (proliferating cell nuclear antigen)is a 36kD-intra-nuclear-polypeptide and component of polymerase-delta; the MPF stands for mitose- or M-phase-promoting-factor.
- Alternatively to these antisense-cDNAs, various sense-cDNAs, encoding suppressor-oncogenes, such as plO5RB and p53 can be transfected to prevent uncontrolled cell proliferation. By transfection of extra-copies of the p53 and/or RB-cDNAs,somatic cells, including leukocytes, can be made more resistant against different carcerogenic agents.
- The uncontrolled proliferation can be switched off also by cell fusion with normal cells, expressing the wild type or the wild-type p53.
- One of the points, according to the invention, is the prevented expression of the MHC II or MHC I complex on the cell construct, achieved by the transfection of the MHC II or MHC I-encoding antisense-cDNA. The antisense-cDNA can be replaced (a) by ribozymes, (b) by psoralent derivatives of the antisense-oligonucleosides or—oligonucleosidemethylphosphonates, and (c) by antigen—and antisense-oligonucleotid-intercalator-conjugates.
- (a) The advantage of ribozymes, called also “catalytic RNA”, over the corresponding antisense-cDNA is their irreversibility as they cleave the sense-DNA. The smallest and simplest self-cleaving domain of ribosome is the “hammerhead”-structure, e.g. the “structure I”, described by Uhlenbeck or the “form IV”, reported by Haselhoff and Gerlach.
- (b) The psoralene-derivatives of antisenseoligonucleosidmethylphosphonates are also irreversible in their action; here, the desired sense-DNA is switched off by the photoinduced DNA-crosslinking.
- (c) When the technique, based on oligonucleotid-intercalator-conjugates is used, the irreversibility is achieved by the conjugation of antisense-cDNA or -RNA with the chemically (Cu2+-phenanthroline) or photochemically (ellipticin) inducible intercalator-molecules.
- The immunotherapy of malignancies and autoimmune disorders, as well as of bacterial and (retro)viral infections is based on the same principles as the improvement of conventional vaccines and prevention of graft rejection, namely (a) on the deblockade of the hyperactivated state of immunocompetent cells and/or (b) on the elimination or inactivation of hyperactivated effector cells (“microimmunosurgery”). (a) This deblockade of the hyperactivated state of immunocytes can be achieved, according to the invention, by combining agents which block the “voltage-operated” and/or “receptor-operated” Ca2+-channels (“component I”), with agents which reduce the intracellular cAMP or the cAMP/cGMP-ratio, respectively (“component II”).
- The “component I” comprises “classical” Ca-antagonists (Ca-channel-blockers) of all subtypes, e.g. phenylalkylamines, dihydropyridines, benzothiazepines, piperazines, quinoxalines, quinazolines (e.g. bepridil and perhexilin). Alternatively or additionally, a parallel inhibition (blockade) of alpha-plus B adrenoceptors, of H2-plus H1-histamine receptors, of A2-plus Al-adenosine receptors, of 5-HT/serotonine) receptors and/or receptors of various inflammation mediators (e.g. bradykinin, kinin-cascade, complement-cascade, especially c5a, c4a, c3a, PAF etc.) is recommended. Examples of preferred combinations are listed below; they can be combined with sub-dosed nitro-compounds, including molsidomine, Ca-overload.blockers, e.g. cinnarizine, Ca-antagonists, BRM and/or cytokines. The combination of molsidomine and nicerogoline (an alpha-blocker), with or without Ca-overload-blocker(s) (e.g.cinnarizine) is of a special interest.
- The “component II” comprises cAMP/cGMP- or cAMP-reducing agents. Examples are antagonists of all cell receptors which are coupled via the Gs-protein to the membrane-associat,ed adenylate cyclase (AC). This effect is increased if agonists of Gp-, Gi- or Go-protein-coupled receptors and/or of cGMP-increasing, Cai, reducing nitro-compounds (e.g. isosorbid-mono- and -dinitrate, glycerol-trinitrate/nitroglycerol, erythrit-tetranitrate, pentaerathrit-tetranitrate, amylnitrite, molsidomine) are given parallelly. The antagonists of those Gs-coupled receptors whose normal, physiological agonists bind at the same time Pp-,Gi- or Go- coupled receptors are of a special interest. After having blocked the. Gs-coupled receptors, the Gs-coupled receptors, the endogenous ligand bind the Gp-, Gi- or Go-coupled receptors to a higher degree. In this way, B-blocker achieve 2 effects, the cAMP-drop and the cGMP-rise in cytosol of immunocompetent target cells. Examples of such endogenous agonists are catecholamines (adrenaline and nonadrenaline), histamine and adenosine. So, the antagonists of B-adrenoceptor (on immunocytes, e.g. T cells and monocytes/macrophages) cause catecholamines, primarily adrenaline, to interact with the alpha- instead of B-adrenoceptor. Similarly, the antagonists of H2-histamine receptor make the histamine ligate the cAMP-lowering H1- instead of the cAMP-increasing H2-receptor. In the presence of A2-antagonists, the endogenous agonist adenosine binds to the cAMP-depressing A1- instead of to the cAMP-raising A2-subtype P1-adenosine receptor.
- It is also advantageous to use the agents which inhibit reversibly both, the Ca- and the Na-channels. The working mechanism is the increase of the resting potential of immunocompetent cells which is decreased during the hyperactivated state. This class of substances comprises (a) some Ca-antagonists like cinnarizine, flunarizine, fendiline, bepridil, tiapamil and partly verapamil and gallopamil, further (b)sub-dosed antiarrhytmics (class I to IV), especially the combination of class IB with class III, due to the equilibrated K-efflux (class IB) and K-influx (class III) and synergism in the inhibition of Na-channel (among these agents are adrenoceptor-blockers sotalol and propranolol). The combination of cinnarizine and propranolol is of a special interest.
- The central point of this invention is the combination of agents which decrease the cAMP-level or the cAMP/cGMP-ratio with those which block the “voltage-operated” and/or “receptor-operated” Ca-channels. In special cases, the “component I” and “component II” are identic. So, some special nitro-compounds, such as syndnonimine derivatives (e.g. mosidomine), show both effects (cGMP-rise, Cai-decrease); they are also subject of this invention.
- Both, the therapy of the diseases discussed above and the efficiency of conventional vaccines can be further improved by methylxanthines, by pHi-increasing substances, ba redox-potential, GSH/GSSG and NADP)H/NAD(P)+ correcting agents, as well as by ionic homeostasis and K-balance influencing substances.
- (b) Inactivation/elimination of hyper- or persistently activated immunocompetent cells.
- The principle of this in vivo inactivation or depletion of hyperactivated effector cells is the “microimmunosurgery”, a new technique which would compete with or complement the gene-therapy in future. The principle is the selective inactivation of disease-inducing and disease-maintaining lymphocyte-subclones by the combination of (b1) panT- or T subclass-specific Mabs or Mab-derived immunotoxins, plus (b2) alloreactive-T cells of a healthy donor. This combination of humoral (Mab) and cellular (allogeneic T cells) technique is able to increase essentially the efficiency of the Mab-mediated depletion of pathogenic immunocyte-subclones, as shown in animal model. Tumor patients as well as patients with (chronic) infections (including HIV) and those, suffering from CFS (chronic fatigue syndrome) show a strongly increased number of CD8-positive (Ts) and/or HLA-DR(MHC II)-positive T cells. By the combination of anti-CD3- or anti-CD8-Mabs plus allogeneic donor-PBM/PBL or donor T cells whose cell death is “preprogrammed”/“predetermined” by a special in vitro-treatment, the meotioned pathologic (hyperactivated) CD8:HLA-DR-positive effector cells can be selectively eliminated in vivo. In this way, a 94-100%-survival rate in tumor-bearing mice could be achieved.
- The “preprogramming” of cell death in allogeneic donor PBM/PBL or T cells is a multistep in vitro procedure, comprising the following steps:
- (1) Synchronization of “donor effector cells” (a) by their incubation in serum-free medium, followed by the incubation in serum-containing medium, or (b) by cell incubation first in the absence and later in the presence of essential aminoacids (e.g. isoleucin), or (c) by cell incubation in the presence of synchronizing cytotoxic agents, such as vinchristine, hydroxyurea or bleomycin.
- (2) Treatment of “donor-effector cells” by (a) bifunctional alkylating agents, i.e. DNA-cross-linking agents (e.g. mitomycin C) and/or (b) by inhibitors of the enzyme ribonucletoid-reductase (e.g. hydroxyurera) which block the DNA- but not the RNA- or protein-synthesis.
- (3) Incubation of “donor effector cells” in the presence of inhibitors of DNA-reparases (DNA repair system) (e.g. hydroxyurea).
- (4) A thorough washing of cells, e.g. by PBS or RPMI 1640.
- (5) Infusion of so pretreated “donor effector cells” into the recipient (e.g. tumor patient).
- An alternative procedure consists of the incubation of “donor effector cells” (a) with radiolabeled DNA-constituents (purine- and pyrimidine bases) and/or (b) with radiolabeled aminoacids.
- A further alternative is the irradiation of “donor effector cells”, followed by their incubation in the presence of inhibitors of DNA-reparases (e.g.hydroxyurea).
- In the special case of autoimmune disorders, the target cells of “preprogrammed” alloreactive donor T cells are also the HLA-DR(MHC II)-positive autoaggressive T cells (mostly T4, partly T8 cells).
- The procedure consists of the in vivo depletion of T cells (by anti-panT/CD3-Mabs) or their T8 and/or T4 subclass. Because of the high costs for the “pure” Mabs and Mab-derived immunotoxins, their combination with cytotoxic agents, especially cyclophosphamide is recommended.
- A further improvement of the technique is the reinfusion of patient's peripheral blood cells which have been preactivated ex vivo against the donor PBMs/PBLs, into the patient, after the premanipulated donor effector cells have eliminated the pathologically activated recipient lymphocytes.
- As animal experiments have shown, the efficiency of “microimmunosurgery” is so high that the donor effector cells are able to lyse patient's pathologic leukocyte-subclones even (a) without a preceding in vivo Ts-depletion (by Ts- and/or panT/CD3-specific Mabs), though the combined attack on the cellular and humoral level remains the most efficient approach. All experiments, however, show an enormous rise in their efficacy when the in vivo used Mabs are combined with the cell death-preprogrammed effector cells. This concerns the therapeutically used anti-tumor-Mabs, the Mabs, utilized in the recipients of organ grafts (e.g. anti-CD3-Mabs) and the Mabs, used in the treatment of autoimmune disorders (e.g. anti-CD4-Mabs).
- A further possibility (a) to bridge the critical immunoincompetent phase, e.g. after the excision of primary tumor or following the BMT, and (b) to prevent GvHR (but not GVLR), is as follows:
- (a) Patients, e.g. those with solid tumors, are first “conditioned” by anti-CD3-Mab (or the corresponding immunotoxin), or by the Mab-saving combination of cytotoxic agent (e.g. cyclophosphamide=plus Mab
- b) In addition, the CD8:HLA-DR/DQ-double positive suppressor fraction is eliminated by means of “microimmunosurgery”.
- (c) The next step is the in vivo depletion of donor effector cells by patient's (i.e. autologous) T cells or PBMs/PBLs. The ratio between the autologous T cells or PEMs/PBLs (point (c)) on the one hand and the corresponding leukocyte-subpopulations of the healthy donor (point (b)) on the other hand should be 3:1 to 10:1; in this case, the cell death-programming can be omitted. Both, the donor effector cells (point(b)) and the autologous effector cells (point (c)) can, but must not be prealloactivated. It is advantageous if parental PBMs/PBLs are used as donor effector cells.
- The presensibilization of donor alloreactive effector cells against the recipient lymphocytes brings an additional advantage: The so presensibilized (primed) donor effector cells are blastogenically pretransformed and can be activated in vivo, in some analogy to the effector cells of the secondary MLC and those of the PLT 1-2 days earlier as the non-primed clones. This fact confers to the presensibilized (primed) donor cells the crucial advantage, that they are able to eliminate—following their infusion into the patient—his pathologically (hyper)activated, MHC II-positive subpopulations before the patient's defense against these therapeutically utilized donor-effectors can be organized. For this reason, the number of donor effectors to be transfused can be reduced and the cell death-preprogramming possibly omitted.
- (c) Improvement of organ grafts (kidney-, heart/lung-, liver-allografts)—The acute rejection, leading to the loss of the graft organ can be essentially improved, according to the invention, if the classical procedures, based (a) on a generalized immunosuppression (azathioprine, prednison, (methyl)prednisolon, cyclosporinA), and/or (b) on the in vivo T cell depletion by anti-CD3-Mabs or ALG or ATG, are completed or partly replaced by the “microimmunosurgery” or by the cell death-preprogrammed effector cells.
- (d) Improvement of conventional vaccines—The same principle (deblockade and/or inactivation /elimination of hyperactivated effector cells) can be used to improve the conventional antibacterial and anti(retro)viral vaccines, including the anti-HIV-vaccines; the target cells are here the CD8: MHC II-double positive suppressor effector cells. The principle is the increase of the absolute number of blastogenically pretransformed, pathogen-specific Th-, Tc/CTL- and/or B(plasma) cells by (a) deblockade and/or (b) inactivation /elimination of pathogen-specific Ts cells. In an early phase, these Ts inhibit the generation of pathogen-specific Th-, Tc/CTL- and B-memory cells. By (a) deblocking and/or (b) inactivating/eliminating the Ts-cells, the clonal expansion of “positive” memory cells (Th, Tc, B) is strongly increased and the protection of infection significantly improved.
- (a) The deblocking of Ts-cells occurs by the combination of “component I” and “component II”
- (b) The inactivation/elimination of CD8:HLA-DR/DQ-positive Ts-cells is performed by alloreactive, cell-death-preprogrammed effector cells (see above)
- (c) The “immunologic memory”, induced in a pathogen-specific way by vaccination, can be further improved by eliminating in vivo the pathogen-specific Ts-cells of the vaccinated person with subset (CD8/Ts)- and/or panT(CD3)-specific Mabs or corresponding immunotoxins
- (d) The number of pathogen-specific Th-, Tc- and B-cells can be increased also by delaying the antibody-production through Mabs (and immunotoxins), directed against (d1) B-cells, (d2) Th(T4)-cells, (d3) B-plus Th(T4)-cells, (d4) monocytes/macrophages (“suppressor monocytes”), and/or (d5) B-cells plus suppressor-monocytes.
- Again, “pure” Mabs can be replaced by the Mabs-saving mixture of cytotoxic agents (e.g. cyclophosphamide) plus Mab.
- (e) Support and partial replacement of glucocorticoids (e.g. cortison) by low-dosed antagonists of Gi(Gp,Go)-coupled receptors and/or by low-dosed agonists of Gs-coupled receptors
- Glucocortocoids, characterized by strong side-effects, can be supported or partly replaced by sub-dosed blockers of Gi-, Gpor Go-coupled receptors and/or by low-dosed ligands of Gs-coupled receptors. These agents can be combined with sub-dosed Ca-antagonists.
- The indication of these novel combination preparations corresponds to that of “classical” glucocorticoids. Again, the antagonists of those Gi(GP, Go)-coupled receptors which share the endogenous ligand with a Gs-coupled receptor (e.g. catecholamines, histamine, adenosine) are of a special interest. With such combinations, other clinically used immunosuppressive agents (e.g. cyclosporine, FK506, rapamycin, azathioprin, cyclophosphamide) can be supported or partly replaced.
- Since the hyperactivated state of effector cells (T cells, macrophages etc.) is an important element in the pathogenesis (a) of cancer (b) of autoimmune disorders (c) atherosclerosis (d) infectious diseases (including HIV), the procedures, described under the point (a) (“Deblocking of hyper- or persistently activated immunocompetent cells”) and under the point (b) (“Inactivation/elimination of hyper- or persistently activated immunocompetent cells”) are valid for all these diseases.
- The reduction of background-signals, i.e. “filtering out” of non-specific (non-productive) transmembranal signals increases the susceptibility of immunocompetent cells for specific, immunorelevant signals.
- 1 Combination of sub-dosed B-(B1- plus b B2-) and sub-dosed alpha-(alphal- plus alpha2) adrenoceptor blockers (antagonists) (objective: prevention of hypoergic or anergic state of hyperactivated immunocompetent cells by lowering the level of non-specific background-signals).
- 1.1 Combination of preparations on pindolol-basis (e.g. durapindol/−15/-retard (26.039) or pinbetol/forte (26.067) plus preparations on phenoxybenzamine-basis (e.g. dibenzyran 1/5/10(81.091)). Pindolol is a B1- plus B2-sympatholytic, phenoxybenzamin an alphal- plus alpha2-blocker. Recommended dose: 1×15 mg/d or 3×5 mg/d or 2-3×1 mg/d dibenzyran.
- 2 Combination of sub-dosed B-(B1- plus B2-)-adrenoceptor-blockers with sub-dosed alphal-receptor-antagonists, blocking at the same time the H1-histamine and the 5-HT(serotonin) receptor (objective: see point (1)).
- 2.1 Combination of drugs on pindolol-basis (e.g. durapindol/−15/-retard (26.039), or pinbetol/forte (26.067) plus preparations on indoramin-basis (e.g. wydora/50(16.039)). Indoramin is the antagonist of alphal-adrenoceptor, of H1-histamine receptor and of 5-HT receptor. Recommended dose: durapindol (see above); indoramin 1×25 mg/d.
- Combination of sub-dosed B- (B1- plus B2-) adrenoceptor-antagonists with sub-dosed alpha- (alphal- or alpha2-) receptor blockers (objective: see point (1) and (2)).
- 3 Combination pf preparations, based on 3.1.1. alprenolol (e.g. aptin (26.002)), 3.1.2. bupranolol (e.g. betadrenol 50/−100(26.017)), 3.1.3. penbutolol-sulfate (e.g. betapressin (26.019)), 3.1.4. bisoprololfumarat (e.g. concor 5/10 (26.025)) or 3.1.5. carteolol (e.g. endak 5/10 (26.046)) plus preparations, based on 3.1.1. urapidil (e.g. ebrantil 30/60/90 (16.032)), 3.1.2.(doxazosinmesilate (e.g. cardular 1 mg/-2 mg/-4 mg (16.029) or diblocin 1mg/-2mg/-4mg (16.030)) or 3.1.3. terazosin (e.g. heitrin 1/2/5 (16.035)). Recommended doses: aptin-duriles 1×200 mg/d; betadrenol 1-2×50 mg/d; betapresin 0,5-1×40 mg/d; concor 1×5 mg or 1×10 mg/d; endok 5 mg/d; ebrantil 30 mg/d, cardular 1 mg/d; diblocin 1 mg/d; heitrin 0,5-1 mg/d.
- 4 Combination of sub-dosed H2- and Hi-histamine receptor antagonists (objective: see above).
- 4.1 Combination of preparations, based on cymetidine (e.g. sigacimet 200/−400/−800 (59.102) or tagamet 200/−400/−800 (59.105) or H2-blocker ratiopharm (59.096) plus preparations, based on 4.1.1. oxatomid (e.g. barpet (07004)), 4.1.2. bromopheniramine-hydrogenmaleate (e.g. dimegan (07.005)), 4.1.3. dimetindenmaleate (e.g. fenistil (07.006)) or 4.1.4.terfenadine (e.g. hisfedin (07.009)). Recommended doses: sigacimet 1×200 mg/d; tagamet 1×200 mg/d; H2-blocker ratiopharm 1×200 mg/d; barpet 1×30 mg/d; dimegan 1×12 mg/d; fenistil 1×1 mg/d; hisfedin 0.5-1×60 mg/d.
- 5 Combination of sub-dosed antagonists of A2- plus A1-P1-purinergic (adenosine) receptors (objective: see above.
- 5.1 Combination of preparations, based on methylxanthines (theophylline) (e.g. aerobin mite (27.102) or contiphyllin retard (27.113) or euphyllin N (27.125)) plus preparations, based on ipratropium-bromide (e.g. atrovent (27.048) or itrop (09.028)). Recommended doses: aerobin 0.5-1×200 mg/d; contiphyllin 0.5-1×300 mg/d; euphyllin N 1×73mg/d; atrovent 0.5-1×200mg/d; itrop 0.5-1×10 mg/d. Combinations, based on cromoglicinic acid (diNa-salt) and ketotifen-hydrofunarate are also of an interest.
- Sub-dosed antagonists under the points (1) (2) (3) and (4) can be combined. In this case, the dose has to be reduced to 5-50% of the dose, quoted under the points (1)(2)(3) and (4). The strongly sub-dosed antagonist under the points (1)(2)(3) and (4) can be combined with conventional Ca-antagonists and/or with sub-dosed agonists of Gp- and Gi-coupled receptors.
- (1) The restoration of the immunocompetence following the sublethal irradiation or high-dose chemotherapy can be accelerated -according to the invention- if cytokines such as M-CSF or GM-CSF are combined with (a) antagonists of Gs-coupled receptors, (b) agonists of Gi(Gp/Go)-coupled receptors, and/or (c) Ca-antagonists.
- (2) Therapeutic approaches, based on tumor-specific Mabs (and corresponding immunotoxins), can be improved essentially by combining these Mabs (a) with anti-CD3- and/or anti-CD8-Mabs, and (b) with “micro-immunosurgery”, tumor patients are (a) first treated by the combination of Mab-saving cyclophosphamide plus anti-CD3- or anti-CD8-Mab, then (b) injected by alloreactive donor effector cells (PBM/PBL or T cells) which can be primed against the recipient and (c) treated again by cyclophosphamide plus anti-CD3- or anti-CDB-Mabs in order to eliminate the alloreactive donor cells, and (d) finally reinjected with the autologous PBM or T cells, collected before the start of therapy, to restore the recipient's immunocompetence. In a simplified version, the step (c) can be omitted.
- (4) The reinduction of tumor-specific Ts cells can be prevented (a) by Mabs, directed against immature T cells (e.g. anti-T6-, antiT9-, anti-T10-Mabs), (b) by antagonists of Gs-coupled receptors, and/or (c) by agonists of Gi-coupled receptors.
- (5) To prevent an early RES-elimination of allogeneic effector cells during the “microimmunosurgery”, a simultaneous injection of allogeneic erythrocytes or inactivated autologous erythrocytes is recommended (temporary “RES-blockade”)
- (6) The combination of (a) insuline or antidiabetes with (b) glucose or di- and tricarbonic acids can amplify the above described deblocking process of hyperactivated macrophages and T cells. Instead of di- and tricarbonic acids, their alkali-salts are recommended, which lead to the rise of intracellular pHi:
- (7) The combination of (a) amiloride plus plasma-acidifying agents (e.g. NH4C1, Iysine.HC1, methionine HC1) with (b) TNF (or TNF-inducers such as LPS) or interferon, augments their ROI-mediated target cell damaging by inhibiting the synthesis of ROI-cleaving enzymes (e.g. SOD).
- (8) Since hyper- or persistently activated effector cells (macrophages, T cells etc.) represent a common element (a) in neiplastic, (b) in autoimmune diseases (c) in atherosclerosis, (d) in bacterial and (retro)viral infections, including HIV, and (e) in vaccines, the use of antagonists of Gs-coupled receptors and of agonists of Gi(Gp)-coupled receptors, as well as of Ca-antagonists/Ca-overload-blockers is recommended in all these situations.
- (9) The efficiency of “microimmunosurgery” can be further increased by the in vivo or in vitro sensibilization of donor effector cells against the recipient (patient). Blastogenic pretransformation confers the donor effector cells a higher efficacy and a time advantage of 24 days which allows these donor cells to inactivate the patient's pathological subclone(s) before the recipient can organize the anti-donor defense. In this way, the pretreatment of the recipient (patient) by cyclophosphamide plus Mab can be reduced to a minimum.
- (10) Agents, increasing the intracellular cGMP, such as (a) nitrocompounds (e.g. glycerolnitrates, isosorbit-mono- and dinitrates), vasodilators (e.g. minoxidil, (di)hydralazine, Na-nitroprusside) and (c) molsidomine can be used alone or in combination with BRMs, lymphokines, growth factors, methylxanthines (e.g. theophylline), Ca-antagonists or Ca-overload-blockers, agonists of Gi(Gp)-coupled receptors, antagonists of Gs-coupled receptors and/or pHi-increasing or redox potential-correcting substances.
- (11) Since vasodilators (e.g. nitrocompounds) and molsidomine inhibit the IP3-mediated Ca2+-mobilization, they can be used, alone or combined with Ca-antagonists, for a rapid deblockade of those hyperactivated effector cells which show a strongly increased Ca2+-level due to an excess of signals, as observed e.g. in chronic inflammation and autoimmune disorders. Favorable is the combination with pHi-increasing and/or redox potential correcting agents.
- (12) The combination of molsidomine plus nicergoline (with or without cinnarizine) is of a special interest.
- (13) Infection and inflammations can be treated by combining NSAID with sub-dosed (a) antagonists of Gs-coupled receptors (b) agonists of Gi(Gp)-coupled receptors and/or (c) sub-dosed Ca-antagonists (optimally: Ca- and Na-channels-inhibiting Ca-overload-blockers, such as cinnarizine).
- (14) With the same classes of substances, the in vitro generation of LAK- and TL-cells could be improved essentially.
- (15) The suppressor-monocytes seem to play a crucial negative role in the process of immunosuppression. Therefore, they have to be depleted in vivo by anti-Macrophage-Mabs (or immunotoxins), along with the neutralization of their secretory products (monokins) by Mabs, directed against TNFalpha and IL-1. In addition, the macrophage-stimulating gamma-IFN must be neutralized by the specific Mab.
- The effector cells, active in the “microimmunosurgery” process, seem to inactivate both the hyperactivated T cells and the pathologically activated macrophages.
- (16) The cGMP-synthesizing guanylate cyclase (G.C.) can be stimulated, according to the invention, (a) by nitro compounds (“organic nitrates”), such as glycerol-, erythrite- and isosorbite-nitrate, (b) by further vasodilators, such as minoxidil, (di)hydralazine, Na-nitroprusside, (c) by compounds such as arginine, N-methyl-D-aspartate(NMDA), L-glutamate, S-acetylthiocholin-iodide, paraquate, D- and L-ornithine, further extreme low concentrations of NO and cb. The most act via stimulation of NO-synthetase (NOS). The monokines such as TNFalpha and L-1 and lymphokines, such as IFN-gamma (a) switch the cell function from the cell proliferation to the cell differentiation, and (b) induce the secretion of numerous cytokines via the H2O2-intermediate. Interestingly, the H2O2 per se is able to induce, at very low concentrations, the TNF-production. The NO-synthesis goes parallel with the ROI (H2O2) -formation and is dependent in its last step (oxydation of the hydroxylamine-intermediate) on the cooperation with the compound I (catalase: H2O2-complex). The NO is oxydized to N0 2 and N0 3.
- The cGMP-synthesis and mediately the secretion of cytokines can be achieved also by extremely low concentrations of ROI (e.g. H2O2 or Mg-peroxide or (NH4)2S2O4).
- On the other hand, by the inhibition of NO-synthetase or by ROI-scavengers and reducing agents (e.g. N-acetyl-cysteine, glutathione, cysteine, ascorbate, penicillamine etc.), the (hyper)production of cytokines can be inhibited.
- (17) The efficacy of the treatment can be increased by the intratumoral/intralesional application (a) of NOS-activators (b) of agonists of Gi(Gp)-coupled receptors and/or (c) of antagonists of Gs-coupled receptors.
- (18) Since the cGMP-increasing agents (e.g. nitrocompounds, molsidomine) decrease the Cai-concentration, the combination of these compounds with Cai- and pHi-increasing agents is recommended. By a fine mutual balancing of these substance classes, first the energy of immunocompetent cells, caused by hyperactivity, can be broken by nitrocompounds and subsequently the biosynthesis of cytokines and growth factors can be induced by a parallel Cai- and pHi-elevation.
- (19) On the other hand, the combination (a) of Cai-reducing stimulators of NOS (b) with agonists of Gs-coupled receptors or with antagonists of Gi(Gp)-coupled receptors and/or (c) with Ca-antagonists results in the inactivation of pathologically hyperactivated subclones. This effect can be strengthened by the TNF (or TNF-inducers, like LPS), IFN-gamma and IL-I.
- Of a special interest is also the combination of Ca-overload-blockers, e.g. piperazines (cinnarizine, lidoflazine, flunarizine) with Ca-antagonists (controlled Cai- and cGMP-rise)
- (20) The use (a) of agonists of Gi(Gp)-coupled receptors, (b) of antagonists of Gs-coupled receptors,, and/or (c) of NOS-stimulating compounds helps to save cytokines and growth, factors. By a fine mutual balancing, a parallel Cai-, pHi- and cGMP-rise and herewith a maximal cytokine production can be achieved.
- (21) The pretreatment (“conditioning”) of recipient, i.e. tumor patient with the cyclophospharnide plus anti-CD3- or anti-CD8-Mab as part of the “microimmunosurgery” can be replaced by the treatment with the cyclophosphamide plus anti-T6 (anti-T9; anti-T10; anti-TdT)Mab.
- The combination of cyclophosphamide with the mixture of Mabs, directed against the mature cells (anti-CD3 Mabs) and T cell precursors (e.g. anti-T6-Mabs) is also recommended.
- (22) A combination (a) of antagonists of Gi(Gp)-coupled receptors, (b) of Ca2+-influx inhibiting Ca-antagonists, (c) of Ca2+-mobilization-inhibiting nitrocompounds, (d) of agonists of Gs-coupled receptors (B-sympathomimetics) and/or (e) of alkalizing agents could be lifesaving even during a fatal immune over-reaction (septic or anaphylactic shock). The K-preparations, O2-scavengers and tolbutarnide or biguanine plus glucose can support this treatment.
- (23) The Ts-cells can be converted to the CTL/Tc-cells (and vice versa). The intracellular ADP/ATP-ratio seems to be critical: a n ATP-drop or an ADP-rise seems to signalize the Tc:Ts-interconversion.
- A key role seems to play also the ADP/ATP-dependent cAMP/cGMP-ratio. The AMP, formed by the reaction: 2ADP=ATP+AMP, is partly dephosphorylated to adenosine which raises, via A2, the purinergic receptors, the intracellular cAMP-level. The ADP/ATP-decrease (in different stress situations, such as O2-deficit, physical work, cold, heat) is associated by catecholamine (adrenaline)-rise. The adrenaline causes also the rise of intracellular cAMP-level. In order to increase the ADP/ATP-ratio, the following agents are recommended:
- (a) O2 or O2-carriers (b) glucose, di- and tricarbonic acids (as alkali-salts), along with antidiabetics (tolbutamide, biguanine etc.), (c) ribose and/or (d) glutamine, glycine and other ATP-precursors. The adenosine or adrenaline-induced cAMP-rise can be inhibited by the corresponding receptor blockers.
- (24) The reinduction of tolerance against the tumor cells after removal of primary tumor (a) by surgery and/or (b) by chemotherapy and/or (c) by radiotherapy can be inhibited by the antagonists of Gs-coupled receptors and by ligands of Gi(Gp)-coupled receptors. In the case of B-blockers, the H2-antihistaminics and A2-purinergic blockers, the ligands are directed from Gs- to Gi(Gp)-coupled receptors.
- (25) The therapy of (a) lymphomas and (b)leukemias of the T-type can be performed by the “microimmunosurgery” like in solid tumors; again, the sublethal whole body irradiation or high-dose chemotherapy is replaced by the T cell depletion (by Mab-saving cyclophosphamide plus anti-CD3-Mabs). The transformed T cells are eliminated by allogeneic donor effector cells. The mature (post-thymus) malignant,cells are MHC II-positive. The immature (pre-thymus) cells are recognized and depleted via blast-specific structures.
- (26) Autologous BMT in patients with blood cell tumors and those with solid tumors (e.g. lung cancer) can be improved by the in vitro treatment of autologous BM with allogeneic effector cells whose cell death is preprogrammed. This Ts-depletion on cellular level can be combined with that on humoral level, i.e. with anti-CD8-Mabs and/or with the depletion of contaminating tumor cells (“purgic”).
- (27) A further elegant technique of deblockade of hyperactivated effector cells and of their reactivation in the short opening of the voltage-operating Ca2+-channels (a) by a high frequency (HF)current, or (b) by magnetic induction.
- The HF-currents must be significantly lower than those, used in the electroporation or electrofusion (Zimmermann). The deblocked or reactivated state can be “frozen” by Ca-antagonists.
- (28) The efficiency of “microimmunosurgery” can be increased by the combination of Gs- and Gi(Gp)-influencing agents.
- (29) The disappointing efficacy of (a) LAK- and (b)TIL-cells in vivo can be explained by the cortisol-depression in plasma. Therefore, (a) the use of adrenostatics (e.g.metopiron), inhibiting the 11-B-hydroxylation of glucocorticoids during the LAK- and TIL-infusion, and (b) the admixing of LAK- or TIL-cells, pretransfected in vitro by the cDNA, encoding either the cortisone-cleaving enzyme 20alpha-hydroxysteroid-dehydrogenase (20 alpha SDH) or the cortisone-inactivating enzyme B-glucuronidase, are recommended.
- (30) The efficacy of “microimmunosurgery” can be increased also by the pretreatment of the recipient (a) with the ERMs or (b) with the lymphokines (e.g. IFNgamma or IL-4), to render target cells, i.e. pathological subclones more vulnerable.
- (31) The standardized “microimmunosurgery” comprises the following steps: (a) Pooled PBs/PBLs or T cells (from donor A, B, C) whose pathogen-specific subclones can be clonally postexpanded in vitro, e.g. by lectins, are (b) “cell death-preprogrammed” and (c) frozen in a medium (e.g. RPMI1640), containing special cryoprotectants (based on PEG and/or PVP) which warrant the preservation of the preactivated cell state, in addition to an improved cell viability. (d) Treatment of patients, suffering e.g. of cancer or autoimmune disorders is restricted to the T cell depletion because the “microimmunosurgery” is based on the simple replacement of the pathologic patient's T set by the healthy donor's T set.
- (32) According to a modified “microimmunosurgery”-procedure, the immature T- and B-cell precursors, both of the donor (in vitro) and of the recipient (patient) are eliminated temporarily by specific Mabs or Mabs plus cyclophosphamide; then, the patient's pathological subclones are eradicated and -as the last step- the depleted precursors are replaced by autologous or allogeneic (T-depleted) bone marrow. The special advantage is the early exclusion of inducer and transducer suppressor T cells.
- The effector cells can be supported by allogeneic LAK-cells; these can be either premanipulated to express a preprogrammed cell death or depleted of their T cells (10% of cells). In certain situations, the so pretreated allogeneic LAK-cells can be used alone to eliminate the pathologic subclones.
- (33) Immunocompetent cells, e.g. macrophages express a variety of additional, not typically “immunologic” receptors (e.g. for the insuline, the glucagon, the parathormone etc.) which have been neglected up to date though they contribute essentially to the activity of immunocompetent cells. The therapeutic manipulation of all these receptors by agonists and antagonists is subject of this invention.
- (34) Since the early induction of tolerance involves inducer- and transducer suppressor cells which are both CD4-positive, the use of anti-VD4-Mabs (or immunotoxins) is recommended for the prevention of tolerance in general. An established tolerance, on the other hand, is maintained by mature, CD8-positive Ts cells. The same concerns the reinduction of tolerance against the same antigen. In both cases, the use of anti-CD8-Mabs is recommended. Since immature, CD4-positive inducer and transducer Ts cells are involved in the reinduction of tolerance, anti-CD4-Mab (alone or combined with anti-CD8-Mab) are recommended.
- (35) As the IL-2(Tac) receptor (=CD25) is expressed only on (hyper)activated macrophages/monocytes and on the T cells, the parallel depletion of both pathologically hyperactivated subpopulations can be achieved by anti-CD25-Mabs (or immunotoxins). This procedure can improve the “microimmunosurgery” (e.g. in the bone marrow and organ transplantation).
- (36) Fibroblasts support the immunosuppressive “tissue repair”/“wound healing”-function of macrophages and increase e.g. their PGE2 secretion. Therefore, the neutralization of specific fibroblast growth factors, e.g. PDGF, bFGF, FAF, FGTB, PF4 and LTBS is recommended.
- (37) As pathologic processes, such as GvHR, autoreactivity or sarcoidosis, arise from a mutual stimulation of T4 cells and monocytes/macrophages, the interruption of this activation chain by Mabs against IL-I, TNFalpha and/or IFNgamma is recommended.
- (38) Similarly, in BMT the mutual activation cascade, leading to GvH- and HvG-reactivity, has to be interrupted, according to the invention, by neutralizing the involved cytokine(s) The use of Mabs is favorable. It is directedagainst the TNFalpha, IL-1, IFNgamma, GM-CSF, M-CSF, IL-6 and IL-4.
- (39) The combating of residual tumor cells and (premicro) metastases, following tumor excision has best chances if the following 2 principles are combined: (a) 1st principle: MHC II-expression on the patient tumor cells, both (al) by the in vitro MHC II-postexpression, induced by IFNgamma, TNFalpha and/or IL-4, and (a2) by the fusion of tumor cells with autologous or allogeneic MHC II-positive cells (b) 2nd principle: transfection of patient tumor cells with cytokines, primarily GM-CSF and IL-4. Before their reinfusion, such modified tumor cells can be manipulated to express the preprogrammed cell death. The local cytokine enrichment can be achieved by the addition of allogeneic B cells.
- (40) To increase the humoral response e.g. against HIV, the combination of antibodies of the IgG- or IgM-isotype with those of the IgE-isotype is recommended. The latter can be constructed by the replacement of the Fc gamma or Fcu-subunit by the Fc epsilon-subunit. Alternatively, the IgE-percentage in vivo can be increased by the simultaneous injection of anti-IFNgamma and IL-4(IL-5).
- (41) A long-term incubation of PBMs with lectins (e.g. 1 week with ConA or 3 weeks with PHA) leads to a high enrichment of CD8-positive Ts cells; therefore, the depletion of so selected Ts cells (a) by anti-CD8-Mabs (plus complement) or (b) by alloreactive effector cells, with preprogrammed cell death, is recommended. The residual PBMs—released of the depression by the Ts cells—are able to post-generate the Tc/CTLs and Th cells.
- In a next procedure, the patient's PBMs are first incubated in vitro with lectins (e.g.PHA) and thereafter treated by increasing concentrations of anti-CD8-Mab (+complement), until the onset of the Tc- and Th-deblockade. Among the deblocked Tc- and Th-cells, tumor-specific clones can be expected; after a further clonal expansion, these tumoricidal subclones can be reinjected into the patient.
- (42) During their maturation process, the erythrocytes lose the nuclea. Therefore, the ennucleated precursors (reticulocytes) are of a special interest as carriers of temporarily limited functions (e.g. in vivo production of cytokines, Mabs and suppressor factors or local source of irradiation). In these cells, the cell death need not be preprogrammed.
- (43) The controlled DNA-damaging described above (“cell death preprogramming”) can be carried out by DNA-selective cytotoxic agents, primarily vinca alkaloids, bleomycin, ICRF-159, busulfan, DDP, VP16231 (EPE) and EPT, in addition to the above mentioned mitomycinc. The controlled DNA-cross-linking can be achieved by so called “bifunctional alkylating agents”.
- According to a further aspect of the invention, the use of the combination of a Ca-antagonist plus an agent, decreasing the cAMP/cGMP-ratio is recommended as the drug for the treatment of cancer, viral and bacterial infections, as well as autoimmune disorders.
- In addition, the use of a combination, consisting of an agent, eliminating hyperactivated effector cells, and of alloreactive cells with preprogrammed cell death is recommended as the drug for the treatment of cancer, viral infections and autoimmune diseases.
- According to the invention, an additional approach in the treatment of cancer, viral infections and autoimmune disorders, based on the elimination or down-regulation of immunological effector cells, enables the patient's own immune system to restore the pre-disease state.
- A drug, affecting the hyperactivated.immunologic effector cells, comprising (I) a Ca-antagonist and (II) an agent, reducing the intracellular cAMP/cGMP-ratio, is being described. In addition, a drug, affecting the hyperactivated immunologic effector cells, consisting (I) of an agent, eliminating the hyperactivated effector cells and (II) of alloreactive cells with predetermined cell death, is being described as well.
Claims (15)
1. Drugs, affecting hyperactivated immunologic effector cells, consisting of (I) a Ca-antagonist, and (II) an agent, reducing the intracellular cAMP/cGMP-ratio.
2. Drugs, according to the claim 1 , specified by the fact that Ca-antagonist is a Ca-overload-blocker.
3. Drugs, according to the claim 1 or 2, specified by the fact that Ca-antagonist is-cinnarizine.
4. Drugs, according to one of the preceding claims, specified by the fact that component (II) is a drug which decreases the cAMP-level in the cell and/or a drug which increases the cGMP-level.
5. Drugs, according to the claim 4 , specified by the fact that the cAMP level-decreasing drug is an antagonist of Gs-coupled receptors and/or an antagonist of Gi/Gp/Go-coupled receptors.
6. Drugs, according to the claims 4 or 5, specified by the fact that component (II) is an antagonist of B-adrenergic receptors, histamine receptors and/or A2-purinergic receptors.
7. Drugs, according to the claim 6 , specified by the fact that the antagonist of B-adrenergic receptors is propranolol.
8. Drugs, affecting hyperactivated immunologic effector cells, comprising (I) an agent, eliminating hyperactivated effector cells, and (II) alloreactive cells with a preprogrammed cell death.
9. Drugs, according to the claim 8 , specified by the fact that component (I) is a T cell-depleting agent.
10. Drugs, according to the claim 9 , specified by the fact that complement (I) comprises antibodies, directed against CD8 and/or CD3.
11. Drugs, according to one of the claims 8 to 10 , specified by the fact that component(I) contains in addition a cytotoxic agent, especially cyclophosphamide.
12. Drugs, according to the claims 8 to 11 , specified by the fact that component (II) comprises allogeneic cells whose DNA was manipulated in a controlled way and which are able to inactivate the pathologic Ts cells and/or hyperactivated macrophages.
13. The use of a combination of a Ca-antagonist and a drug, able to reduce the intracellular cAMP/cGMP-ratio, to produce a drug for the treatment of cancer, viral and bacterial infections and autoimmune disorders.
14. The use of a combination, consisting of an agent, eliminating the hyperactivated effector cells, and of alloreactive cells with the preprogrammed cell death to produce a drug for the treatment of cancer, viral infections and autoimmune diseases.
15. Procedure for the treatment of cancer, viral infections and autoimmune disorders, based on the elimination of hyperactivated immunological effector cells or their down-regulation to the normal state which enables the patient's immune response to restore the pre-disease state.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/406,077 US20040053832A1 (en) | 1993-06-23 | 2003-04-02 | Immunological methods of treating cancer |
US11/804,182 US20070231326A1 (en) | 1993-06-23 | 2007-05-17 | Immunological Methods of Treating Cancer |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4320878.9 | 1993-06-23 | ||
DE19934320878 DE4320878A1 (en) | 1993-06-23 | 1993-06-23 | Considerable improvements in immunotherapy and transplantation of bone marrow and organs |
DE19934324877 DE4324877A1 (en) | 1993-07-25 | 1993-07-25 | Novel therapeutic mixtures, based on the prevention of intracellular Ca<2+>i overloading and Ca<2+>i independent influencing of the intracellular pHi of immunocompetent cells |
DE4324877.2 | 1993-07-25 | ||
DE19944411956 DE4411956A1 (en) | 1994-04-07 | 1994-04-07 | Agents for influencing hyperactive immunological effector cells |
DE4411956.9 | 1994-04-07 | ||
US08/564,370 US6156312A (en) | 1993-06-23 | 1994-06-19 | Agents, affecting the hyperactivated immunological effector cells |
US69413100A | 2000-10-20 | 2000-10-20 | |
US10/406,077 US20040053832A1 (en) | 1993-06-23 | 2003-04-02 | Immunological methods of treating cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US69413100A Continuation | 1993-06-23 | 2000-10-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/804,182 Continuation US20070231326A1 (en) | 1993-06-23 | 2007-05-17 | Immunological Methods of Treating Cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040053832A1 true US20040053832A1 (en) | 2004-03-18 |
Family
ID=27205254
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/564,370 Expired - Lifetime US6156312A (en) | 1993-06-23 | 1994-06-19 | Agents, affecting the hyperactivated immunological effector cells |
US10/406,077 Abandoned US20040053832A1 (en) | 1993-06-23 | 2003-04-02 | Immunological methods of treating cancer |
US11/804,182 Abandoned US20070231326A1 (en) | 1993-06-23 | 2007-05-17 | Immunological Methods of Treating Cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/564,370 Expired - Lifetime US6156312A (en) | 1993-06-23 | 1994-06-19 | Agents, affecting the hyperactivated immunological effector cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/804,182 Abandoned US20070231326A1 (en) | 1993-06-23 | 2007-05-17 | Immunological Methods of Treating Cancer |
Country Status (5)
Country | Link |
---|---|
US (3) | US6156312A (en) |
EP (1) | EP0705111B1 (en) |
AT (1) | ATE405291T1 (en) |
DE (1) | DE59410457D1 (en) |
WO (1) | WO1995000175A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060151574A1 (en) * | 2002-11-29 | 2006-07-13 | Gpc Biotech Ag | Formulations useful against hepatitis C virus infections |
US20100029002A1 (en) * | 2006-10-13 | 2010-02-04 | Jill Giles-Komar | Enhancement of hybridoma fusion efficiencies through cell synchronization |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413967B1 (en) * | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
CA2649290C (en) * | 2006-04-13 | 2017-04-04 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
US11732239B2 (en) | 2019-09-16 | 2023-08-22 | Figene, Llc | Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof |
CN115927192A (en) * | 2022-08-10 | 2023-04-07 | 浙江康佰裕生物科技有限公司 | Preparation and application of novel universal CAR-T cell |
-
1994
- 1994-06-19 EP EP94919641A patent/EP0705111B1/en not_active Expired - Lifetime
- 1994-06-19 US US08/564,370 patent/US6156312A/en not_active Expired - Lifetime
- 1994-06-19 DE DE59410457T patent/DE59410457D1/en not_active Expired - Fee Related
- 1994-06-19 AT AT94919641T patent/ATE405291T1/en not_active IP Right Cessation
- 1994-06-19 WO PCT/EP1994/001992 patent/WO1995000175A1/en active IP Right Grant
-
2003
- 2003-04-02 US US10/406,077 patent/US20040053832A1/en not_active Abandoned
-
2007
- 2007-05-17 US US11/804,182 patent/US20070231326A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060151574A1 (en) * | 2002-11-29 | 2006-07-13 | Gpc Biotech Ag | Formulations useful against hepatitis C virus infections |
US20100029002A1 (en) * | 2006-10-13 | 2010-02-04 | Jill Giles-Komar | Enhancement of hybridoma fusion efficiencies through cell synchronization |
US8216842B2 (en) * | 2006-10-13 | 2012-07-10 | Centocor Ortho Biotech Inc. | Enhancement of hybridoma fusion efficiencies through cell synchronization |
Also Published As
Publication number | Publication date |
---|---|
EP0705111A1 (en) | 1996-04-10 |
DE59410457D1 (en) | 2008-10-02 |
ATE405291T1 (en) | 2008-09-15 |
WO1995000175A1 (en) | 1995-01-05 |
US20070231326A1 (en) | 2007-10-04 |
US6156312A (en) | 2000-12-05 |
EP0705111B1 (en) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070231326A1 (en) | Immunological Methods of Treating Cancer | |
Klarnet et al. | Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. | |
Spittler et al. | Immunomodulatory effects of glycine on LPS‐treated monocytes: reduced TNF‐α production and accelerated IL‐10 expression | |
Dwyer et al. | Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells | |
JP6072347B2 (en) | Pharmaceutical composition for suppressing immune response by inducing differentiation into regulatory T cells and promoting proliferation | |
US20220401474A1 (en) | Hdac6-activated macrophages, compositions, and uses thereof | |
JP2018529753A (en) | Methods and compositions for the treatment of metastatic and refractory cancers and tumors | |
JP2022503685A (en) | A pharmaceutical combination that treats tumors, including anti-CD19 antibodies and natural killer cells | |
Land | Emerging role of innate immunity in organ transplantation part III: the quest for transplant tolerance via prevention of oxidative allograft injury and its consequences | |
US20100092499A1 (en) | Alpha Thymosin Peptides as Cancer Vaccine Adjuvants | |
CN115137752A (en) | Method for stem cell transplantation | |
US5504092A (en) | Use of Linomide to increase hemopoietic cell precursors | |
ES2234668T3 (en) | RHODAMINE DERIVATIVES FOR DIAGNOSIS AND PHOTODYNAMIC TREATMENT. | |
US20020094542A1 (en) | Drugs and methods for treating cancer | |
Zeltzer et al. | Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application | |
US20100129390A1 (en) | Dkk1 as a universal tumor vaccine for immunotherapy of cancers | |
Svirshchevskaya et al. | Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity | |
US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
Wimer | Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA | |
EP0522001B1 (en) | Supportive use of linomide (r) | |
Sharma | Inhibition of the generation of cytotoxic lymphocytes by potassium ion channel blockers. | |
TWI785268B (en) | Combination of natural killer cells with cyclophosphamide compounds for the treatment of cancer | |
DE4320878A1 (en) | Considerable improvements in immunotherapy and transplantation of bone marrow and organs | |
RU2518889C2 (en) | 5-oxypyrimidine derivative possessing antineoplastic activity | |
KR20230085116A (en) | Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |